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ABSTRACT
The expanded programme of immunization was introduced in The Gambia over 30 years 
ago, using empirically developed vaccines with limited understanding of exactly how they 
work. Observational studies showing vaccines have heterologous beneficial or deleterious 
effects on disease susceptibility, dependent on sex, have been controversial, with no 
immunological data to support these epidemiological findings. The live measles vaccine 
(MV) seems to have beneficial protective effects, while diphtheria, tetanus, whole cell 
pertussis (DTwP) vaccine increases disease susceptibility, both effects being more 
prominent in females. These effects are modified when the vaccines are given 
simultaneously.
This thesis describes the results of a randomized trial primarily aimed at studying the 
heterologous effects of MV and DTwP vaccination of 9 month old Gambian infants. 
Assays included multiplex cytokine analysis of culture supernatants, flow cytometric 
intracellular staining, vaccine antibody assays, and whole transcriptome microarray 
analysis.
Measles and DTwP antibodies were not affected by combining vaccines or by gender. 
When DTwP is given with MV, the measles-specific response was skewed away from a 
protective CD8 IFN-y response, while TT responses become more pro-inflammatory 
suggesting that MV has an adjuvant effect on DTwP immunity.
A striking finding was the immunosuppressive effect of DTwP, particularly in females. 
There was a reduction in pro-inflammatory cytokines and reduced IFN-y:IL-10 ratios in 
aCD3/28 cultures, alongside down-regulated interferon response gene pathways, and 
increased innate IL-10 production in DTwP vaccinated females. By contrast, DTwP 
vaccinated males a more pro-inflammatory profile than females with only upregulated 
genes post-vaccination. Males vaccinated with MV+DTwP were less pro-inflammatory
12
than females, and had only down-regulated genes suggesting this combination had 
opposite effects in males and females.
The results provide plausible immunological explanations for the observed beneficial and 
deleterious effects of MV and DTwP respectively. These will now need to be tested in 
carefully designed prospective studies.
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CHAPTER 1 
INTRODUCTION
1.1 Infectious Disease Burden in Infants
According to World Health Organization (WHO) estimates, about 20% of all deaths occur 
in children under 5 year old (WHO) (1996b). In 2011, approximately 7 million children 
under the age of five died, which amounts to about 800 children dying every hour globally 
(Figure 1.1) ((WHO), 2012a). This is a reduction from the 12 million deaths reported for 
1990. The highest under five death rates occurred in the WHO African Region with 106 
deaths per 1000 live births; which is about 8 times higher than that observed in the WHO 
European region (Figure 1.2) ((WHO), 2012a).
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Figure 1.1 Under-five mortality rate for the year 2011.
24
Trend in under-five mortality rate (per 1000 live births) 
Globally and by WHO region, 1980-2011
Update: 13 September 2012
200
£  150
2  100 
S'
50
1980 1985 1990 1995 2000
Year
Source: UNICEF, WHO, The World Bank, UN DESA/Poputation Division. 
Levels and Trends in Child Mortality -  Report 2012. UNICEF, 2012.
Africa 
H Americas
Eastern Mediterranean 
Europe
South-East Asia 
Western Pacific
2005 2010 2015
■  World
®WHO. All right reserved.
Figure 1.2 Global trend in under-five mortality rate fo r the period 1980 - 2011
Deaths in infants aged 1 to 6 months are mostly caused by acute respiratory infections 
(e.g. respiratory syncytial virus (RSV), Bordetella pertussis, Haemophilus influenzae B 
(Hib), Streptococcus pneumoniae or diarrhoeal diseases (e.g. rotaviruses, 
Salmonellaspp., Shigella spp .) (Siegrist, 2007). The major causes of death in infants aged 
1 to 56 months from 2000 to 2011 were due to pneumonia (13%), diarrhoea (9%), non- 
communicable diseases (8%) and other infectious and parasitic diseases accounting for 
13% (Figure 1.3) ((WHO), 2012a).
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Causes of deaths among children under 5 years, 2011
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Figure 1.3 Worldwide causes o f death among children under-five years old for the 
year 2011.
Before the introduction of measles vaccine, measles was the leading cause of death in 
children worldwide. For example, in the western pacific region, measles reported cases 
has declined for 3, 382, 000 in 1974 (pre-immunization) to about 146,750 in 2008 (post­
immunization) ((WHO), 2004).
1.2 Introduction of The Expanded Programme of Immunization (EPI) by WHO
The greatest public health intervention of the twentieth-century was the introduction of The 
Expanded Programme of Immunization (EPI) by the World Health Organization in 1974. 
This has greatly reduced infectious disease burden in children worldwide. Between 1900 
and 1973, the use of available vaccines was largely confined to industrialized countries, 
particularly the higher classes (Clements, 1996). Diphtheria, and whole cell pertussis 
vaccine were introduced in 1923 and 1926 respectively, tetanus toxoid (TT) and BCG in 
1927 while yellow fever vaccine became available in 1935 (Andre, 2003). Other vaccines 
were introduced after the second world war which are still being used today including the
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inactivated and oral polio vaccines introduced in 1955 and 1958 respectively, and the live, 
attenuated measles, mumps and rubella (MMR) vaccine which became available in 1971 
(Andre, 2003). Gradually, these vaccines were made available to developing countries.
Currently, it is recommended that children are all immunized against diphtheria, tetanus, 
pertussis, hepatitis B virus, H. influenzae type b, poliovirus, Streptococcus pneumoniae, 
rotavirus, measles, mumps, rubella, TB and yellow fever in endemic areas ((CDC), 2011; 
(WHO), 2011). EPI was implemented in The Gambia in 1979 where there is consistently 
reported high immunization coverage. Immunization coverage in one year olds was 
reported as above 95% in 2009 for measles, yellow fever and the third dose of DTP, Hib, 
HBV and polio ((WHO)-UNICEF, 2011). The current full routine immunization schedule for 
The Gambia is shown in Table 1.
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Table 1.1 Current EPI vaccine schedule in The Gambia
Timing Vaccinations
Birth BCG, first dose of polio (OPV), first dose of HBV
2, 3 and 4 months DTwP/Hib/HBV combined; third, fourth dose of polio; PCV-13
9 months Measles (MV), yellow fever (YF), fifth dose of polio
16 months DTwP/Hib/HBV combined
18 months Sixth dose polio
Plus vitamin A every 6 months (from 6 months of age till 59 months)
Key
BCG Bacillus Calmette Guerin
OPV Oral polio vaccine
HBV Hepatitis B virus
DTwP Diphtheria, tetanus with whole-cell pertussis combined vaccine
Hib Haemophilis influenza B
VitA Vitamin A
MV Measles Vaccine
YF Yellow Fever
PCV-13 Pneumococcal conjugate vaccine
Adapted from (Payne et al., 2013).
DTwP/Hib/HBV vaccine is a Pentavalent vaccine
1.3 The Value of Infant Vaccination
Vaccination has been a key player in reducing morbidity and mortality caused by 
infectious agents. Vaccines work by presenting pathogen antigens to the immune system, 
which responds by evoking an immune response that eliminates the effects of an 
infectious pathogen or a disease process. The antigenic material can either be live 
attenuated pathogens, killed or inactivated forms of these pathogens, or purified or 
recombinant material such as proteins (Olesen et al., 2009). The aim of vaccination is the 
induction of long-lasting protective immune memory that is able to respond quickly upon 
infection with the vaccine specific pathogens. This effect is elicited by the adaptive arm of
28
the immune system. The innate arm of the immune system is also activated by vaccines 
and is characterized by limited specificity, but is now thought to influence the magnitude, 
quality and duration of the adaptive responses (Palm and Medzhitov, 2009). Antibody 
levels may persist for many years following immunization of adults and older children, but 
levels wane more rapidly after infant immunization. The mechanisms behind the 
persistence of antibody are not well understood (Crotty et al., 2003; Kelly et al., 2005; 
Amanna et al., 2007).
Success stories of vaccination include the eradication of smallpox from the world, the 
almost complete elimination of poliomyelitis, and a decrease of more than 95% in the 
incidence of diseases such as diphtheria, tetanus, pertussis, measles, mumps and rubella 
(Rappuoli et al., 2002).
The current challenge for neonatal vaccination is to develop, and promote at a global 
level, vaccines that can be safely administered soon after birth and are effective after one 
or two early doses. This is a difficult task given the immaturity of the immune system in 
early life (Siegrist, 2001).
Many notable, highly effective vaccines have been designed empirically, with limited 
understanding of how and why they work. The recommended schedule is based on 
studies of sero-conversion and protection, and on assumed feasibility of the schedule 
(Ramsay et al., 1993). There is therefore a need to understand how commonly used 
childhood vaccines work and how the immune system responds to them more generally. 
This is the subject of this thesis and will become of increasing importance as vaccine 
preventable diseases decline and newer generation vaccines are introduced.
1.4 The Immune System
There are two main branches of immunity; the innate immune system, which is non­
specific, and the adaptive immune system, which has specificity (Reviewed in (Kaufmann
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and Kabelitz, 2010)). Innate immune elements include phagocytic cells (neutrophils, 
monocytes, macrophages), granulocytes that release inflammatory mediators (basophils, 
mast cells and eosinophils), natural killer (NK) cells, NK T cells, dendritic cells, 
complement, cytokines, and acute phase proteins (Figure 1.4). These function as the first 
line of defense against foreign antigen (Delves and Roitt, 2000). The adaptive immune 
response involves antigen-specific reactions mediated through T and B lymphocytes.
The innate immune response is rapid and immediate while the adaptive immune response 
evolves more slowly (days or weeks). Adaptive immunity has memory and remembers 
past encounters with a pathogen and hence the response to subsequent encounters is 
stronger and more rapid than the initial response (Delves and Roitt, 2000). There is 
increasing evidence that the various components of the innate immune system exhibit 
memory characteristics, despite initial assumptions that innate immunity was a fixed entity 
with no memory (Netea et al., 2011).
1.4.1 Innate Immunity
Innate immunity evolved earlier than the adaptive immune system and is mediated by 
cells such as macrophages, NK cells and dendritic cells (DC) (Wan and Flavell, 2009). 
Dendritic cells (includes the interdigitating dendritic cells of lymph nodes, veiled cells in 
the blood, and Langerhan’s cells in the skin) are professional cells and act as antigen 
presenting cells (APCs) upon activation. They possess pattern recognition receptors 
(PRRs), which include the Toll-like receptors (TLRs), on their surface that recognize 
specific pathogen-associated molecular patterns (PAMPs) on the surface of the pathogen 
(Figure 1.4) (Medzhitov and Janeway Jr, 1997; Parkin and Cohen, 2001; Mills, 2004).
Research during the past 10 years has identified a major role for the innate immune 
system in programming protective immune responses to vaccines and adjuvants via 
different innate signals such as Toll-like receptors (Pulendran and Ahmed, 2011). The 
innate immune system can instruct the adaptive immune response (Janeway and
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Medzhitov, 2002). The neonate possesses a functionally distinct innate immune system, 
including a bias against Th1-cell-polarizing cytokines, thus contributing to a distinct pattern 
of neonatal adaptive immune responses (Levy, 2007; Kollmann et al., 2012).
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Figure 1.4 Innate immune effector cells, including macrophages, dendritic cells (DCs), 
neutrophils and natural killer (NK) cells (not shown), together with various protein 
components o f the complement system; provide the first line o f defense against invading 
microorganisms. Mills K.H. G. et al. 2004
1.4.1.1 Natural Killer cells
Natural killer (NK) cells are large granular lymphocytes of the innate immune system. NK 
cells develop in the bone marrow from the common progenitor cell and circulate in the 
blood. NK cells are innate immune effectors that, by cytokine production or cytotoxicity, 
help to contain an infection until an effective adaptive response is mounted. They are 
distinct from T and B cells in that they are controlled by a limited repertoire of germ line-
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encoded receptors that do not undergo somatic recombination (Lanier, 2005). They were 
later recognized as a separate lymphocyte lineage, with both cytotoxicity and cytokine- 
producing effector functions. These cells constitute the third major lymphocyte subset and 
represent approximately 10-15% of circulating lymphocytes in blood. NK cells play an 
important role in host immunity because they have the ability to quickly mediate cellular 
cytotoxicity against pathogen-infected or malignantly transformed cells and to produce a 
wide variety of chemokines and cytokines that influence other cellular compartments of 
the immune system. They have a limited life-span in-vivo and hence must be continually 
replenished to maintain homeostasis (Yokoyama et al., 2004).
NK cells have a multitude of inhibitory and activating receptors that engage MHC class I 
molecules, MHC class I—like molecules, and molecules unrelated to MHC. NK cells are 
restricted in what target cells they can engage by the expression of the target’s MHC 
ligands, but in a very complex fashion that remains incompletely understood (Ljunggren 
and Karre, 1990). CD8 T cells and NK cells complement each other in that they both have 
a role in target recognition and host defense, and their similar mechanisms of cytolysis, 
suggesting that these 2 cell types may have each evolved from a common ancestral 
cytolytic effector cell (Sun and Lanier, 2011). The killing mechanism uses direct 
exocytosis of secretory lysosomes that contain lytic proteins such as perforin, granzymes, 
and Fas ligand (Trapani and Smyth, 2002; Bossi and Griffiths, 2005). NK cells may 
instruct and shape adaptive immune responses through the release of cytokines (Biron et 
al., 1999; Shi et al., 2000) or by direct interaction with dendritic cells (Munz et al., 2005; 
Zitvogel et al., 2006).
1.4.1.2 Natural Killer cell Receptors
The cell surface phenotyping most commonly used for defining human NK cells within the 
lymphocyte gate on the flow cytometric analyzer shows an absence of CD3 (thereby 
excluding T cells and NKT cells which express CD3 on their surface) and expression of 
CD56 (Trinchieri, 1989), the 140-kDa isoform of neural cell adhesion molecule (NCAM)
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found on NK cells and a minority of T cells (Ritz et al., 1988; Lanier et al., 1989). NK cells 
may also express CD44, CD11a and CD16 on their surfacel (Cooper et al., 2001; Lima et 
al., 2002).
1.5 Adaptive Immunity
Adaptive immunity evolved after innate immunity and is mediated by T cells and B cells 
(Wan and Flavell, 2009) in order to enhance pathogen eradication by providing antigen 
specificity and memory onto pre-existing innate immunity. Adaptive immunity is defined by 
the antigen-driven differentiation of clonally restricted lymphocyte precursors into effector 
cells with enhanced functional potential (Wan and Flavell, 2009). The adaptive arm of the 
immune system is divided into B cell and T cell compartments. The B cell functions can be 
further divided into different functional and memory populations and also according to the 
secretion of different classes of antibodies. CD4 and CD8 T cells have different effector 
functions and can be identified by the co-expression of the cell-surface protein CD3, with 
either CD4 or CD8 respectively. CD4 is expressed on the surface of a variety of T cell 
subsets with diverse functions (Th1, Th2, Th9, Th17, Th22, Tregs). CD4 T cells recognize 
peptide in association with MHC class II molecules (Kenneth et al., 2008). CD8 is 
expressed by cytotoxic T-cells and this cell type can act against viruses and other 
intracellular pathogens via specific recognition of peptides bound to MHC class I 
molecules on the surface of the infected cells by their T cell receptors (TCRs). This leads 
to apoptosis and killing of target cell or release of cytokines with antiviral properties that 
subsequently lead to viral clearance (Whitton and Fujinami, 2001). Apart from their 
antiviral activities, CD8+ T cells also have the ability to protect against intracellular 
bacteria and tumours (Best et al., 2013).
1.5.1 B cells
B cells develop in the bone marrow from progenitor cells and reside in the marrow for the 
entire length of their development. Antigen-specific receptors, the B cell receptors (BCRs), 
are formed by gene rearrangement and recombination events, which are important for
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generating a diverse repertoire of the BCR (Parkin and Cohen, 2001). These B cells 
constitute about 15% of all cells circulating in peripheral blood and their main function is 
the production of immunoglobulins (Chaplin, 2010). B cells produce five immunoglobulin 
(Ig) classes, namely, IgM, IgD, IgG, IgA and IgE. These antibodies have various functions 
such as neutralizing (toxin) effects, binding to mucosal surfaces and hence preventing 
organisms from binding to the surface, activation of complement, opsonization of bacteria 
for phagocytosis, and sensitization of tumor and infected cells for antibody-dependant 
cellular cytotoxicity (ADCC) and subsequent killing (Kaufmann and Kabelitz, 2010). 
Antibodies therefore augment elements of the innate immune system.
1.5.1.1 Antibody Classes
When an antigen binds to a B cell receptor (BCR) on the surface of the B cell, the cell 
proliferates and differentiates into a plasma cell. The plasma cell is the effector form of B 
lymphocytes and produces antibodies, which are a secreted form of the BCR and have 
identical antigen specificity. Antibodies are immunoglobulins (Ig). There are five different 
classes of immunoglobulins, IgM, IgD, IgG, IgA and IgE. They can be distinguished by 
their C-region. In humans, IgG can be divided into four subclasses namely lgG1, lgG2, 
lgG3 and lgG4, and IgA antibodies have two subclasses called lgA1 and lgA2. The IgG 
subclasses are named in order of their abundance in serum with lgG1 being the most 
abundant (Kenneth et al., 2008). The abundance of antibodies is variable depending on 
the site, for example, IgM is more abundant in the vascular system while IgG is the 
predominant antibody found in blood and tissues, and IgA predominates in the mucous 
membranes of the respiratory and gastrointestinal tracts (Parkin and Cohen, 2001).
1.5.1.2 Role of Neutralizing Antibodies in vaccination
The hallmark of an effective vaccine response is regarded as the presence of persisting 
antibodies following vaccination. The antibody response is the first line of the adaptive 
memory component of host defense against infection (Siegrist, 2008; Plotkin, 2010). The 
EPI vaccines can induce defined protective serum antibody titres which can be measured
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by an enzyme-linked immunosorbent assay (ELISA), or by haemagglutination or 
neutralization assays, and these serve as markers of vaccine efficacy (Plotkin, 2010). 
Antibodies can neutralize viruses that infect humans or animals in a number of ways. For 
example, they may interfere with virion binding to receptors, block virus uptake into cells, 
prevent uncoating of the viral genome in endosomes, or cause aggregation of virus 
particles (McLain et al., 1995; Parren and Burton, 2001). Furthermore, induction of lysis of 
enveloped viruses can occur when antiviral antibodies and serum complement disrupt 
membranes (Burton, 2002).
1.5.1.3 Development of immunity in early life
The foetal immune system is Th2 skewed, most likely as a strategy to avoid triggering an 
alloimmune Th1-type responses to maternal tissues that might lead to premature birth or 
spontaneous abortion (Philbin and Levy, 2009). At birth, babies are no longer protected by 
the sterile environment of the womb and are exposed to foreign antigens in the outside 
environment, for example in the air they breath and on their skin. The neonatal immune 
system is therefore required to develop protective mechanisms to combat these 
challenges.
Newborns rely heavily on their innate immune system for protection when they first 
encounter foreign antigens (Adkins et al., 2004). Neonatal monocytes and antigen 
presenting cells (APCs) have reduced capability in producing Th1 cytokines such as TNF- 
a and IFN-y upon antigenic stimulation. Both of these cytokines are important for 
protection against intracellular pathogens and are important for the development of the 
subsequent adaptive immune system. This reduced response however is dependent on 
the type of antigenic stimuli; some of which can induce neonatal APCs adequately 
(Reviewed in (Burl et al., 2011)). The Burl study found reduced Th1 polarizing cytokine 
responses in cord blood, with the highest response obtained with TLR8 agonist 
stimulation at birth. In the same study, proinflammatory cytokine responses were 
enhanced by 1 month of age and were more pronounced in response to TLR4, -5 and -8
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agonists, but this changed with time up to the 1 year of age (Burl et al., 2011 ).These TLRs 
are well developed and fully functional in newborns. In healthy infants, TLR expression 
and signaling up to the first 5 years of life is similar to adult levels in mononuclear cells 
(Kollmann et al., 2012). The immune system of term infants is intrinsically Th2 skewed, 
have high levels of the anti-inflammatory cytokine IL-10, and the Th17 supporting 
cytokines IL-6 and IL-23. They then rapidly acquire antiviral (IFN-a) and pro-inflammatory 
(TNF-a, IL-13) innate responses as the IL-10, IL-6 and IL-23 responses wane (Angelone 
et al., 2006; Kollmann et al., 2012). IL-6 is believed to provide protection at birth by 
inducing an acute, initial response against bacterial infections and gets rid of microbial 
products and PRR agonists (Angelone et al., 2006).
1.5.1.4 Development of the B cell response in early life
It has long been established that infants do not mount adequate antibody responses to 
polysaccharide vaccines against Streptococcus pneumoniae, Haemophilus influenzae, 
Neisseria meningitidis. Indeed, at birth the infant is better able to respond to protein 
antigens than glycoproteins and polysaccharides (Glezen, 2001). Induction of humoral 
responses to vaccines is initiated in the germinal centre of lymphoid follicles by follicular 
dendritic cells (FDC). FDCs play a central role in the activation of B cell differentiation into 
plasma cells or memory B cells for antibody production (Figure 1.5) (Lambert et al., 2005; 
Amanna et al., 2006). The poor antibody response to these antigens has been attributed 
to a delayed maturity of germinal centres in human neonates since the number of mature 
germinal centres increases with age of the infant with germinal centres first becoming 
apparent about 4 months after birth (Pihlgren et al., 2003; Adkins et al., 2004; Kruschinski 
et al., 2004).
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Figure 1.5 Model of B-cell differentiation during an antiviral immuneresponse
Following antigenic stimulation, naive B cells undergo clonal expansion and form clusters 
of activated B cells known as extra-follicular foci. These activated B cells can either 
differentiate into short-lived plasma cells, or they can migrate into the follicle and initiate a 
germinal centre reaction. After proliferation and affinity maturation, germinal centre B cells 
produce both short- and long-lived plasma cells that produce high affinity antibodies, and 
memory B cells that have high affinity B-cell receptors (Amanna IJ et al., 2006).
The antibody response to polysaccharide vaccine antigens is T cell-independent and 
takes place in the marginal zone of the spleen. However, infant spleen histological studies 
have revealed that the marginal zone does not reach full development until two years of 
age, probably accounting for the delayed antibody response to these encapsulated 
bacteria (Zemlin et al., 2007). Despite this impaired primary antibody response, some 
neonatal B cells in germinal centers differentiate into memory B cells.
1.5.1.5 Development of the antibody response in early life
Humoral immunity can be acquired in response to a vaccine or any other antigen 
encountered in life. The response on second encounter with the same antigen is larger in 
magnitude and quality, and occurs more rapidly than during the primary encounter; this is 
the basis for the success of vaccination (Murphy et al. (2008). IgM is the first antibody 
secreted after encountering an antigen, followed by IgG, IgA or IgE after class switching 
(Pan-Hammarstrom et al., 2007). In utero infants make some immature low affinity IgM 
but at birth it is maternally derived IgG that dominates in the neonate. As IgM levels rise
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on antigen encounter and maternal IgG levels decline, infant derived IgM becomes the 
dominant antibody at about 3 months of age (Reviewed in (Ygberg and Nilsson, 2012)).
1.5.1.6 Maternal antibodies and inhibition of infant vaccine antibody responses
Newborn infants transplacentally acquire IgG antibodies from their mothers that are 
important for protection against infections that occur in the first months of life. There is 
variability in both the level and rate of waning of maternally acquired antibodies (MAbs). 
The antibody levels wane over the first 6 months of life and are usually gone by 1 year of 
age. lgG1 isotype is the most efficiently transferred transplacentally to the foetus followed 
by lgG4, lgG3 and lgG2 (Reviewed in (Palmeira et al., 2012). For example, the main 
antibody subclass that protects against encapsulated bacteria such as H. influenzae b is 
lgG2. Since lgG2 is rarely transported across the placenta to the fetus, newborns are not 
protected from this pathogens until 4 - 5  months of age when they start to develop their 
own antibodies. The other immunoglobulin subclasses including IgM are unable to cross 
the maternal-placenta interface and therefore any present at birth is derived from the 
infant.
Human breast milk is also a good source of protective maternal antibodies for the 
neonate. It contains a high concentration of secretory IgA and IgG together with cytokines, 
antibacterial peptides and other immune cells (Brandtzaeg, 2008).
In addition to protecting against infections, maternal IgG antibodies also affect the infant’s 
response to immunizations. Thus MAb is thought to be capable of inhibiting infant vaccine 
responses, as initially described for the live measles vaccine (Albrecht et al., 1977) and 
oral poliomyelitis vaccine (Perkins et al., 1959). Inhibition has also been reported for non- 
live vaccines such as pertussis (Burstyn et al., 1983; Englund et al., 1995), tetanus and 
diphtheria toxoids (Claesson et al., 1989; Bjorkholm et al., 1995), Hib conjugate vaccine 
(Claesson et al., 1989; Daum et al., 1991) and hepatitis A vaccine (Kanra et al., 2000). 
However it should be borne in mind that other studies reported no influence of MAb on
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responses to the same vaccines (Gans et al., 1998; Siegrist et al., 1998a; Siegrist et al., 
1998b; Gans et al., 1999).
The practice of administering repeated doses of vaccines such as for DTP, polio, Hib or 
pneumococcal vaccines, is often sufficient to overcome the inhibition by MAbs (Sarvas et 
al., 1992). The titre of MAb present at the time of immunization is the main determinant of 
the MAb-mediated inhibition of antibody responses in neonatal mice and humans 
(Markowitz et al., 1996; Gans et al., 1998; Siegrist et al., 1998a; Siegrist et al., 1998b; 
Gans et al., 1999). The hypothesis for MAb inhibition is that introduction of vaccine 
antigen into an infant with pre-existing passive antibodies results in the formation of 
antigen-antibody complexes. MAbs bind to specific B-cell vaccine epitopes, preventing 
infant B cells from having access to such epitopes; the importance of this inhibitory 
influence depends upon the vaccine antigen I MAb ratio (Siegrist, 2003).
Recommendations for measles immunization have traditionally been based on the age of 
MAb disappearance for the majority of infants (Williams et al., 1995), thus it is given at 9 
months of age in many developing countries including The Gambia, although more 
recently WHO have recommended deferring it to 12 months of age in countries with low 
rates of transmission ((WHO), 2009a). This strategy however, fails to prevent early cases 
of infection, which are often the most severe. In relation to this, a randomized trial by Aaby 
and colleagues found that when the first dose of MV was given at 4.5 months in addition 
to MV at 9 months, there was a 94% vaccine protective efficacy against measles during 
an outbreak, with 100% protection against admission to hospital and death due to 
measles (Martins et al., 2009).
1.5.1.7 Role of humoral immunity in vaccination induced protection
The majority of commonly used childhood vaccines were developed empirically, with the 
intention of inducing protective antibodies. Indeed, almost all available licensed vaccines 
elicit a robust antibody response that correlates with the level of protection elicited by the
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vaccine (Plotkin, 1999; Plotkin, 2001). Neutralization by antibodies can occur on mucosal 
surfaces during replication, in an extracellular state after passaging through the 
bloodstream or in a transient extracellular phase (Plotkin, 1999; Plotkin, 2001).
It was believed in the last years of the 20th century that the cell mediated immune 
response confers protection to intracellular pathogens, while protection against 
extracellular pathogens is dependent on antibody-mediated responses. It is now believed 
that antibody-mediated immunity is also responsible for the protection induced by most 
viral vaccines as well (Moore et al., 2003), with the exception of certain chronic 
intracellular infections, for example Mycobacterium tuberculosis, where a CMI response is 
central to protection.
Humoral immunity has a critical role in protection against measles, which is demonstrated 
by the protection conferred to infants by maternal antibodies acquired through the 
placenta (Albrecht et al., 1977). Neutralizing antibodies are elicited by measles virus 
haemagglutinin and fusion surface glycoproteins, and studies in humans have 
demonstrated that at least 120 mlU/mL of neutralizing antibody are necessary for 
protection (Chen et al., 1990). The proportion of infants who develop protective antibody 
titres when given measles vaccine at 9 months of age is estimated at 85%, while 90%- 
95% will respond when measles vaccine is given at 12 months of age.
1.5.2 T cells
The human thymic epithelium and medulla develop from the third pharyngeal pouch and 
cleft complex. Haematopoietic stems cells start to enter the thymus as early as gestational 
age (GA) 8 weeks. By GA 20 weeks, the thymus is fully developed (Reviewed in (Ygberg 
and Nilsson, 2012)). T cell development in the thymus has already started by GA 1 6 - 2 0  
weeks and T cells begin to enter the blood stream at this time to form the peripheral T cell 
pool. There is a continuous migration of T and B cells as well as monocytes after birth into
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lymphoid tissue with increasing age and with exposure to new antigens (Reviewed in 
(Hoorweg and Cupedo, 2008)).
T cells are classified into specific subpopulations based on the expression of cell surface 
molecules, as mentioned previously. CD4 and CD8 T cells form the majority of T cells. 
Most of these express a T cell receptor (TCR) made up of the a|3 chain heterodimer and 
are referred to as conventional T cells. Other T cell types include those expressing a TCR 
consisting of y and 5 chains called the gamma-delta (y§) T cells and NKT cells.
1.5.2.1 T cell immunity in the newborn
The newborn child has intrinsically Th2 biased immunity and suboptimal APC function 
(IFN-y production) both factors that impact on the success of vaccination (Angelone et al.,
2006), The Th2 bias in the APC response might be due to the fact that TGF-(3, 
progesterone and prostaglandin E2 produced by placental tissues increases Th2 cytokine 
production, as well as the presence of high levels of adenosine (an immunosuppressive 
endogenous purine metabolite) in neonatal plasma (Levy et al., 2006; Levy, 2007). 
Neonatal Tregs behave differently and are found in high concentrations in human foetal 
lymphoid tissues (Michaelsson et al., 2006) and cord blood (Godfrey et al., 2005; Wing et 
al., 2005; Flanagan et al., 2010). Neonatal Tregs may serve to control immunity to self 
antigens but can also limit adaptive responses by suppressing T cell proliferation and IFN- 
y production (Angelone et al., 2006). This suppression can be advantageous in protecting 
the neonates on first exposure to the outside environment, but can also be a disadvantage 
since it may limit responses to infections (Fernandez et al., 2008)and vaccines (Toka et 
al., 2004; Stober et al., 2005).
1.5.2.2 Gamma-delta (y8) T cells
These cell types develop mainly in the thymus and their TCR is formed through 
recombination events of the VDJ gene segments that encode antigen receptors, leading 
to repertoire diversity of the y§ TCR. Cells expressing the y5 TCR are CD3+ T cells and
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constitute 1-10% of the CD3+ T cell population in peripheral blood, lymph nodes and 
spleen (Hayday, 2000; Grant et al., 2002). These cells do not express CD4 or CD8 and 
are therefore referred to double negative T cells. They do not recognize antigen bound to 
MHC-I or MHC-II molecules but rather recognize antigen in the context of the MHC class I 
related-protein CD1. CD1 presents glycolipid components of mycobacteria and other 
bacteria to a subset of y5 T cells (Grant et al., 2002); while another subset recognizes the 
MHC class I chain-related proteins known as MIC (Wu et al., 2002b).
Gamma delta T cells have both innate and adaptive features. For example non-peptide 
molecules from a variety of microorganisms can activate them. Human peripheral blood y5 
T cells express effector functions via secretion of IFN-y, TNF-a and granzymes, and a 
subset of these cells that produce IL-17 are enriched in the dermis and intestinal lamina 
propria (Reviewed in (Vantourout and Hayday, 2013)). Activated yS T cell effector 
functions are therefore similar to ap T cells (Beetz et al., 2008). These cells have the 
ability to lyse infected macrophages thereby containing the dissemination of the infectious 
pathogen (Oliaro et al., 2005) and can also kill many tumor cells (Kabelitz et al., 2004). 
Depending on the physiology of the disease, human activated T cells can produce Th2 
cytokines including IL-4, as has been demonstrated in allergic asthma patients (Spinozzi 
et al., 1995).
Most studies of y5 T cells in early life were done in human neonates. Neonatal y8 T cells 
are highly functional and seem to be conditioned in utero, which give the neonate the 
ability to mount a strong cell mediated immune response in the absence of a mature a(3 T 
cell immunity (Gibbons et al., 2009). Humans are born with high levels of yS T cells but 
these decline with age.
1.5.2.3 CD8 T cell activation and differentiation
Cytotoxic T cells that express the CD8 co-receptor and recognize peptide-MHC class I 
complexes have a key role in clearing intracellular pathogens such as viruses. For
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example, infection with a virus causes naive CD8+ T cells expressing the virus-specific T 
cell receptors (TCRs) to clonally expand and differentiate into effector CD8+ T cells that 
control the primary infection. These effector cytotoxic T lymphocytes (CTLs) can destroy 
virally infected cells through the targeted secretion of perforin and granzymes from lytic 
granules (Kaech and Cui, 2012). Most of these activated CTLs die by apoptosis after 
performing their effector function. However, an effective immune response ensures 
production of a stable population of antigen-specific long-lived memory CD8+ T cells that 
can respond rapidly to clear secondary infections (Joshi and Kaech, 2008; Parish and 
Kaech, 2009; Jenkins and Griffiths, 2010). Besides their cytolytic activity, CD8+ T cells (Tc 
cells) also have a function in the control of activation and differentiation of CD4 T cells 
mediated via secreted cytokines and chemokines, or via cell-cell interaction. CD8 T cells 
therefore display the ability to alter the balance of Th1/Th2 responses in vivo (Holmes et 
al., 1997; Noble etal., 1998).
1.5.2.4 Tc1 and Tc2 CD8+ T cells
CD8+ T cells are further classified into two distinct effector cell types, Tc1 and Tc2 cells, 
on the basis of their cytokine profiles. Tc1 cells characteristically produce type 1 cytokines 
IFN-y, IL-2 and TNF-aand Tc2 cells secrete type 2 cytokines IL-4, IL-5, IL-6, IL-10 and IL- 
13 thus mirroring the Th1 / Th2 dichotomy of CD4+ T cells (Sad et al., 1995). The 
domination of a type 1 or type 2 cytokine response in the Tc cell populations will thus 
dictate the ability to defend against certain pathogens. Both type 1 and 2 cytokines 
secreted by activated CD8+ T cells play important roles in regulating the overall immune 
response and the 2 arms antagonize one another (Xu et al., 2009) which will ultimately 
determine a beneficial or deleterious immune response (Seder, 1995).
IFN-y and IL-12 promote differentiation to Tc1 cells (Sad et al., 1995; Vukmanovic-Stejic 
et al., 2000). Tc1 cells elicit their effector function via the perforin pathway, as 
demonstrated in perforin-deficient mice which lack killing function. IL-12 induces 
expression of the transcription factor T-bet which is necessary for Tc1 differentiation(Sad
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et al., 1995). A considerable amount of IL-4 is required for Tc2 differentiation, and 
inhibiting the action of IFN-y is crucial (Sad et al., 1995). Tc2 cells also possess the ability 
to kill via the perforin pathway, like their counterparts the Tc1 cells. The transcription 
factor GATA-3 is required for Tc2 differentiation and is induced by IL-4 (Sad et al., 1995). 
Several groups have reported the induction of functional Tc1 cells in vivo for example, 
lesions lepromatous leprosy lesions (Salgame et al., 1991) and HIV (Maggi et al., 1994),
1.5.2.5 IL-10 Producing CD8+ T cells
A regulatory role of effector CD8+ T cells in alleviating excessive tissue injury via the 
secretion of the immunosuppressive cytokine IL-10 has also been described (Sun et al., 
2009; Palmer et al., 2010; Trandem et al., 2011). These effector CD8+ T cells have been 
studied in various viral infection models in the lung and brain and have been reported to 
produce large amounts of IL-10 at these local sites of infection, in contrast, CD4+ T cells 
are the main producers of IL-10 in secondary lymphoid organs (Sun et al., 2009; Palmer 
et al., 2010; Trandem et al., 2011). The IL-10+CD8+ population is thought to be a 
transient and reversible state of CD8+ T cell differentiation rather than a separate effector 
lineage, and helps to better balance pathogen clearance with bystander tissue damage. 
Following transfer of IL-10+ and IL-10- effector CD8+ T cells into a coronavirus-induced 
encephalitis model, they differentiate in similar frequencies into IL-10 producing 
populations (Trandem et al., 2011). The key roles of IL-2 and the transcriptional repressor 
(Blimp-1) have been demonstrated in an influenza virus infection model whereby IL-10 
production was dependent on the synergistic cooperation between CD4+ T cell-derived IL- 
2 and innate (mainly neutrophil) derived IL-27. In the same model, the expression Blimp-1 
by CD8+ T cells was required for IL-10 production (Sun and Lanier, 2011) (Figure 1. 6).
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Figure 1.6 Self-control by effector CD8+ T cells in infected peripheral tissues. CD8+
T cells transiently produce IL-10 in a BLIMP-1 dependent manner after receiving 
additional local signals from CD4+ T cell-derived IL-2 and innate cell-derived IL-27. 
Production of IL-1o lead to control of local inflammation and tissue damage.
1.5.2.6 CD4 T helper cell activation and differentiation
Naive CD4 T helper (Th) cells are activated when their T cell receptor (TCR) recognises a 
peptide bound in the groove of major histocompatibility complex (MHC) class II on the 
surface of antigen-presenting cells (APCs). This TCR and MHCII interaction (signal I) is 
required for CD4 T cell activation. The nature of the antigenic stimulus influences Th 
polarization (Constant and Bottomly, 1997; Tao et al., 1997). Studies using altered peptide 
ligands showed that the affinity between TCR and peptide-bound MHCII, that is the 
strength of TCR stimulation, affects lineage commitment (Sloan-Lancaster et al., 1997). 
Naive Th cells divide upon activation giving rise to effector T cells, each specific for the 
peptide-class II MHC complex by which it was activated (Goldsby et al., 2003; Kaiko et 
al., 2007). A second signal, co-stimulation (signal II) that is essential for efficient T cell 
activation is mediated through CD28-B7 and other surface molecules (Freeman et al., 
1993; Schweitzer et al., 1997).
CD4+ T cells can be divided into 6 major subsets, designated Th1, Th2, Th9, Th17, Th22 
and T regulatory cells (Mosmann et al., 2009). Differentiation of naive Th cells into one of
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these subsets occurs within a few days of direct contact with APCs (Lafaille, 1998), the 
type produced being depending on many factors, in particular the antigen type and the 
local cytokine milieu. The different cell types can be distinguished by their unique cytokine 
production profiles and their functions, and also through the expression of different
patterns of cell surface molecules as indicated in Table 1.2 below.
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Figure 1.7 T-helper-cell differentiation.At the initiation of CD4+ T cell activation, the 
antigen presenting dendritic cells secrete a variety of cytokines that instruct the naive T 
cell to activate one of several alternative T helper cell developmental pathways leading to 
Th1, Th2, Th17 or Treg lineage. Each T helper phenotype produces its signature 
cytokines that mediate its distinct immune functions.
Table 1.2 CD4+ T cells subsets, their characteristics and functions
Subset Tx factor Effector molecules Homing receptors Target cells Function
Th1 T-bet IFN-y CXCR3, CCR5 Macrophages Bacteria
Th2 DATA-3 IL-4, IL-5, IL-13 CCR4, CCR3, CRTh2 Eosinophils Parasites
Th17 RORyt IL-17, IL-22, GM-CSF CCR6+CCR4 Neutrophils Bacteria and fungi
Th9 PU.I IL-9 n.d Mast cells Helminthes
Th22 AHR IL-22 CCR4+CCR10 Epithelia Skin protection?
TFH Bcl-6 IL-21 CXCR5 B cells Antibody responses
Treg FoxP3 TGF-p CCR7, CCR6, CCR4 DC/T cells Regulation
Trl n.d IL-10 CX3CR1 T cells Regulation
n.d., not determined.
Trl = T cells with regulatory functions. Adapted from (Zielinski et al., 2011)
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1.5.2.7 Th1 CD4+T cells
The signature cytokine for Th1 cells is interferon (IFN)-y, although they can also produce 
other pro-inflammatory cytokines such as IL-2 and tumor necrosis factor a (TNF-a) (Wan 
and Flavell, 2009; (Zhu et al., 2010a). Th1 cells are required for pro-inflammatory 
responses, migration of effector cells and cytolytic activity by CD8+ T cells (Reviewed in 
(Boyman and Sprent, 2012)). Production of lgG2 antibody by B cells is enhanced by Th1 
cells in humans. IFN-y from these cells has an important role in the control of viral, 
bacterial, fungal, mycobacterial and parasitic infections (Dorman et al., 1999; Sen, 2001). 
Apart from pathogen elimination, the proinflammatory cytokines produced by Th1 cells 
can cause tissue damage, promote inflammatory disease (e.g. inflammatory bowel 
disease) and self-reactivity to antigens (Boyman and Sprent, 2012).
CD4+ T cells in secondary lymphoid organs are the main producers of IL-2. IL-2 has 
autocrine and paracrine effects. It has long been established that CD8+ T cell responses 
require CD4+ T cell help. This help is provided by CD4+ T cells or DCs via their IL-2 
paracrine signaling, but it has recently been shown that antigen-specific CD8+ T cells rely 
more on autocrine signals from the IL-2 that they produce rather than that produced by 
CD4+ T cells (Feau et al., 2011). Differences in the types of cytokines produced by 
individual Th1 CD4 T cells have implications on their capacity to mediate effector 
functions or become sustained as memory cells or both. In this regard, CD4+ T cells that 
secrete only IFN-y have a limited capacity to develop into memory cells compared with IL- 
2 or IL-2 and IFN-y producing CD4 T cells (Hayashi et al., 2002; Wu et al., 2002a; Younes 
et al., 2003). This implies that, for example, vaccines eliciting a high frequency of single­
positive IFN-y producing cells may be limited in their ability to provide durable protection.
An adequate CD4 Th1 response is critical to protect hosts from intracellular bacteria such 
as Mycobacterium tuberculosis, Mycobacterium avium (Kobayashi et al., 1997), 
Salmonella typhimurium (Mastroeni et al., 1999) and Listeria monocytogenes (Buchmeier 
and Schreiber, 1985); and also viruses such as herpes simplex virus (HSV) (Fujioka et al.,
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1999), influenza A virus (Sareneva et al., 1998) and vaccinia virus (Tanaka-Kataoka et al.,
1999). In addition to the beneficial effects of clearing foreign pathogens, the Th1 CD4 
response also plays a role in tumour immunity (Micallef et al., 1997).
1.5.2.8 Th2 CD4+ T cells
Th2 signature cytokines include IL-4, IL-5, IL-13 (Zhu et al., 2010a) and IL-10 (Wan and 
Flavell, 2009). In addition, they also produce IL-9 and IL-25 (IL-17E) (Paul and Zhu, 
2010). These cells were initially thought to be unable to produce IL-2, but results from 
later studies indicated that Th2 cells could often produce modest amounts of IL-2 (Zhu et 
al., 2010a). Th2 cells promote lgG1 and IgE class-switching and eosinophil recruitment 
(Arthur and Mason, 1986; Coffman and Carty, 1986; Mosmann et al., 1986) through the 
production of IL-4. IgE forms immune complexes by cross-linking the high affinity Fc 
receptors on the surface of cells of the innate immune system such as basophils and mast 
cells leading to their degranulation and Th2-type effector functions. These granules 
contain cytokines, chemokines, histamine, heparin, serotonin and proteases, the release 
of which cause smooth muscle constriction, increased vascular permeability and 
inflammatory cell recruitment (Paul and Zhu, 2010). Unlike the Th1 response, the Th2 
response is often associated with robust antibody responses during which high levels of 
pathogen-specific immunoglobulin are generated to neutralize foreign organisms.
The Th2 response is key to resisting extracellular forms of pathogens, such as helminths 
and nematodes (Finkelman et al., 1991; Sher and Coffman, 1992). Th2 cells also play a 
vital role in mucosal immunity (Lai and Rogers, 2010). Similar to Th1 responses, an over- 
exuberant Th2 response can lead to pathological changes in the host. Chronic 
inflammatory airway diseases, such as atopic asthma and allergy, characterized by local 
infiltration with allergen-specific CD4 T cells and eosinophils, are attributed to over- 
exuberant Th2 immunity (Wierenga et al., 1990; Kay, 1991; Parronchi et al., 1991).
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1.5.2.9 Th17CD4+T cells
Th17 cells are an effector subset of CD4+ T cells (Boyton and Altmann, 2002). Upon 
activation, Th17 cells produce IL-17A, IL-17F, and IL-22, and have important functions in 
the clearance of extracellular bacteria and fungi, predominantly at mucosal surfaces. 
Retinoid-related orphan receptor (ROR)yt is a transcription factor induced by TGF-(3 that is 
required for Th17 cell differentiation. RORyt is not entirely induced by TGF-p alone, but in 
conjunction with the proinflammatory cytokines IL-6, IL-21 and IL-23, which are all 
essential for activation of phosphorylation of the transcription factor STAT3 (Chen et al.,
2007). Naive T cells in the presence of TGF-3 and other proinflammatory cytokines can 
differentiate into Th17 cells (Veldhoen et al., 2006). By contrast, naive T cells in the 
presence of TGF-p and absence of IL-6, they differentiate into induced Tregs (iTregs) 
(Bettelli et al., 2006). This would suggest that both cell types (Th17 and Tregs) can 
originate from the same precursor T cell which is dependent on the cytokine milieu 
(Bettelli et al., 2006).
A number of other cell types also produce similar cytokines to Th17 cells, namely y5 T 
cells, NK cells, NKT cells, and lymphoid tissue inducer (LTi) cells (Reviewed in (Gaffen, 
2009)). Th17 cells function mainly at mucosal surfaces and can initiate proinflammatory 
danger signals that lead to enhanced neutrophil migration and production of antimicrobial 
proteins. Th17 cells also promote inflammatory pathology in many autoimmune diseases. 
Th17 cells have been implicated in vaccine-induced immunity and immunotherapy 
(Reviewed in (Khader et al., 2009)). In a study by Higgins et al, IL-17 contributed to 
vaccine-induced protective immunity against B. pertussis. In their study, administration of 
whole-cell pertussis vaccine resulted in induction of Th17 cells and when they neutralized 
IL-17, they observed a reduction in protection after pulmonary challenge with B. pertussis 
(Higgins et al., 2006a). Immunization of mice with whole cell pertussis (wP) vaccine 
induced Th1 and Th17 responses, but further studies in IFN-y deficient mice revealed a 
dominant role of Th1 cells in mediating vaccine induced protection (Ross et al., 2013). In 
contrast, the same study revealed that immunization of mice with acellular pertussis (aP)
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vaccine resulted in the induction of Th2 and Th17 cells but not Th1 cells; this induction of 
Th17 responses to aP has not yet been fully studied in humans (Ross et al., 2013). Banus 
S et al. reported similar findings in mice infected with B. pertussis with wP stimulating a 
mixed Th1/Th17 cytokine profile but this was not the case with aP vaccine (Banus et al., 
2008). Therefore, IL-17 appears to be a major modulator of the memory response 
generating strong protection in response to wP immunization, which is not observed in aP 
immunization. Incorporation of IL-17 in aP vaccines to improve efficacy by skewing the 
response to a dominant Th1/Th17 mixed profile is currently an attractive option (Poland, 
2012).
1.5.2.10 CD4+ regulatory T cells (Tregs)
The primary role of Tregs is the modulation of immune responses. Tregs are broadly 
classified into two groups; natural Tregs (nTregs) and induced or adaptive Tregs (iTregs). 
nTregs develop in the thymus and are characterized by the expression of CD4 and CD25 
molecules on their surface and by expression of forkhead box transcription factor P3 
(FOXP3) in the nucleus that is crucial for their development (Sakaguchi S et al. 2006). 
They produce the cytokines TGF-|3 and IL-10, which switch off or inhibit pro-inflammatory 
immune responses. This mechanism counteracts the inflammatory component of an 
immune response and thus avoids harm to the host (Sakaguchi, 2006; Kaufmann and 
Kabelitz, 2010).
There are currently two known main pathways for the generation of Tregs. The majority of 
Tregs are generated in the thymus during T cell maturation upon high avidity recognition 
of self-antigens and express FOXP3, called thymus-derived Tregs (also called natural 
Tregs) (Bluestone and Abbas, 2003). These cells express cell surface CD25 (IL-2Ra) and 
co-inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA4) on their surface as well 
as in the cytoplasm (Sakaguchi et al., 2008).
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The second pathway involves generation of Tregs in the periphery, upon encounter of a 
mature naive CD4+T cell with persistent self-antigen. These peripherally derived Treg 
cells have also been called adaptive or induced Treg (iTreg)) cells (Sakaguchi et al.,
2008). There is a subset or iTreg that are FOXP3+ and indistinguishable from nTregs. The 
CD8 Tregs and Tr1 and Th3 are all FOXP3 negative. The iTreg cells are of three main 
types, namely, CD8+ regulatory T cells from activated naive CD8+CD25- T cells; and Th3 
and Tr1 cells differentiated from activated naive CD4+CD25- T cells (Mills, 2004). T 
regulatory 1 cells produce high amounts of IL-10 with no or low levels of IFN-y and no IL- 
4; on the other hand T helper 3 cells (Th3) secrete high amounts of TGF-J3 (Figure 1.8) 
(Mills, 2004). CD8 T are regarded as cytotoxic cells that produce IFN-y, but these cells or 
a subtype of them have recently been described as IL-10 producers hence the name 
regulatory CD8+ T cells (Figure 1.8) (Mills, 2004). A study in mice by Gratz and 
colleagues have revealed the life history of both thymic and peripherally derived Tregs 
and that they have similar steps of differentiation from naive to effector to memory (Gratz 
et al., 2013).
CD4+ CD25+ FOXP3+ 
Tfieg cell
Antigen 
(foreign or self)
CD8+ regulatory T cell
Thymus
Antigen 
(foreign or sett)
Tn1 cell
Nature Reviews | immunology
Mills K.H.G. 2004: (4) 841-855
Figure 1.8 Differentiation of Treg celis.Natural regulatory T cells express the cell- 
surface marker CD25 and the transcriptional repressor FOXP3 (forkhead box P3). Other 
populations of antigen-specific regulatory T cells can be induced from naive CD4*CD25' or 
CD8+CD25~ T cells in the periphery under the influence of semi-mature dendritic cells, 
interleukin-10 (IL-10), transforming growth factor-/3(TGF-(S) and possibly interferon-a (IFN- 
a).
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1.5.2.11 Transcription factors are critical regulators of Th cell differentiation
Transcription factors are critical for CD4 T cell differentiation and cytokine production. At 
least two types of transcription factors are required for cell fate determination in each 
lineage, the master regulators and the signal transducer and activator of transcription 
(STAT) proteins (Figure 1.9).
Tbet 
STAT 4
IL-12
( RORyT >  IL-17IL-27
IL-6
Foxp3
Figure 1.9 T-helper cell differentiation and regulation. Green arrows indicate up- 
regulation, while red lines indicate inhibition. Transcription factors for particular lineages 
are placed in the nucleus (Steinman, 2007).
Some STAT proteins mediate induction of the expression of master regulators. The 
STATs and master regulators often work synergistically in regulating cytokine production 
by directly acting on cytokine genes. The essential transcription factors of Th lineages are 
T-bet/STAT4 (Th1), GATA-3/STAT5 (Th2), RORyt/STAT3 (Th17), and FOXP3/STAT5 
(iTreg) (Zhu and Paul, 2010).
The activation, differentiation, and expansion of Th cells are regulated by the activity and 
relative expression of specific transcription factors. In an ideal situation, the immune 
response should be sufficient to clear pathogens but controlled to prevent collateral 
damage. An inappropriate regulation may lead to chronic infection, whereas an 
uncontrolled response can lead to extensive self-tissue damage. An undesirable activation
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of Th1, Th17, or Th2 cells can also result in organ-specific autoimmune diseases (Th1, 
Th17) or allergic inflammatory diseases and asthma (Th2). Therefore, understanding the 
networks of cytokines and transcription factors produced during CD4+ T-cell differentiation 
is critical for diagnosis and treatment of many immune-related human diseases (Zhu and 
Paul, 2010).
1.5.2.12 Memory T cell responses after vaccination
The ultimate goal of a vaccine is to develop long-lived immunological protection, whereby 
previous encounter with a pathogen is ‘remembered’, and either completely prevents re­
infection or reduces the severity of the disease. This is called immunological memory.
Memory responses result from the clonal expansion and differentiation of antigen-specific 
lymphocytes that may persist for a lifetime. It is suggested that immediate protective 
memory is mediated by effector memory cells ( T Em) that migrate to inflamed peripheral 
tissues and display immediate effector function (Bautista-Lopez et al., 2000; Lanzavecchia 
and Sallusto, 2000). By contrast, longer-term recall responses are thought to be mediated 
by central memory T cells (Tcm) that reside in lymph nodes (LN) and circulate at low 
frequencies in the peripheral circulation. These T Cm have little or no effector function, but 
readily proliferate and differentiate to effector T cells upon antigenic stimulation (Campbell 
et al., 1998; Potsch et al., 1999; Romero et al., 2007). Human T Cm are CD45R0+ memory 
cells that constitutively express cell surface CCR7 and CD62L. These two receptors are 
also expressed by naive T cells and are required for entry through high endothelial 
venules and migration to T cell areas of secondary lymphoid organs (Campbell et al., 
1998; Forster et al., 1999; Romero et al., 2007). T Cm have higher sensitivity to antigenic 
stimulation than naive T cells, are less dependent on co-stimulation, and up-regulate 
CD40L to a greater extent, hence providing more effective stimulatory feedback to 
dendritic cells and B cells. Upon TCR stimulation, T Cm produce mainly IL-2, but efficiently 
differentiate to effector cells after proliferation to produce large amounts of effector 
cytokines (Figure 1.10) (Sallusto et al., 2004; Romero et al., 2007).
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Human T Em are memory cells that have lost the constitutive expression of CCR7, are 
heterogeneous for CD62L expression (Tripp et al., 1995; Sallusto et al., 2004; Romero et 
al., 2007), and display chemokine receptors and adhesion molecules that are required for 
homing to inflamed tissues (Figure 1.10) (Potsch et al., 1999; Xie et al., 1999; Romero et 
al., 2007). In contrast to T Cm, T Em are characterized by rapid effector function. Some TEM 
lose their surface CD45RO and regain CD45RA expression. These have been called 
Tem ra cells, and have been shown to have significant effector function, for example CD8 
Tem ra carry high amounts of intracellular perforin (Baars et al., 2000; Sallusto et al., 2004).
Naive CIM' 
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Figure 1.10 Models for effector and memory Tcell differentiation.
(a)CD4+ Tcell differentiation can be modeled as a linear process, in which cells 
progressively gain functionality with further differentiation, until they reach the stage that is 
optimized for their effector function (such as the production of interleukin2 (IL2), 
interferon-y (IFN-y) and tumour-necrosis factor-a (TNF-a)). (b) Following stimulation, naive 
CD8+ T cells fully differentiate into activated effector CD8+ T cells that secrete IFN-y, 
most with cytolytic activity. Two models for the generation of CD8+ central memory T cells 
(Tcm  cells) and CD8+ effector memory T cells ( T Em cells) are depicted by colour (‘linear 
differentiation’ is shown with black dotted arrows; ‘fixed lineage’ with red dotted arrows; 
and black arrows depict transitions for both models). Adapted from Seder RA et al. Nat 
Rev Immunol. 2008; 8(4): 247-58.
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Understanding the memory T cell response to vaccines is key to designing new and better 
vaccines and has been well studied in BCG vaccinated humans. In a tetanus toxoid (TT) 
model of re-immunization of TT-immune adults, Cellerai et al. have shown that there was 
high expression of IL-7Ra and Bcl-2 prior to TT re-immunization, resembling central 
memory T cells and with production of IL-2 but not IFN-y ex-vivo. However, 5 to 15 days 
post vaccination with TT, a large proportion of the CD4+ T cells acquired the ability to 
produce IFN-y, began to proliferate and down-regulated IL-7RA and Bcl-2. In contrast to 
this, 60 days and more post vaccination, TT-specific CD4+ T cells were more of the IL- 
7RAhigh and Bcl-2high phenotype (Cellerai et al., 2007). Memory T cell responses in B. 
perfryss/'s-vaccinated pre-adolescent children demonstrated memory T cells specific to B. 
pertussis many years after vaccination. The authors found IFN-y and TNF-a producing 
cells were detected in 65% and 53% of the children respectively. Majority of the antigen- 
specific cells were CD45RA‘CCR7' T Em cells whether defined by proliferation or cytokine 
production. Furthermore, the proliferative capacity of wP vaccinated children was higher 
than in aP vaccinated children although a longer time had elapsed for the wP vaccination 
than aP. The number of children that had detectable cytokine response was greater in the 
wP group than in the aP group (Smits et al., 2013).
1.6 Measles vaccine
Measles, also known as Rubeola, is an infection of the respiratory system caused by a 
virus, specifically a paramyxovirus of the genus Morbillivirus. Morbilliviruses, like other 
paramyxoviruses, are enveloped, single-stranded, negative-sense RNA viruses. The 
measles virus genome is made up of 8 proteins that include haemagglutinin (H) and 
fusion (F) proteins. Neutralizing antibodies provide lifelong protection against the H protein 
after infection (de Swart et al., 2005). The measles virus normally grows in the cells that 
line the back of the throat and lungs. A high fever persists for 2 or 3 days after contracting 
the virus (Orenstein et al., 2004). Coughing, sneezing, close personal contact or direct 
contact with infected nasal or throat secretions spreads the virus from person to person. 
Measles is still common in many developing countries -  particularly in parts of Africa and
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Asia, and is increasing in developed countries such as the UK due to reduction in 
vaccination of infants ((WHO), 2012b). More than 20 million people are infected with 
measles each year and it remains one of the leading causes of death among young 
children globally, despite the availability of a safe and effective vaccine. Measles vaccine 
was first introduced in the 1960s and has a successful and an impressive record of safety 
and effectiveness. From 2001 to 2011 more than one billion children aged 9 months to 14 
years who live in high-risk countries were vaccinated against the disease. Global measles 
deaths have decreased by 74% from 535,300 in 2000 to 139,300 in 2010 ((WHO), 
2012b). The fourth Millennium Development Goal (MDG 4) aims to reduce the under-five 
mortality rate by two-thirds between 1990 and 2015, and reductions in measles deaths will 
make a major contribution to this aim ((WHO), 2012b).
Measles vaccine contains live, attenuated measles virus. It is available as a single-antigen 
preparation and in combination formulations, such as measles-rubella (MR), measles- 
mumps-rubella (MMR), and measles-mumps rubella- varicella (MMRV) vaccines. Measles 
vaccine is given subcutaneously or intramuscularly as a single or combined antigen, in a 
dose of 0.5ml. A single dose of measles-containing vaccine administered in the second 
year of life induces immunity in about 95% of vaccinees (King et al., 1991), and 
approximately 95% of persons who fail to respond to the first dose respond to a second 
dose (Watson et al., 1996). In the developing world it is given at 9-12 months of age, 
although studies suggest that earlier dosing may be beneficial (Aaby et al., 2010).
1.6.1 The immune responses to measles vaccine
Both humoral and cellular immunity are induced by measles vaccination. Two 
independent studies have identified neutralizing antibody levels above 120-200 mlU/ml as 
a correlate of protection from measles (Chen et al., 1990; Samb et al., 1995). However, 
other studies have demonstrated that some MV-vaccinated subjects with low neutralizing 
antibody titres have detectable MV-specific T lymphocytes in their peripheral blood (Ward 
et al., 1995; Bautista-Lopez et al., 2000). Significant protection from measles has also
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been shown for MV-vaccinated subjects with undetectable MV-specific neutralizing 
antibodies as compared with non-vaccinated subjects (Samb et al., 1995).
Both clinical and experimental data have shown that the cellular immune response is very 
important in recovery from measles virus infection (UytdeHaag et al., 1994). A generalized 
immunosuppression of T cell responses is associated with measles vaccination 
(Smedman et al., 1994), which may be more pronounced in infants (Gans et al., 1998; 
Gans et al., 1999; Gans et al., 2001). However, measles immunization at 9 months of age 
has been shown to induce CTL responses similar to that found in children or adults with 
acute measles, therefore mature CTL can be generated by vaccination in the first year of 
life (Jaye et al., 1998).
Measles vaccine induces a Th1 immune response, characterized by high levels of IFN-y 
and IL-2, quickly followed by a prolonged Th2 or mixed Th1/Th2 response with the 
production of IL-4, IL-13, and TNF-a, and persistently elevated IL-10. A delayed 
maturation of Th1 cell-mediated immunity was suggested in studies assessing responses 
to measles immunization at 6, 9 or 12 months of age, compared with antigen naive adult 
controls (Gans et al., 2001). This latter study aimed to investigate measles virus-specific 
cellular immunity in relation to age and the presence of passive maternal antibodies at the 
time of immunization in large cohorts of infants who were vaccinated at 6, 9, or 12 
months. The authors found no age related differences in the three groups in T cell 
proliferation; in contrast, antibody titres to measles and mumps were lower in 6-month-old 
infants with no detectable mAbs. In the same study, when 9-month-old infants were 
immunized in the absence of mAbs, their antibody response was similar to those of the 
12-month-old infants. A >90% protection from measles or at least severe disease was 
reported for infants aged 6 and 9 months by the use of both humoral and cellular immunity 
as a readout for vaccine immunogenicity (Gans et al., 2001). Other studies reported 
significantly lower antigen-specific T-cell proliferation and IL-12 responses to measles 
vaccination in infants and, although adult-like antigen-specific IFN-y responses were
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observed, infant T cells showed a limited capacity to increase their IFN-y release in 
response to IL-12 supplementation, as compared with adults (Gans et al., 1999; Chougnet 
et al., 2000).
Cellular responses cannot be over emphasized, but very little is known about the cellular 
immune responses that are induced by measles vaccination especially the relative 
importance of CD4+ and CD8+ T cells. Part of the reason for this is because measles 
virus induces immunosuppression and it has been difficult to induce stimulation in 
experiments. With new available technology like ELISPOT and multiparameter flow 
cytometry, this is becoming possible. Ovsyannikova and colleagues measured the 
frequency of measles virus-specific CD4+ and CD8+ memory T cells years after 
completion of a two-dose vaccine series in adults who were either seronegative or highly 
seropositive for measles vaccine IgG-specific antibody and reported similar predominance 
of IFN-y over IL-4 in both groups. The median frequency of measles virus-positive CD8+ T 
cells secreting IFN-y as measured an ELISPOT assay was 0.09% in seronegative 
subjects while in highly seropositive subjects, it was 0.43% in (P = 0.04). With CD4+ T 
cells secreting IL-4 in response to stimulation with measles virus, the frequency was 
0.03% in seronegative subjects and 0.09% in highly seropositive subjects (P = 0.005). 
These results provide evidence that measles virus-specific cellular immunity can be 
detected post measles vaccination in humans (Ovsyannikova et al., 2003).
1.7 Diphtheria vaccine
Diphtheria is a disease caused by infection with bacteria called Corynebacteria 
diphtheriae. Dissemination is usually by air droplets and symptoms begin 1 to 5 days after 
infection. The first sign is usually a mild sore throat and pain on swallowing. It is also usual 
to experience a low-grade fever, nausea, vomiting, headache and a fast heart rate. In 
most cases the bacteria produce a powerful toxin (toxigenic diphtheria) that can destroy 
nearby tissue and cause a membrane of dead cells to form. The toxin can also travel 
through the bloodstream to the heart and nerves; resulting in damage to the heart muscle
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which can lead to heart failure and sudden death (Department of Health, 2003). Before 
the introduction of the antitoxin in the 1890s, case-fatality rates from some diphtheria 
outbreaks reached or exceeded 50%. Although most infections with C. diphtheriae are 
asymptomatic or run a relatively mild clinical course, high case-fatality rates (>10%) have 
been reported even in recent outbreaks ((WHO), 2006a). Indeed, the while number of 
cases has decreased, the fatality rate has not fallen despite modern management (Chin,
2000). The worldwide total number of reported cases ranged from 74,000-94,000 per 
year in the 1970s to 23,000-28,000 per year in 1990-1992, with a 70% global decline in 
diphtheria morbidity over this 20-year period.
Diphtheria vaccine is a preparation of diphtheria toxoid. Usually it is available as a 
preparation adsorbed with aluminium hydroxide or phosphate and often combined with 
other toxoids or vaccines. Currently, diphtheria toxoid is almost exclusively available in 
combination with tetanus toxoid (T) as DT/dT, or with tetanus and pertussis vaccine as 
DTP (the origin of the pertussis component either being whole-cell (wP) or acellular (aP). 
Antibodies to the variable K-antigens of the bacterial cell wall induce type-specific 
protection against carriage and mild forms of localised disease. Immunity to severe forms 
of localised and systemic disease depends mainly on the presence of IgG antitoxin 
antibodies ((WHO), 2006a). Antibody concentrations of >0.01 lU/ml are thought to provide 
some protection, while levels of >0.1 lU/ml are considered fully protective and are 
associated with long-term protective immunity ((WHO), 2006a). Circulating antitoxin levels 
below 0.01 lU/ml are non-protective.
1.8 Tetanus vaccine
Tetanus (commonly known as ‘lockjaw’) is caused by the bacterium Clostridium tetani. 
Unlike diphtheria and pertussis, tetanus is not communicable. Spores of the bacteria are 
present in soil and manure and can be acquired through a scratch, puncture wound, burn 
or more serious injury. The bacteria release toxins, which act locally at the site of an injury 
and also on the central nervous system (CNS) to cause the disease symptoms. The
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majority of cases occur within 3 days to 3 weeks of exposure (Department of Health, 
2003).
Neonatal tetanus was considered a major public health problem at the end of the 1980s. 
The WHO estimated that in the year 2000, 309,000 people died of tetanus ((WHO), 2001), 
including 200,000 cases of neonatal tetanus (World Health Organization (WHO), 2002), a 
reduction of about 75% when compared to 1988. Neonatal tetanus now contributes to 
about 5% of global neonatal mortality, compared to 14% in 1993 ((WHO), 1996a).
Tetanus toxoid vaccines are available as a single toxoid (TT), or adsorbed with aluminium 
phosphate or hydroxide, combined with diphtheria toxoid (DT) or low-dose diphtheria 
toxoid (dT), or in combination with diphtheria and pertussis vaccines (DTwP, DTaP, 
dTaP). WHO stipulates that not less than 60 III should be administered per dose (Myers 
et al., 1982). DTwP is used mostly in developing countries because it is much cheaper to 
produce than aP, and is more immunogenic. However, it is associated with more side- 
effects than aP and as a result wP was replaced with aP in the developed world due to the 
better safety-profile of the latter ((WHO), 2009b), albeit at the expense of the inferior 
immunogenicity.
Tetanus toxoid is a T cell dependent antigen, which induces long-lasting immunity against 
tetanus (Kroon et al., 1999) via the production of anti-tetanus antibodies. Protection can 
be achieved through active (tetanus vaccination) or passive (tetanus-specific 
immunoglobulin) immunization. Immunization of pregnant women with at least two doses 
of tetanus toxoid-containing vaccine: the first dose as early as possible during pregnancy 
and the second dose at least 4 weeks later is recommended by WHO. The immunized 
mother passes antitoxin IgG Abs via the placenta to the foetus, thereby preventing 
neonatal tetanus ((WHO), 2006b). This has been incorporated into antenatal care 
programs in many African countries leading to a dramatic reduction in death from neonatal 
tetanus.
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The immune response to TT vaccination has been extensively studied in populations in 
developed countries to show that protection is dependent on the amount of IgG 
antibodies, the subclass distribution, which is mainly dominated by lgG1, and the avidity of 
the produced antibodies (Kroon et al., 1999). To obtain long-lasting immunity booster 
doses are required approximately every 10 years throughout life. Past studies on TT 
vaccination in developing countries concentrated mostly on the effect that parasite 
infections had on the vaccine efficacy. To this effect, studies conducted on onchocerciasis 
infected patients reported low responses to TT vaccination as defined by reduced IFN-y 
production by T cells and reduced antibody concentrations (Prost et al., 1983; Cooper et 
al., 1998; Cooper et al., 1999). The cytokine balance in schistosomiasis patients after 
tetanus vaccination was skewed towards a Th2 response compared to a Th1 and ThO 
response in uninfected controls (Sabin et al., 1996). These studies were done on young 
adults. In a study in Gabon in which TT booster was administered to school children 
between the ages of 7 and 12 years; semi-urban children showed a Th1 cytokine profile 
while a Th2 cytokine profile was observed in rural children (van Riet et al., 2008). Mayer et 
al. demonstrated that IFN-y production after TT booster vaccination of healthy donors was 
exclusively from CD4+ T cells. In vitro assays in which they depleted CD8+ T cells and NK 
cells did not affect IFN-y production; in contrast, upon depletion of CD4+ T cells, IFN-y 
production was almost non existence (Meyers et al., 2002). Flowever, responses to 
vaccines containing alum adjuvant such as tetanus toxoid are often Th2 biased (Petrovsky 
and Aguilar, 2004).
While most studies have reported that IFN-y is the predominat cytokine produced by TT- 
specific CD4+ T cells in humans (Fernandez et al., 1994; Cellerai et al., 2007), more 
recently an adult study revealed that the memory responses for Th1, Th2, IL-10 and IL-17 
cytokines could be identified following TT immunization, which shows that the response to 
TT has a heterogeneous cytokine profile (Livingston et al., 2013).
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1.9 Whole-cell Pertussis vaccine (wP)
Pertussis is caused by infection with the bacterium Bordetella pertussis, a strictly human 
pathogen that causes the respiratory disease whooping cough. The bacteria are 
transmitted from infected to susceptible individuals through cough droplets. The 
incubation period is usually 9-10 days (range 6-20 days), after which the infection 
progresses to the catarrhal phase (including cough), then there is progression to the 
paroxysmal phase that can persist for months, followed by the convalescent stage 
(Heininger et al., 1997). The catarrhal, paroxysmal and convalescent stages combined 
typically last for approximately 3 months ((WHO), 2010).
Bordetella species may change their phenotypic characteristics and show different 
expression of virulence factors depending upon environmental conditions. These factors 
include the nature of the pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin 
(PRN), fimbriae (FIM) type 2 and type 3, adenylate cyclase toxin (ACT), tracheal cytotoxin 
(TCT), lipooligosaccharide and B. pertussis endotoxin ((WHO), 2010). Pertussis 
pathogenesis is not completely understood but FHA, PRN and FIM facilitate attachment to 
targeted host cells, and PT, TCT and ACT enable the bacterium to destroy the epithelial 
lining and evade the host’s immune system ((WHO), 2010).
Worldwide, pertussis remains an important cause of infant death and therefore is a public 
health concern even in countries with high vaccination coverage. WHO estimates suggest 
that about 16 million cases of pertussis occurred worldwide in 2008, 95% of which were in 
developing countries, and that about 195,000 children died from the disease (Black et al., 
2010). The incidence of pertussis is on the rise despite the availability of an effective 
vaccine that is used worldwide, in part due to decreased vaccine uptake in the developed 
world. The number of cases of pertussis was almost zero in the 1980s in California; this 
has increased in 2010 to match rates reported in 1947 (Kuehn, 2010). The epidemiology 
of pertussis is also changing and the infection is increasingly being found in older children
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and adolescents. This was demonstrated in a serological study in the United States that 
found 21% of adults with a cough lasting greater than 2 weeks had pertussis (Wright et 
al., 1995). The UK has high vaccine coverage and a booster dose of pertussis is included 
in the preschool booster. This has led to a decline in the cases of pertussis between 1998 
and 2009. In spite of this, UK has been having periodic outbreaks since 2011 particularly 
among adolescents and adults((HPS), 2012), while the increase in cases in 2012 affected 
mainly very young infants ((HPS), 2012).
Pertussis vaccine has been highly successful in preventing severe pertussis in infants 
worldwide. Two types of pertussis vaccine are available: whole-cell (wP) vaccines based 
on killed B. pertussis organisms at a concentration of more than 4 IU, and acellular (aP) 
vaccines based on highly purified, selected components of the whole cell agent 
(Njamkepo et al., 2002). Most of the licensed aP vaccines contain 4 or 5 separately 
purified pertussis antigens (PT, FHA, PRN and FIM 2/3). The wP vaccines are based on 
standardized cultures of selected B. pertussis strains that are subsequently killed, usually 
by heating and treatment with formalin. Most wP vaccines are combined with diphtheria 
toxoid and tetanus toxoid. All available wP vaccines contain aluminium salts as an 
adjuvant ((WHO), 2010). Vaccine trials have demonstrated that antibody levels to B. 
pertussis antigens including PT, FHA, PRN and fimbriae correlate with protection against 
whooping cough. High anti-B. pertussis IgG was found in mice to correlate with rapid 
clearance of the bacteria in a respiratory infection model, but a pertussis-specific CM I 
response was required for complete elimination of the organism from the lungs. In vitro, B. 
pertussis survives in human monocytes and other mammalian cells, therefore, a CM I 
response may be necessary for eliminating this pathogen which has the potential of 
becoming an intracellular reservoir of bacteria (Gwendolyn and Richard, 1998). B. 
pertussis specific Th1 cells are found in humans after vaccination or infection, implying a 
role for cell-mediated immunity.
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1.10 The diphtheria, tetanus, whole cell pertussis (DTwP) combined vaccine
The DTwP vaccine is prepared from the inactivated diphtheria and tetanus toxins 
(rendered harmless and called toxoids) combined with one or more strains (types) of 
whole pertussis bacteria that have been killed. There is still no immune correlate of 
protection for pertussis and earlier studies relied on geometric mean titres (Miller et al., 
1995).
Earlier studies of DTwP induced immunity in the UK reported the possible need for a 
booster dose of the vaccine in the second year of life, as was practiced in North America 
and many European countries. Despite booster doses in these countries, there were still 
reported cases of whooping cough in adults after many years of low incidence, indicating 
that the protection does not always extend into adulthood but can be boosted from natural 
exposure (Reviewed in (Miller et al., 1995). Miller and colleagues studied the responses of 
pre-school children given a booster dose of DTwP after a three dose primary 
immunization at 3, 5, and 10 months (former UK schedule) and they observed more 
adverse events in children administered with DTwP than the DT control group, but a good 
antibody response was obtained after the DTwP boost (Miller et al., 1995). Another group 
reported similar findings; a good boosting was obtained at 18 months to all components of 
DTwP vaccine, and it was well tolerated (Nolan et al., 1998). With the advent of DTaP, 
introduced in the 1970s, many studies were carried out in children to compare DTwP and 
DTaP vaccines reporting more adverse effects with DTwP compared to DTaP (Trollfors et 
al., 1995; Greco et al., 1996; Gustafsson et al., 1996; Miller et al., 1997; Simondon et al., 
1997).
DTwP is generally thought to boost a Th2 profile with a reduced IFN-y to IL-4 ratio 
(Graham et al., 1993; Lindblad et al., 1997; Moran et al., 1999; Fischer et al., 2000). 
However, studies have shown that that vaccination with the wP component alone induces 
a Th1 (IFN-y and IL-2) cellular response (Ryan et al., 1997), while those vaccinated with
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aP show a mixed Th1/Th2 cytokine profile (Ryan et al., 1998). Other studies in infants 
after immunization have reported a selective activation of Th1 cells with wP and a strong 
antibody and Th2 biased response with aP (Ausiello et al., 1997; Ryan et al., 1998; Dirix 
et al., 2009; White et al., 2010). Although the Th2/Th1 cytokine ratio was higher in aP than 
wP vaccinees, tetanus-specific T cells responses were higher in the latter group (Dirix et 
al., 2009). Similar findings were reported in murine respiratory challenge models of 
parapertussis (Sato et al., 1980) and revealed a requirement of both humoral and cell 
mediated immunity for the clearance of 8. pertussis from mice lungs (Mills et al., 1998). 
Antigen-specific Th17 cells are induced by wP vaccination in immunized mice (Higgins et 
al., 2006a), which together with Th1 cells promote bacterial clearance via the recruitment 
and induction of macrophages and neutrophils thereby eliminating 8. pertussis (Mahon 
and Mills, 1999; Higgins et al., 2006a). Thus Th1 cells and Th17 cells have a protective 
role in immunity against 8. pertussis infection, and ideally should be induced by 
vaccination.
1.11 Vaccine adjuvants
Glenny and colleagues first described the adjuvant effect of aluminium compounds 
(Glenny et al., 1926; Lindblad, 2004). Adjuvants may be molecules, compounds, or 
macromolecular complexes that have the ability to enhance the potency, quality, or 
longevity of specific immune responses to antigens. Adjuvants should not be too toxic. 
There are broadly two classes of adjuvants, immune modulators and delivery vehicles, but 
some adjuvants can exhibit both properties. Adjuvants target antigen-presenting cells 
(APC) which are central in both innate and adaptive immunity (Alving et al., 2012).
It has been suggested more recently, that the antigens adsorbed onto the aluminium salts 
are presented in a particulate multivalent form, making them more efficiently internalized 
by APCs (Morefield et al., 2005). Many of the EPI vaccines such as DTwP and Hepatitis B 
vaccine contain aluminium-based adjuvants (Clements and Griffiths, 2002), in order to 
enhance their immunogenicity. However, aluminium salts primarily enhance Th2-driven
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antibody responses and have little effect on Th1-type responses, which are instrumental 
for protection against many pathogens (Leroux-Roels, 2010).
A number of toll-like receptor (TLR) agonists have recently been discovered as potent 
vaccine adjuvants. TLRs are pathogen recognition receptors that recognize pathogen 
associated molecular patterns. These TLRs are immunoenhancers that function via direct 
stimulation of cells of the innateimmune system such as monocytes, macrophages and 
dendritic cells (Skeiky et al., 2004; Didierlaurent et al., 2009; Coffman et al., 2010). There 
are 10 known TLR agonists recognized by humans. TLR2, 3, 4, 5, 7, 8, and 9 are the best 
characterized molecules which are derived from bacterial or viral components, all of which 
have reached clinical testing as vaccine adjuvants (Barton, 2007; Bode et al., 2011; Tomai 
and Vasilakos, 2011). In the mouse, there are 12 recognized TLR members (Kumar et al., 
2013; Reynolds and Dong, 2013). Human TLR2 is engaged by bacterial lipopeptides 
(Philbin and Levy, 2009). TLR3 agonists are endosomal receptors derived from viral 
double stranded RNA such as poly (l:C), which has been used in clinical trials for cancer 
(Seya et al., 2003). TLR4 is a plasma membrane receptor found on human dendritic cells 
and macrophages, which bind bacterial lipopolysaccharide, monophosphoryl lipid A 
(MPLA). Bacterial flagellin is a TLR5 agonists, single stranded RNA is a TLR7/8 agonist, 
and CpG oligonucleotides act as TLR9 agonists. TLR7/8 agonists hold promise as a novel 
neonatal vaccine adjuvant as it stimulates a strong Th1 response in neonates (Philbin and 
Levy, 2007; Burl et al., 2011). TLR8 is also expressed by human Treg cells and plays a 
key role in the reversal of Treg function when exposed to TLR8 agonists, thus overcoming 
immunosuppression and enhancing immunity (Philbin and Levy, 2007; Burl et al., 2011).
1.12 Immune polarization and vaccines
The classic assumption is that live vaccines such as BCG and measles vaccine induce 
type 1 immunity, whereas the killed / inactivated vaccines such as DTwP or HBV skew 
towards type 2 responses. While this might be true in animals, the situation is more 
complex in humans. The measles vaccine response is often type 2 skewed in human
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infants (Karp et al., 1996), and the pertussis component of DTwP can induce type 1 pro- 
inflammatory responses (Sharma and Pichichero, 2012). Furthermore, aside from the 
classical Th1/Th2 dichotomy, other arms of the immune system need to be considered 
such as the induction of Th17 cells and Tregs following vaccination. Th17 CD4 T cells are 
a recently described lineage, that confer protection against extracellular bacteria and 
fungi, particularly at epithelial surfaces (Weaver et al., 2006; Bettelli et al., 2007; Weaver 
and Murphy, 2007). IL-17 producing Th17 cells are primed upon administrating whole cell 
pertussis vaccine, and when IL-17 is neutralized there is a significant reduction in vaccine- 
conferred protection in mice (Higgins et al., 2006b).
1.13 Non-specific or heterologous effects of vaccines
Aside from inducing vaccine specific memory responses, there is compelling evidence 
that vaccines also have non-specific effects on morbidity and mortality from non-vaccine 
infections. These morbidity / mortality effects therefore cannot be accounted for by 
decreased cases of the targeted vaccine disease. These so called non-specific effects 
(NSE) or heterologous effects of vaccines have been overlooked in the past because it 
was assumed that the impact on survival would be proportional to protection against the 
targeted infection. Observational studies have repeatedly shown that vaccines can alter all 
cause mortality, and now randomized trials are emerging which confirm these findings 
(Knudsen et al., 1996; Aaby et al., 2003a).
One of the first widely accepted evidence that vaccines can alter all cause mortality came 
from the high-titre measles vaccine (HTMV) trials. In 1989 HTMV was recommended by 
WHO for use in high measles endemic settings. Randomized trials conducted in Senegal, 
Guinea Bissau and Haiti showed that although HTMV protects against measles infection, 
there was increased female mortality in the HTMV females compared to those that 
received the standard MV and compared to males in both groups (Knudsen et al., 1996; 
Aaby et al., 2003a). As a result HTMV was withdrawn by WHO in 1992. Later it was
67
suggested that it was the subsequent DTwP dose that increased the mortality two-fold in 
females (Aaby et al., 2003c).
Bacillus Calmette-Guerin vaccine (BCG) has been shown in randomized trials to reduce 
mortality from infections other than tuberculosis (Roth et al., 2006; Roth et al., 2010; 
Shann, 2010; Aaby and Benn, 2011) suggesting a non-specific protective effect. The fact 
that BCG is used as a treatment for bladder cancer further confirms that it can have non­
specific immune effects unrelated to induction of immunity against TB (Alexandroff et al., 
1999). These non-specific effects are maximal in the first six months after vaccination and 
are largely determined by the last vaccine administered (Shann, 2010). In general, live 
vaccines such as measles vaccine (MV) and BCG have been shown to have non-specific 
beneficial effects. Unfortunately inactivated vaccines, including DTwP, have been shown 
to have non-specific deleterious effects, with females being more susceptible than males 
(Aaby et al., 2004b; Veirum et al., 2005; Aaby et al., 2006a). These observations have 
been highly controversial and as yet the mechanisms have not been elucidated although 
a number of potential mechanisms have been postulated (Flanagan et al., 2011; Flanagan 
et al., 2013b).
1.13.1 Non-specific effects of Measles Vaccine
Early observational studies suggested that measles vaccination could reduce all-cause 
mortality, and that the effect could not be attributed solely to a reduction in measles 
infections (Aaby et al., 1996b; Aaby et al., 1996a; Aaby et al., 2003a). Many studies in 
Africa reported a 40% or more reduction in child mortality after the introduction of measles 
vaccine in the late 1970s and early 1980s (Aaby et al., 1981; Aaby et al., 1984; Aaby et 
al., 1989; Aaby et al., 1993; du Lou et al., 1995). Studies in other countries reporting 
similar findings included Bangladesh and Haiti (Clemens et al., 1990; Holt et al., 1990). 
This reduction was larger than was expected as measles infection in these regions causes 
considerably less that 40% of all-cause mortality, leading to the suggestion that measles 
vaccine may have non-specific beneficial effects that is protecting against infections other
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than measles (Aaby et al., 1995). A follow-up study by Kristensen et al., in which the 
authors assessed the association between routine childhood vaccination and survival in 
Guinea Bissau, the mortality ratio of measles vaccinated children was 0.48 (0.27 to 0.87). 
However, on the exclusion of measles deaths, the mortality ration was 0.51 (0.28 to 0.95) 
indicating a beneficial protective effect against dying from the measles vaccine (Figure 
1.12) (Kristensen, 2000).
More recently randomized trials in Sudan and Guinea-Bissau of providing an additional 
early dose of MV have confirmed this effect of reducing death from non-measles causes 
(Aaby et al., 2006a; Aaby et al., 2010). One of these studies was a large 2 dose RCT in 
which MV was administered at 4.5 months of age and the second dose at 9 months of 
age. The results revealed a 30% (6 -  48%) reduction in mortality between 4.5 and 36 
months compared with those that received a single dose of standard MV at 9 months 
(Aaby et al., 2010). This effect could not be accounted for by a reduction in measles 
deaths alone, and remained at 24% (0 -  45) after the contribution of measles deaths was 
allowed for.
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Figure 1.11 Kaplan-Meier survival curves for recipients and non-recipients o f 
measles vaccine. Six months follow up o f 3,414 children initially aged 7-13 months, 
Guinea Bissau, 1990-6 (Kristensen, 2000).
69
1.13.2 Non-specific effects of DTwP Vaccine
When DTwP vaccination was introduced into Guinea-Bissau there was a significant 
increase in mortality in those children that received the vaccine (Aaby et al., 2004a). Thus, 
those children in Guinea-Bissau aged 2-8 months that were administered with DTwP had 
higher mortality than those that did not receive DTwP, the mortality rate ratio (MR) being 
1.92 (95% Cl: 1.04,3.52) for the vaccinated group. The reasons for not receiving the 
DTwP vaccine included illness or travelling, or occasionally because DTwP was not 
available (Aaby et al., 2004a). There was no evidence in this study to suggest that the 
unvaccinated children were a low risk group, indeed unvaccinated children are usually a 
high-risk group (Fine et al., 2009).
It has been deemed unethical by WHO to delay DTwP in randomized trials (Shann, 2010). 
However, a recent analysis of all available studies (n=35) of DTwP vaccination on child 
survival concluded the following: 1) DTwP vaccinated children had higher mortality than 
unvaccinated children; 2) DTwP vaccinated females have higher mortality than males in 
all studies; and 3) Reducing time of exposure to DTwP as most recent vaccine by giving 
BCG or MV reduced child mortality (Aaby et al., 2012).
1.14 The interaction between DTwP and measles vaccine
In The Gambia EPI schedule, three doses of DTwP are given at 8, 12 and 16 weeks of 
age, and measles vaccine is given at 9 months of age. However, vaccines are frequently 
delayed, for reasons such as illness, inability to attend clinic, lack of electricity to store 
vaccines, particularly in resource poor settings. WHO recommend that when a child 
presents for routine vaccinations, any missed vaccines be given (Decker, 2001). Thus 
children who come for MV and are missing one or more DTwP vaccines are given both 
vaccines simultaneously. Several observational studies suggest that receiving DTP 
together with MV is associated with higher mortality than those receiving MV only. A 
Gambian study showed a relative risk of death of 5.59 (2.10; 14.8) for children having a 
third DTP (DTP3) together with MV compared with children having MV only (Aaby et al.,
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2006b). A study from Congo showed a mortality rate ratio (MRR) of 5.38 (1.37; 21.15) 
(Aaby et al., 2006a), and from Malawi of 5.27 (1.11; 25.0) for children who received DTwP 
together with MV compared with children who received MV only (Aaby et al., August 
2006). Part of the explanation for these observations might be selection bias whereby 
children who come late for their vaccines have poorer health seeking behaviour. However, 
the effect estimates are so large that it seems implausible that they are due to selection 
bias alone (Agergaard et al., 2011).
1.15 Sex differences in non-specific effects of vaccination
Generally it is females that are more susceptible to the non-specific / heterologous effects 
of vaccines than males. Thus females seem to benefit more than males following measles 
vaccination; but conversely females fare worse than males after DTwP vaccination (Figure 
1.13a and 1.13b respectively) (Aaby et al., 2002; Aaby et al., 2004a; Aaby et al., 2004b; 
Veirum et al., 2005; Aaby et al., 2006b; Benn et al., 2009a). For example, overall female 
mortality is increased after DTwP vaccination but males remain unaffected (Kristensen, 
2000; Aaby et al., 2004a; Jensen et al., 2007). By contrast, BCG and measles vaccination 
lower mortality in females, with a less significant effect in males (Aaby et al., 1995; Aaby 
et al., 2003b; Roth et al., 2006).
In a randomized study in Guinea Bissau, administration of DTP+OPV with MV had 
negative effects on growth and morbidity if girls (Agergaard et al., 2011). In the same 
study, whenever adverse events were observed in the group that received 
MV+DTP+OPV, the authors consistently found a female-male ratio below 1 in the 
MV+OPV group and above 1 in the MV+DTP+OPV group (Agergaard et al., 2011).
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Figure 1.12 The female /  male mortality is consistently <1.0 following measles vaccination 
(A), whereas it is >1.0 after DTwP vaccination (B) in trials conducted in Africa and Haiti. 
This suggests that females benefit more from the NSE o f MV, and fare worse than males 
after DTwP. (P Aaby, personal communication)
Vitamin A supplementation (VAS) appears to amplify these NSE in a sex-differential 
manner, thus enhancing the negative effects of DTwP and the beneficial effects of live 
vaccines (Benn et al., 2003). VAS was associated with increased mortality for girls who
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had received DTwP as their most recent vaccine (Benn et al., 2009b; Benn et al., 2009a; 
Benn et al., 2010). This result supports other reports that receiving DTwP after measles 
vaccine affects females in a negative way (Benn and Aaby, 2012). Another study in 
Ghana showed that girls randomised to VAS had two-and-half fold higher mortality if they 
received DTwP during follow-up whereas boys receiving vitamin A had lower mortality 
than placebo recipients (Benn et al., 2009a).
If the exsistence of sex-differential and non-specific effects of vaccines are proven and 
become accepted, then suggestions for different vaccine schedules in males and females 
in the future might be justified (Flanagan et al., 2011). Convincing epidemiological data 
from randomized trials and clarification of the mechanisms needed to convince the 
scientific community. Some of these studies are now emerging (Flanagan et al., 2013b).
1.16 Sex differences in specific immunity to infections and vaccines
Studies in humans and mice have demonstrated that the intensity and prevalence of 
infection with viruses, bacteria, and parasites are higher in males than females, which 
likely involves physiological as well as behavioral differences (Merkel et al., 2001; Kahlke 
et al., 2002). Higher innate and adaptive immune responses to pathogen challenge have 
been reported in adult females than their male counterparts (Klein, 2000; Klein, 2005). 
Cells isolated from <50 years olds and cultured with rhinovirus produced significantly 
higher IFN-y and IL-13 in women than men (Carroll et al., 2010). Production of the 
immunosuppressive cytokine IL-10 from adult PBMCs stimulated with TLR8 and TLR9 or 
viruses (influenza and Herpes-simplex-1) was significantly lower in females, alongside 
higher amounts of IFN-a after TLR7 stimulation compared to males (Torcia et al., 2012). 
This increased immunity in females can be beneficial for clearing infections, these 
immune responses can be detrimental if they become too robust or remain elevated for 
too long, leading to the development of immunological pathology.
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There is compelling evidence that suggest that CD4+ T cell activation is different in males 
and females. Females lean toward a Th2 immune responses and B cell activation, while 
males show a more prominent Th1 CD4+ and CD8+ T cell response (Reviewed in 
(Pennell etal., 2012)).
A handful of studies describe male / female differences in vaccine responses. Females 
have more robust innate responses than males to yellow fever vaccination. Females also 
have higher antibody responses to the influenza vaccine, combined measles, mumps, 
rubella (MMR) vaccine, and hepatitis A and B vaccines (Klein et al., 2010). In a study 
carried out in children aged 6 months administered simultaneously with standard-titre 
Schwarz measles vaccine and vitamin A, females were found to be less likely to 
seroconvert than males (OR = 0.34) (Semba et al., 1995). These data support sex 
differences in response to vaccination are evident in both adults and children, although 
the available data remain limited.
1.17 Potential mechanisms for sex differences in immunity to vaccines
Mechanistic explanations include a role for sex steroids. Thus, testosterone, oestradiol 
and progesterone all bind to specific receptors on immune cells including macrophages, 
lymphocytes and DCs (Reviewed in (Klein, 2012)). This binding activates cell signaling 
pathways such as NF-kB, cJun and interferon regulatory factor 1 (IRF-1). This leads to the 
production of different cytokines and chemokines (Reviewed in (Klein, 2012)). Differences 
in the balance of sex hormones could account for the sex differences in immune 
responses to vaccines in early life. Oestrogens are known to regulate Th1 and Th2 
responses in females during the menstrual cycle in a bi-phasic manner. It has been 
reported that low-dose oestrogen during menstruation and during the luteal phase induce 
Th1 immune responses; on the other hand, high-doses during the follicular phase promote 
Th2 mediated immunity (Pernis, 2007).
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There are two X chromosomes in females (XX) but one is generally silenced (inactivated) 
in-vivo; males (XY) have only one X chromosome and one Y chromosome, both being 
universally expressed. Since many the immune response genes are X-linked, this 
provides a possible explanation for sex differences in immunity to infections and 
vaccination (Fish, 2008). Some of the X-linked genes involved in immune responses 
include immune response related proteins, cytokine receptors, TLRs and transcriptional 
and translational effectors (Fish, 2008). These theories have never been formally studied 
in the context of vaccination.
1.18 Gene signatures after vaccination
Systems biology is an interdisciplinary approach that systematically describes the 
complex interactions between all the parts in a biological system, with a view to 
elucidating new biological rules capable of predicting the behaviour of the biological 
system. Systems biology focuses on studying the structure and dynamics of the whole 
system (Kitano, 2002). The immune response to vaccination involves a complex network 
of interrelated immune pathways and yet most vaccine immunogenicity studies focus on 
the induction of vaccine specific antibodies or T cells (Pulendran, 2009). The immune 
response network theory states that the response to a vaccine is the cumulative result of 
genes and their interactions and is, therefore, theoretically predictable (Poland et al., 
2008). The complete sequencing of the human genome along with technical advances in 
microfabrication has led to the development of methodologies to allow high throughput 
analysis of transcription profiles. Systems biology offers new and exciting potential to 
study the immune response to vaccination. These systems biology approaches might be 
used to identify the gene expression patterns or molecular signatures that are induced 
rapidly after vaccination. These might then be correlated with, and predict, the later 
development of protective immune responses (Pulendran, 2009).
Analysing the transcription profile ex-vivo in unstimulated whole blood or peripheral blood 
mononuclear cells (PBMCs) provides a ‘snapshot’ of the dynamics of the entire immune
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system at a single point in time. If whole blood is used then genes from all cells in the 
blood will be represented, whereas PBMC analysis limits the information to those cell 
populations within the PBMC fraction; namely B cells, T cells, NK cells, monocytes, 
macrophages and dendritic cells (DCs). There is relatively little day-to-day background 
variation in global gene expression in whole blood and PBMCs from healthy individuals, 
although factors such as time of day, sex of the subject and age do affect the profile 
(Reviewed in (Flanagan et al., 2013a)). A number of studies have shown that the whole 
human transcriptome profile is altered in disease states such as autoimmunity, 
haematological malignancy, infectious diseases and solid organ transplant recipients 
(Chaussabel et al., 2010), however very few studies have examined the ex-vivo 
transcriptome profile to vaccination. Analysis of RNA extracted from whole blood samples 
collected directly into PAXgene tubes (Qiagen) has been used to study the immune 
response to influenza vaccine (Bucasas et al., 2011b). An alternative to the ex-vivo 
approach is to stimulate in vitro with vaccine antigens prior to microarray analysis 
(Reviewed in (Flanagan et al., 2013a)), as used to study the PBMC response to BCG 
vaccination (Fletcher et al., 2009). Vaccines elicit an early pro-inflammatory response 
mediated by innate reactivity to pattern associated molecular patterns and adjuvants 
contained within the vaccine. The memory T cell, B cell and humoral responses generally 
take several weeks to develop, the kinetics depending on the vaccine administered 
(Flanagan et al., 2013a). The time of sampling in these systems studies is therefore very 
important.
Systems biology can be used to aid the analysis of vaccine safety and immunogenicity 
since conventional immunological assays such as ELISPOT, antibody-ELISA, and 
multiplex-cytokine assays could be combined with genome-wide co-expression network 
analysis to provide more informative data. Only a few studies have been published using 
this methodology but they have shown the importance of this approach. In a recent study 
of global gene expression following influenza vaccination using lllumina arrays, the 
authors found maximal expression changes within the first 24h following vaccination,
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which strongly correlated with the magnitude of antibody response (Bucasas et al., 
2011a). Another group used a systems biology approach to identify molecular gene 
signatures that predict the magnitude of adaptive responses in humans vaccinated 
against yellow fever (Querec et al., 2009).
Microarray profiling of vaccinated and unvaccinated infants has enormous potential to 
provide answers as to how NSE / heterologous effects are mediated, and to identify 
biological pathways and biomarkers that might predict them. As mentioned earlier females 
are generally more susceptible to heterologous effects of vaccines (Flanagan et al., 2011). 
Females expressed far more innate immune response genes than males following yellow 
fever vaccination, in particular innate immune response genes (Klein et al., 2010), and a 
similar pattern has emerged following measles vaccination (Flanagan KL et al., 
unpublished data). Analysing males and females together may therefore lead to a loss of 
information since changes in gene expression may only become apparent when males 
and females are analysed separately. Thus transcriptome studies of vaccine responses 
should ideally be analysed separately by sex in addition to analysing all donors together.
1.19 Study rationale
This study was designed as the first comprehensive randomized trial investigating the 
immunological mechanisms of the non-specific effects of MV and DTwP vaccination in 
infants. It should provide insights into why different vaccine schedules exert NSE on 
morbidity and mortality, dependent on sex. Our aim is to establish whether the two 
vaccines lead to distinct immunological footprints that could account for NSE, and whether 
these alter when the vaccines are combined. If the mechanisms of NSE are understood 
this would help guide recommendations for future vaccine combinations as well as 
introduction of new vaccines into the EPI. Furthermore, if proven to be true then the 
current EPI schedules may need to be refined.
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1.20 Study hypotheses
In this thesis we aim to address the following hypotheses:
• Administration of MV or DTwP vaccines to 9 month old infants leads to distinct
polarization of the immune profile, as determined by multiplex cytokine and flow
cytometry analysis following in vitro stimulation with TLR agonists, and vaccine 
specific and non-vaccine antigens.
• MV and DTwP will elicit distinct immune response pathways as determined by whole 
human transcriptome microarray analysis of RNA extracted from whole blood.
• Co-administration of MV with DTwP will alter the above responses.
• Males and female infants will differ in their immunological profiles following MV, DTP
and MV+DTP vaccination.
• The above methodology will identify signatures / biomarkers that could account for the 
increased female susceptibility to the deleterious and beneficial non-specific effects of 
vaccines.
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CHAPTER 2 
MATERIALS AND METHODS
2.1 Polychromatic flow cytometry
Polychromatic flow cytometry was performed on the 9 and 10 month blood samples from 
all infants.
2.1.1 Overnight whole blood cultures
100pl per test of heparinized whole blood was cultured overnight in a 96 well U-bottom 
plate with the following antigens:
• Anti-CD3 (aCD3, Mouse IgG k, Clone UCHT1, 5 (ig/ml; Becton-Dickinson (BD), 
USA) plus anti-CD28 (aCD28, Mouse lgG1 k, Clone CD28.2, 5 i^g/ml; 
eBiosciences, UK)
• Tetanus toxoid (TT, 10 pg/ml; Sanofi Pasteur)
• Purified protein derivative (PPD, 10 pg/ml; Statens Serum Institute, Denmark)
• E. coli K12 Lipopolysaccharide Proteins S (LPS, 1 pg/ml; InvivoGen, San Diego, 
California)
• Measles Haemagglutinin (“H”) Protein peptide pool (15 mer overlapping peptides 
of > 95% purity spanning HA peptide (“H”), 1 pg/ml; Sigma-Genosys, UK). The HA 
peptide was used for the peptide pool, which consisted of a total of 122 peptides 
(Table 2.1). The lyophilized peptides were diluted in Dimethyl sulfoxide (DMSO) or 
RPMI 1640, Sigma-Aldrich) as necessary before pooling them. The manufacturer 
provided information on the weighted average, peptide hydrophobicity, and 
solubility. Peptides with weighted average < 0.5 were hydrophilic and soluble; 
these were diluted with RPMI at 20mg/ml or 40mg/ml. Those peptides with 
weighted average < 1, were of moderate hydrophobicity and solubility (difficult to 
dissolve) were diluted to a give a concentration of 20mg/ml or 10mg/ml. Finally, 
peptides with weighted average > 1 were very hydrophobic and of very low 
solubility (very difficult to dissolve) were diluted DMSO to a concentration of 
5mg/ml and were pooled to give a concentration of 100pg/ml. We then calculated 
the volume of each peptide at the above-mentioned concentrations, needed to 
give a final concentration of 100|xg/ml for peptide pool.
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100pl blood without antigen; medium alone was added (negative control for 
spontaneous cytokine production).
Table 2.1 Amino acid sequences of 122 Measles “H” Peptides incorporated in the 
pool used in this study
Measles ”H“ Peptides, 15mers overlapping by 10
1 mspqrdrinafykdn 26 npdreydfrdltwci 51 myrvfevgvirnpgl 76 Irmetcfqqackgki 101 paevdgdvklssnlv
2 drinafykdnphpkg 27 ydfrdltwcinpper 52 evgvirnpglgapvf 77 cfqqackgkiqalce 102 gdvklssnlvilpgq
3 fykdnphpkgsrivi 28 Itwcinpperikldy 53 mpglgapvfhmtny 78 ckgkiqalcenpewa 103 ssnlvilpgqdlqyv
4 phpkgsrivinrehl 29 npperikldydqyca 54 gapvfhmtnyleqpv 79 qalcenpewaplkdn 104 iIpgqdIqyvlatyd
5 srivinrehlmidrp 30 ikldydqycadvaae 55 hmtnyleqpvsndls 80 npewaplkdnripsy 105 dlqyvlatydtsrve
6 nrehlmidrpyvlla 31 dqycadvaaeelmna 56 leqpvsndlsncmva 81 plkdnripsygvlsv 106 latydtsrvehawy
7 midrpyvllavlfvm 32 dvaaeelmnalvnst 57 sndlsncmvalgelk 82 ripsygvlsvdlslt 107 tsrvehawyyvysp
8 yvllavlfvmflsli 33 elmnalvnstlletr 58 ncmvalgelklaalc 83 gvlsvdlsltvelki 108 ehawyyvyspsrsfs
9 vlfvmflsligllai 34 Ivnstlletrttnqf 59 Igelklaalchreds 84 dlsltvelkikiasg 109 yvyspsrsfsyfypf
10 flsligllaiagirl 35 lletrtlnqflavsk 60 laalchredsitipy 85 velkikiasgfgpli 110 srsfs yfypfrlpik
11 gllaiagirlhraai 36 ttnqflavskgncsg 61 hredsitipyqgsgk 86 kiasgfgpllthgsg 111 yfypfrlpikgvpie
12 agirlhraaiytaei 37 lavskgncsgpttir 62 itipyqgsgkgvsfq 87 fgplithgsgmdlyk 112 rlpikgvpielqvec
13 hraaiytaeihksls 38 gncsgpttirgqfsn 63 qgsgkgvsfqlvklg 88 thgsgmdlyksnhnn 113 gvpielqvecftwdq
14 ytaeihkslstnldv 39 pttirgqfsnmslsl 64 gvsfqlvklgvwksp 89 mdlyksnhnnvywlti 114 Iqvecftwdqklwcr
15 hkslstnldvtnsie 40 gqfsnmslslldlyl 65 Ivklgvwksptdmqs 90 snhnnvywltippmk 115 ftwdqklwcrhfcvl
16 tnldvtnsiehqvkd 41 mslslldlylgrgyn 66 vwksptdmqswvtls 91 vywltippmk nlalg 116 klwcrhfcvladses
17 tnsiehqvkdvltpl 42 Idlylgrgynvssiv 67 tdmqswvtlstddpv 92 ippmknlalgvintl 117 hfcvladsesgghit
18 hqvkdvltplfkiig 43 grgynvssivtmtsq 68 wvtlstddpvidrly 93 nlalgvintlewipr 118 adsesgghithsgmv
19 vltplfkiigdevgl 44 vssivtmtsqgmygg 69 tddpvidrlylsshr 94 vintlewiprfkvsp 119 gghithsgmvgmgvs
20 fkiigdevglrtpqr 45 tmtsqgmyggtylve 70 idrlylsshrgviad 95 ewiprfkvspylfnv 120 hsgmvgmgvsctvtr
21 devglrtpqrftdlv 46 gmyggtylvekpnls 71 Isshrgviadnqakw 96 fkvspylfnvpikea 121 gmgvsctvtredgtn
22 rtpq rftd Ivkfisd 47 tylvekpnlsskrse 72 gviadnqakwavptt 97 ylfnvpikeagedch 122 ctvtredgtnrr
23 ftdlvkfisdkikfl 48 kpnlsskrselsqls 73 nqakwavpttrtddk 98 pikeagedchaptyl
24 kfisdkikflnpdre 49 skrselsqlsmyrvf 74 avpttrtddklrmet 99 gedchaptylpaevd
25 kikflnpdreydfrd 50 Isqlsmyrvfevgvi 75 rtddklrmetcfqqa 100 aptylpaevdgdvkl
Plates were sealed and incubated for 2 hours at 37°C, 5% C02. Brefeldin A (Sigma- 
Aldrich, UK) was then added at a final concentration of 10pg/ml to all stimulated wells and 
further incubated for 16 hours. An unstimulated well was used to control for background 
cytokine production (negative control). For each experiment, unstimulated control cells 
were used to set up compensations (50pl for single stains and 100pl for unstained) (Table 
2 .2 ).
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2.1.2 Intracellular cytokine staining procedure
2.1.2.1 Conjugated antibodies used
All antibodies were titrated in preliminary assays to determine the volume required for 
optimal staining as indicated in Tables 2.2 and 2.3.
Table 2.2 Flow cytometry antibodies used for compensation
Marker Clone Source Fluorochrome Vol/test (pi)
CD3 Mouse lgG2a k, Clone HIT3a BD Pharmingen FITC 2
CD3 Mouse lgG2a k, Clone HIT3a BD Pharmingen PE 2
CD3 Mouse lgG1 k, Clone SK7 BD Pharmingen PerCP 2
CD3 Mouse lgG1 k, Clone UCHT1 e-Biosciences PE-Cy7 1
CD3 Mouse lgG1 k, Clone UCHT1 BD Pharmingen Pacific Blue 1
CD3 Mouse lgG2a k, Clone HIT3a BD Pharmingen APC 5
CD3 Mouse lgG1 k, Clone SK7 BD Pharmingen APC-Cy7 2
CD - cluster of differentiation 
FITC - fluorescein isothiocyanate,
PE - phycoerythrin
PerCP - peridinin chlorophyll protein
APC - allophycocyanin
IgG - immunoglobulin
Vol/test (pi) - denote antibody volumes used per test
Table 2.3 Flow cytometry antibodies used for surface staining and ICS
Marker Clone________________________ Source______________ Fluorochrome Vol/test (pi)
IL-13 Mouse lgG1, clone PVM13-1 e-Biosciences FITC 0.5
IL-2 Rat anti-human, clone MQ1-17H12 Beckton Dickinson (BD) PE 2
CD8 Mouse lgG1, clone SK1 Beckton Dickinson (BD) PerCP 5
CD56 Mouse lgG1 k, clone B159 Beckton Dickinson (BD) PE-Cy7 2
IL-10 Rat lgG1 k, clone JES3-9D7 e-Biosciences Pacific Blue 2
IFN-y Mouse lgG2b, clone 25723.11 Beckton Dickinson (BD) APC 1
CD4 Mouse lgG1 k, clone RPA-T4 Beckton Dickinson (BD) APC-Cy7 1
IL - interleukin
CD - cluster of differentiation 
FITC - fluorescein isothiocyanate,
PE - phycoerythrin
PerCP - peridinin chlorophyll protein
APC • allophycocyanin
IgG - immunoglobulin
Vol/test (pi) - denote antibody volumes used per test
2.1.2.2 Surface staining of cells
After 16 hours of culture, cells were lysed with 200pl RBC lysing buffer (Fluorescence 
Activated Cell Sorter (FACS) lysing buffer reconstituted to 10x original volume with distilled 
water, BD Biosciences) for 10 min at room temperature (RT). The plate was then
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centrifuged at 2,000rpm for 10 mins, washed in FACS buffer (0.5% Bovine Serum 
Albumin, 0.1% Ethylenediamine tetra-acetic acid (EDTA) 0.1% sodium azide (NaN3) in 
phosphate buffered saline (BSA) for 5 mins before being stained with surface antibodies.
Cells were incubated with 30pl of surface antibody cocktail (CD4, CD8, CD56) (Table 2.3) 
for 30 minutes at 4°C in the dark (plate was covered with foil). The plate was then spun at 
2,000 rpm for 5 mins. The supernatants were flicked off, and the plate gently vortexed. The 
cells were resuspended and washed with 200pl FACS buffer. Compensations were done 
electronically for every experiment in order to minimize spectral overlap for each 
photomultiplier on the CyanADP® Flow cytometer (Beckman-Coulter, USA).
2.1.2.3 Staining for intracellular cytokines
FACS lysing buffer contains fixative, so following this step, cells were permeabilised by 
adding 200pl of Cytofix/Cytoperm solution (BD, USA) and incubating for 20 mins at 4°C. 
The plate was then centrifuged at 2,000 rpm for 5 mins and supernatants discarded. 10pl of 
ICS cocktail containing IL-13, IL-2, IL-10 and IFN-ywas added to each well (see Table 2.3 
for amounts used per antibody) and incubated for 30 mins at 4°C. After the incubation time, 
200pl of Perm/Wash (BD) was added and the plates centrifuged at 2,000 rpm for 5 mins. 
Supernatants were discarded and the wash repeated a second time. Supernatants were 
again discarded and 150pl FACS fix (1% Paraformaldehyde (PFA)) was added to each 
well. Cells were transferred to 5ml round bottom tubes (BD Falcon, Cedex, France) before 
acquiring on the flow cytometer.
2.1.3 Cell Acquisition
Cells were acquired on a CyAnADP flow cytometer (Beckman-Coulter, USA) (CyAn). 
Following compensations with each flourochrome, we collected a minimum of 100,000 
lymphocyte events for each sample after gating on FSC/SSC.
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2.1.4 Data Analysis by Flowjo
Data were analyzed using Flowjo software (www.flowjo.com). The gating strategy is 
discussed in detail in chapter 7.
2.2 Bio-plex analysis for multiple soluble cytokines
2.2.1 Antigen stimulation
These cultures were set up exactly the same as in the overnight cultures for ICS detailed 
above except that Brefeldin A was not added (because it blocks cytokine secretion from 
the Golgi apparatus). After overnight culture, plates were centrifuged at 2,000 rpm for 5 
mins and 50pl supernatant collected from each well into pre-labelled tubes. These were 
stored at -20°C for later analysis.
2.2.2 Cytokine multiplex assay procedure
2.2.2.1 Samples, standards and controls
The Bio-Plex 200 Suspension Array system (Bio-Rad Laboratories, France) was used for 
analysis of cytokines in culture supernatants. Supernatants that were collected from the 
overnight cultures were thawed and centrifuged at 1,200 rpm for 2 minutes to pellet out 
any debris so as to avoid blockage when acquiring samples.
25pl of culture supernatants were plated out in a 96 well plate in preparation for the assay. 
All samples were diluted 1:2 with media containing 10% serum before running the assay in 
order to detect the secreted cytokines within the range of the standard curves.
We initially ran a series of Group 1 (MV) and Group 2 (MV+DTwP) 10 month samples 
using a 27-plex cytokine kit in order to identify the key cytokines / chemokines that were 
altered in the combined vaccine group (Group2) compared to the MV group (Group 1), and 
those that differed between males and females. The 27-plex kit consisted of pre-mixed 
beads specific for: IL-10, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL- 
13, IL-15, IL-17, Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-y, IP-10, MCP-1, MIP-1a, MIP-
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1b, PDGFbb, RANTES, TNF-a and VEGF. The 10 cytokines/chemokines that were 
predominantly different between vaccine groups were selected and used to analyse the 
remainder of the 9 and 10 month culture supernatants. The 10 cytokines selected were: IL- 
4, IL-13, IFN-y, IL-10, IL-12(p70), Eotaxin, GM-CSF, PDGFbb, TNF-a and VEGF; 
incorporating a combination of Th1, Th2 and innate cytokines (Table 2.4) below.
Table 2.4 10-Plex cytokines analysed, functions and low-high standard value across 
all plates
Analyte Abbreviation Function Low std (pg/ml) High std (pg/ml)
lnterleukin-4 IL-4 Th2 cell-mediated immunity, IgE class switching in B cells, 
Inhibits differentiation of Th1 cells
0.125 32768
lnterleukin-1 (3 IL-1 P Initiation of acute-phase responses 2 32768
Interleukin-10 IL-10 Auto-regulator of Th1 cell activation, anti-inflammatory, 
Th2 cytokine, can inhibit Th1 responses but not just that.
2 32668
lnterleukin-12p(70) IL-12p(70) Regulation of inflammatory response, 
Mediates T cell-dependent immunity
1 49152
Eotaxin Eotaxin Development of allergic responses 0.1875 32768
Granulocyte, macrophage GM-CSF Promotes proliferation, activation, differentiation of macrophages, 0.125 32768
stimulating factor granulocytes, neutrophils, eosinophils, and monocytes.
Interferon-gamma IFN-y Immunomodulatory effects, inhibits Th2 lymphocyte proliferation, 
anti-viral and anti-parasitic agent
1 32768
Platelet-derived growth factor-bb PDGF-bb Promotes lymphangiogenesis (Cao R et al. 2004) 0.75 32768
Tumour necrosis factor--a TNF-a Cellular proliferation/differentiation, Th1 and innate cytokine 
tumorigenesis, apoptotic or necrotic cell death
0.5 65536
Vascular endothelial growth factor VEGF Vascularization, promotes cell survival 0.5 49152
Std - Standard
The lyophilized standard was reconstituted in 500pl RPMI medium containing 10% bovine 
serum albumin (BSA) (VWR, UK), vortexed and incubated on ice for 30 minutes. The 
manufacturer’s instructions were followed in making 1:4 serial dilutions of the standard 
using the RPMI medium and thus creating 8 standards for the low Photomultiplier Tube 
(PMT) settling, allowing for a broad range standard curve. Eight 1.5ml eppendorf tubes 
were labelled (S1 - S8); 72pl of standard diluent was added to S1 tube and 150pl to the 
rest of the tubes (S2 - S8). 128pl of the reconstituted standard was added to the S1 tube. 
The tube was vortexed and 50pl from this S1 tube was added to the next tube (S2). 50pl 
from this S2 tube was added to the S3 tube and so on making serial dilutions of the 
standard. The pipette tip was discarded after each transfer. The standard ranges differed 
for each analyte and are listed in Table 2.3.
The reagent and wash buffer solutions in the 96 well plate were removed during all steps 
of the assay by vacuum filtration using the Aurum vacuum manifold (BioRad, Belgium) with 
1-2 Hg pressure. A lint free paper towel was used to blot excess fluid from the bottom of 
the plate after each vacuum step.
2.2.2.2 Assay protocol
The filter plate provided with the kit was first pre-wet using 100pl of assay buffer (Bio-Rad 
Laboratories, France). The assay buffer was removed by vacuum filtration and the plate 
was washed twice with 10OpI wash buffer.
The conjugated microsphere beads were then prepared: pre-mixed beads were vortexed 
vigorously for 20-30 seconds to dislodge bead aggregates before diluting with assay buffer 
(according to manufacturer’s instructions) and 50pl was added to each well of the assay 
plate. 50pl samples (single wells), 50pl standards (induplicate) and 50pl RPMI (Blank, 
added to two wells to measure background production of cytokine) were added to the 
appropriate wells. The plate was sealed with sealing tape, covered in foil and incubated by 
shaking at 1,100 rpm for 30 seconds followed by 300 rpm for 30 minutes.
The biotinylated detection antibody was diluted according to the manufacturer’s 
instructions during this incubation time and wrapped in foil. At the end of the incubation, 
the plate was washed three times with 200pl per well of wash buffer with the vacuum 
manifold. Following blotting, the detection antibody was vortexed gently and 25pl added to 
each well. The plate was sealed with sealing tape, covered in foil and incubated for 30 
mins. The streptavidin-PE reporter antibody was diluted 1:10, 25pl added to each well of 
the assay plate (following washing) and incubated (shaking) for 10 minutes. The plate was 
given a final three washes with wash buffer and each well resuspended in 125pl of assay 
buffer. The plate was then shaken for 30 secs at 1,100 rpm before reading it on the Bio-
86
Plex 200 Suspension Array system (Bio-Rad) with Bio Plex Manager software version
4.1.1 (Bio-Rad Laboratories, Hercules, CA).
2.2.3 Calibration and acquisition
The Bio-Plex reader was calibrated before every run using CAL1 and CAL2 calibration kits 
(Bio-Rad, UK) with low RP1 target values (used for broad range standard curves).
Data acquisition was set for 50 beads per region and the bead map at 100 regions. The 
sample volume was set to 50pl and the DD gate value was set at 5,000 (low) and 25,000 
(high). Following data acquisition, normalization of the data was performed including 
removing standard curve outliers with a co-efficient of variation (%CV) greater than 10% 
and observed/expected ratio x 100 (obs/exp*100) outside the range of 100 +/- 20. The MFI 
max (FL-Bkgd) of the individual standard curves was defined as the Fl-Bkgd just before the 
non-linear part of the curved is reached. The checked/corrected bioplex data was exported 
as an excel file. All results had background wells subtracted automatically. Standard 
concentrations were fairly similar across all plates (Figure 2.1).
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Figure 2.1 Per-plate standard curve concentrations. Standard curves forall cytokines 
for all plates with the observed concentrations in pg/ml indicated on the Y-axis and all 
plates on the X-axis. Each colour represents one of the 8 standard 
dilutions/concentrations (ranging from 0.25 pg/ml to 4096 pg/ml). For each cytokine, the 
observed concentration for each of the 29 experiment plates is plotted. The light-grey 
vertical rectangles highlight data coming from the 27-Plex plates. Graphs prepared by 
Thorsten Foster at the Department of Pathway Medicine, University of Edinburgh.
2.2.4 Data analysis
Antigen-stimulated wells had the medium control background value subtracted. Results 
that were out of range were corrected (>OOR or <OOR). Samples >OOR were corrected 
as two times the highest value read for that particular cytokine and samples <OOR were 
corrected as half the lowest value for that particular cytokine before statistical analysis.
2.3 Diptheria, tetanus and pertussis antibody measurements using a multiplex 
immunoassay (MIA)
These assays were kindly performed by our collaborators based at the National Institute of 
Public Health and the Environment (RIVM), Netherlands. This technology has now been 
successfully transferred to MRC, The Gambia as a result of this collaboration.
Samples assayed were 50pl aliquots of plasma from 9 month (pre-vaccination) and 10 
month (1-month post-vaccination) old donors. Multiplex technology can be used for the 
detection and quantification of multiple vaccine antibodies in relevant samples (Pickering et 
al., 2002a; Pickering et al., 2002b; Lai et al., 2004; Lai et al., 2005; Prince et al., 2006; 
Pickering et al., 2007). It allows a higher sample throughput using a small sample volume 
without losing the advantages of the conventional ELISA assay. The multiplex microsphere 
based fluorescent immunoassay quantifies total IgG serum antibodies directed against the 
target antigens: pertussis toxin (Ptx), diphtheria toxoid (Dtx) and tetanus toxoid (Ttx). Dtx, 
Ttx and Ptx standards and controls were prepared in-house (reviewed in (van Gageldonk 
et al., 2008). When diluted human serum is added to these beads, antibodies specific for 
Ptx, Dtx and Ttx bind to the antigen proteins. The bound antibodies were detected using a 
goat anti-human conjugate labeled with R-phycoerythrin. The beads are individually 
measured using a Bio-Plex 200 system.
2.3.1 Conjugation of Ptx, Dtx and Ttx to carboxylated microspheres
The two solutions that make up the bead activation buffer were prepared separately and 
were combined just before use. This bead activation buffer contains 1 x phosphate 
buffered saline (0.01 M; pH 7.2), 2.5 mg/ml 1-ethul-3-(-3dimethylaminopropyl)-carboiimide 
hydrochloride (EDC), and 2.5 mg/ml N-hydroxy-sulphosuccinimide (Sulpho-NHS). The 
microsphere stock solutions were vortexed vigorously for 30 mins on a minishaker. 1ml of 
the homogeneous carboxylated microsphere solution (12.5x106 microspheres) was added 
to a 1.5ml reaction vial (Starlab, Ireland) and centrifuged for 4 mins at full speed in the 
minispin centrifuge (13,400 rpm). The supernatant was discarded and the beads 
resuspended in 1ml of freshly prepared bead activation buffer and vortexed vigorously to 
mix. The tube was then wrapped in aluminium foil and incubated for 20 mins at room 
temperature (RT) under constant rotation on a rotator. The microspheres were then 
washed by centrifuging at 13,400 rpm for 4 mins. The supernatant was carefully removed 
because the microspheres easily come loose. The microspheres were resuspended in 
1ml of buffer (1xPBS) and vortexed briefly. This wash step was repeated 2 more times.
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While performing these washing steps, the antigen solutions for the conjugation step 
were prepared according to the bead conjugation ratio schedule given in Table 2.5 below.
Table 2.5 Bead conjugation ratios used in the multiplex MIA assay
Bead conjugation ratios:______________________________________________
Ptx (60): 10 pg/12.5*106 microspheres
16 pi 0.806 pg/pl PEG004 batch + 628 pi 1xPBS: 500 pi for re-suspension of the beads
Dtx (45): 50 pg/12.5*106 microspheres (before conjugation purified diphtheria toxin (1 
mg/vial = 1 mg/ml when reconstituted in 1 ml sterile water) is dialyzed 2x against 2 Itr 
1xPBS).
50 pi 1 pg/pl Dtx batch (1 mg/ml, D05604) + 450 pi 1xPBS: 500 pi for re-suspension of 
the beads
Ttx (28): 50 pg/12.5*106 microspheres (for conjugation purified tetanus toxin (25 pg/vial 
= 0.1 mg/ml when reconstituted in 250 pi sterile water) is used).
50 pg freeze-dried Ttx (Sigma Aldrich T3194) + 500 pi sterile water: 500 pi for re- 
suspension of the beads__________________________________________________
Ptx = pertussis toxin, Dtx = diphtheria toxoid and Ttx = tetanus toxoid
The protein used for coupling must be free of sodium azide, BSA, glycine, Tris or amine- 
containing additives and must be suspended in PBS, pH 7.4. The supernatant was then 
aspirated until all the remaining fluids were removed and the microspheres were 
resuspended in the 500pl antigen (bead conjugation ratio according to schedule above). 
The tube was vortexed and wrapped in foil and incubated at RT for 2 hrs under constant 
rotation. After 2 hrs of incubation, the microspheres were washed by centrifugation as 
described above, the washing step was repeated two more times. The microspheres were 
centrifuged at 13,400 rpm for 4 mins and the supernatant aspirated. The microspheres 
were then resuspended in 1ml bead storage buffer (1xPBS, 0.05%(w/v) azide, 1.0%(w/v) 
BSA) and vortexed at high speed for 30 secs and sonicated for 30 secs.
10pl of the homogenous aliquoted bead suspensions were diluted 1:20 in storage buffer. 
10pl of the diluted microsphere solution was added to a colony counting chamber (glasstic 
slides Hycor) and the number of microspheres counted in 15 grids in triplex. The count was 
recorded, as it was required for the preparation of the bead solution in the multiplex
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immunoassay. The microspheres were then stored in the dark at 4°C until required for the 
immunoassay. These are stable for up to 12 months.
2.3.2 Determination of the DTP MIA values
Those values that were out of range, were corrected (>OOR or <OOR). Samples >OOR 
were deleted and samples <OOR or with MFI’s below the lowest concentration of the 
standard curves were corrected to the established lower level of quantification (LLOQ) for 
statistical analysis. LLOQ = 1 EU/ml for all Ptx (established with Pertussis standard mBP: 6 
steps 4-fold dilutions (1/200 to 1/204,800); LLOQ = 0.001 lU/ml for DTx (established with 
DT standard Bui: 8 steps of 4-fold dilutions (1/50 to 1/819,200). For each analyte, median 
fluorescent intensity (MFI) was converted to EU/ml or lU/ml by interpolation from a 5- 
parameter logistic standard curve (log-log) for every bead region/standard.
Results marked outside the linear part (>MFI max) of the standard curve (1/200 dilution) 
were accepted when the %CV <20, otherwise these results were discarded and the final 
result is based on the 1/4,000 result only.
2.4 Measles HAI antibody assay
This assay was performed in The Gambia with the help of Jainaba Njie-Jobe.
Plasma samples stored at -20°C were thawed and 40pl of each sample was aliquoted into 
labelled 1.5ml eppendorf tubes and decomplemeted by incubating in a water bath at 56°C 
for 30 mins. A 5% solution of Cercopithecus rbcs, diluted in HAI buffer, was prepared and 
100pl aliquoted into 0.5ml eppendorf tubes and spun at 6,500 rpm in a microcentrifuge for 
1-2 mins. The supernatant was discarded and the red cell pellet was retained. 35pl of the 
decomplemented samples were then added to the pellet in the eppendorf tubes and mixed 
gently using a pipette before overnight incubation at 4°C. The following morning, the tubes 
were spun at 6,500 rpm for 2 mins to pellet the erythrocytes. 25pl of HAI buffer was then 
added to all wells of the microtitre plate using a multichannel pipette. Plasma (25pl) from 
the eppendorf tubes containing the pelleted erythrocytes was carefully added to the
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appropriate well of the microtitre plate. A multichannel pipette was then used to make a 2- 
fold serial dilution by taking 25pl from the wells in the first column and adding it to the wells 
in the second column. The well contents were mixed thoroughly after each transfer and 
the remaining 25pl after the last transfer was discarded. 25pl of the measles antigen 
(diluted 1:600 in HAI buffer) was then added to all wells except the negative control wells 
and the sides of the plate gently tapped to ensure maximum contact. The plate was then 
incubated at 37°C for 3 hours. 25pl of a 0.5% solution of Cercopithecus rbcs (diluted in HAI 
buffer) was then added to all wells and the sides tapped gently to mix. The plates were left 
at room temperature overnight to be read the following morning. Controls were added to 
the assay and were treated the same way as the samples. For positive control wells, 25pl 
HAI buffer plus 25pl of measles antigen plus 25pl of 0.5% Cercopithecus rbcs was used. 
For the negative control wells, we added 50pl of HAI buffer plus 25pl of 0.5% 
Cercopithecus rbcs. Measles antigen was not added to the negative control wells. In-house 
standards were also included in this assay. The standard was serum decomplemented and 
absorbed against Cercopithecus rbcs. It had been calibrated against the second 
international standard antisera and found to contain 500mlU/ml of measles HAI antibody. 
25pl of the standard was diluted 1:4 in HAI buffer and added to the first column of the 3 
standard control wells and treated the same as the samples.
2.4.1 HAI plate reading
The plates were read the next day by placing over a light box by two independent 
observers. The titre was given as the dilution at which no agglutination occurred, i.e there 
was complete neutralization of the agglutinin. The minimum detection level of the assay is
31.2 mill. Results were expressed as log2 units. A protective level is defined as 125mlU 
antibody or a log2 titre > 3 (Samb et al., 1995). Measles HAI antibody tires have been found 
to correlate with neutralizing antibody titres as described (Samb et al., 1995).
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2.5 Whole-human genome microarray analysis
This part of the project was carried out in collaboration with the Division of Pathway 
Medicine, University of Edinburgh. Much of the work in Edinburgh was carried out by my 
collaborators although I had the opportunity to visit the unit and learn the assay and 
software used for analysis of the microarray data but i did not carry out the work.
2.5.1 Samples for RNA extraction
500|jl whole blood collected directly into Paxgene™ tubes (Qiagen, Crawley, UK) and 
frozen at -70°C were thawed at room temperature for 12 hours before RNA extraction. RNA 
extraction was carried out using PAXgene™ blood RNA extraction kits (Qiagen) according 
to the manufacturer’s instructions. Briefly, cells were pelleted by centrifugation at 8,050 
rpm for 10mins, and pellets washed and resuspended in lysis buffer, incubated with 
proteinase K and binding buffer and then transferred to the shredder spin column. The flow 
through was mixed with ethanol and loaded on to PAXgene RNA spin columns. After a 
series of washing steps the DNA was degraded using DNAse and the remaining RNA 
eluted with elution buffer and stored at -70°C. For RNA quantification a 1 j j I  sample was 
loaded on to The Thermo Scientific NanoDrop™ 1000 Spectrophotometer, and the RNA 
concentration calculated and contamination assessed using the 260/280 absorption ratio. 
These steps were carried out in The Gambia and the RNA was then shipped to DPM in 
Edinburgh on dry ice. The RNA was subjected to a second quality analysis on arrival in 
Edinburgh using the Agilent Bioanalyser system (Agilent). Quality control using the Agilent 
Bioanalyser 2100 and Nanodrop ND1000 was used to determine RNA samples of sufficient 
quality and quantity, and 360 samples were selected for subsequent microarray analysis. A 
gel matrix was prepared according to Agilent Technologies manufacturer’s handbook by 
centrifugation of 30pl of gel and 2pl of dye mix. Nine microliters of gel was loaded onto a 
Caliper®, LabChip® under pressure to fill the chip capillaries, 1pl of sample was then 
loaded into each well and 1pl of known marker loaded to the ladder well. The Agilent 2100 
Bioanalyzer was used to process the chips and record the RNA concentration. The RNA
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integrity number (RIN) was used to evaluate RNA degradation according to the 18s/28s 
ratio, with a target RIN of >7.
2.5.2 Whole Human Genome Microarray Analysis
100ng total RNA was converted to double-stranded cDNA, followed by an amplification 
step (in vitro transcription) to generate labelled cRNA, using the Ambion lllumina 
TotalPrep-96 RNA Amplification Kit. This produces an amplified pool of biotin-labelled 
cRNA corresponding to the polyadenylated (mRNA) fraction. The cRNA was quantified 
using OD (nanodrop). The cRNA was normalised and hybridised onto the lllumina HT12 
arrays for 14-20 hours at 58°c (Figure 2.2). The unhybridized and non-specifically 
hybridized cRNA was washed away. The arrays were stained with Cy3-Streptavidin to bind 
to the analytical probes that have been hybridized to the array. This allows for differential 
detection of signals when the arrays are scanned. The lllumina IScan scanner is a two- 
colour laser (532 nm/658 nm) fluorescent scanner with a 0.53 pm spatial resolution 
capable of exciting the fluorophores generated during the staining step of the protocol. 
Light emissions from these fluors were then recorded in high-resolution images of the Array 
sections. The intensities of the images were extracted using Genome Studio (2010.3) 
Gene Expression Module (1.8.0) software.
Biotin Labeled 
* cRNA
u L i
Address Probe
50 bases
Figure 2.2Hybridization of probe to a labeled nucleic acid derived from total RNA
Conversion of total RNAto double-stranded cDNA followed by amplification to produce 
several copies of the transcript creating a pool of biotin-labelled cRNA that correspond to 
the polyadenylated (mRNA) fraction.
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2.5.3 Microarray data processing and statistical analysis
Primary data were obtained from Tepnel/Gen-Probe (Experiment TPS01421). Arrays were 
all quality control tested before proceeding with the next step. The arrays used in the 
experiment were Human HT-12 V3 (lllumina), each comprising 47,293 features. A total of 
360 arrays were QC analyzed using the array Quality Metrics package in Bioconductor 
(Kauffmann et al., 2009). The samples used consisted of 202 gender-matched donors with 
pre- and post-vaccination RNA samples available. Arrays were scored (outliers identified) 
on the basis of 2 metrics, namely maplot, boxplot. Raw data were transformed using a 
variance stabilizing transformation (VST) method prior to normalization across all arrays 
using the robust spline normalization (RSN) method. Expression measures (summarized 
intensities) are in log base 2. As gender information for each sample was provided, a 
"gender check" was performed, using Y-chromosome specific loci to identify male samples.
Twenty-four comparisons, manually chosen to explore the data, were undertaken using 
linear modeling using linear models for Microarray Data (Limma), which is an R package 
for statistical computing. The first step in fitting a model is to form an appropriate design 
matrix for the RNA sources. This requires one or two matrices to be formed; one is called 
the design matrix that identifies the RNA sources and the other is the contrast matrix that 
identifies the comparisons to be made between the RNA samples. The design matrix 
specifies the model. Subsequently, empirical Bayesian analysis was applied (including 
vertical (within a given comparison) p-value adjustment for multiple testing, which controls 
for false discovery rate). Multiple samples from the same individual were taken into account 
when modeling the data. The resulting gene lists were fully annotated and sorted in order 
of decreasing significance.
2.5.4 Functional analysis of significant genes
Both unpaired and paired analyses were carried out since not all 9 month samples had a 
corresponding 10 month sample and vice versa. An overview of the underlying biological 
changes occurring within each paired and unpaired comparison was obtained by functional
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enrichment analysis. This was performed using 2 software tools, namely KEGG pathway 
(www.genome.jp/kegg/) membership and Gene Ontology (GO) 
terms(www.geneontology.org). Although there is always a degree of overlap between 
functional annotations from different sources, each set has information/applications not 
available in the others, and thus it is generally beneficial to consider more than one. The 
level of statistical significance for functional analysis was chosen to be the level at which 
1% of the array features were, on average, significant. For the current dataset, raw p<0.01 
was appropriate for the 18 comparisons performed.
For KEGG analysis significant genes (raw p<0.01) from each comparison were analyzed 
for enrichment of KEGG pathway membership using a hypergeometric test. Enrichment 
(p<0.05) was assessed for up-regulated and down-regulated genes separately.
The GO project uses three ontologies for the description of genes and their associated 
biological processes, cellular components and molecular functions independent of the 
species. This ensures uniformity of queries across databases. Significant genes (raw 
p<0.01) from each comparison were analyzed for enrichment of GO terms across all three 
GO ontologies using a hypergeometric test. Enrichment (p<0.001) was assessed for up- 
regulated and down-regulated genes separately.
2.5.5 Network analysis of the dataset
A data matrix of normalized, anti-logged, intensity values for probesets on all arrays was 
generated. The Pearson correlation between every object (a single probeset's values 
across all arrays) and every other object in that matrix was determined, effectively 
calculating the similarity in the profile of expression of every gene on the array across the 
samples analyzed, to every other gene on the array. All relationships above a certain 
threshold were stored.
The stored annotated data was used as an input file for the generating networks using 
Biolayout software (available at (www.biolayout.org). Networks were laid out for all
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relationships exhibiting a Pearson correlation greater than 0.75. Markov clustering (MCL) of 
nodes was undertaken (expansion value 1.7), and functional analysis of each cluster was 
performed using both public and proprietary expert knowledge.
Expression networks were constructed employing the Ingenuity Pathway Analysis 
software (Ingenuity Systems, (www.ingenuity.com)). lllumina Probe IDs were imported 
into the Ingenuity software and mapped to the Gene Symbol from Ingenuity database. 
Genes that had adjusted p-value, 0.05 and associated with a canonical pathway in 
Ingenuity’s Knowledge Base were used for pathway analysis.
2.6 Statistical analysis of cellular assays and antibody data
2.6.1 Basic analysis of cellular and antibody data
Most of the cellular and antibody data generated in this study were non-normally 
distributed and thus non-parametric tests were used throughout using Prism statistical 
software. Comparisons between males and females, and responses between vaccine 
groups were generally performed using the Mann-Whitney U-test at 5% significance level 
and differences across all groups were analysed using the Kruskal-Wallis test with Dunn’s 
multiple comparison testing. The Benjamini-Hochberg False Discovery Rate was used to 
correct for the many comparisons made (henceforth refered to as FDR) (Benjamini and 
Hochberg, 2005). The FDR accounts for multiple adjustments when more than 1 
parameter is being measured in an assay. It controls the false discovery rate, that is, the 
expected proportion of false positives among the variables for which there is a significant 
difference. This means that the proportion of true null hypotheses is lower than a specified 
threshold. For our 10 cytokines, P-values <0.035 were considered significant to account 
for FDR.
2.6.2 GLS regression model
Development of a model for the soluble cytokine data was done under the guidance of 
David Jeffries and Lindsey Kendall at the Statistics department, MRC Gambia unit.
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Other statistical tools for the Bioplex cytokine data analysis employed a GLS regression 
model using STATA statistical software, STATA 12.1, Copyright 1985-2011 StataCorp LP, 
Statacorp USA, (http://www.stata.com). Since our data were non-normally distributed, they 
were first ranked to make them fairly normal. Interactions between bleed and group by sex, 
as well as sex and bleed by group, for all conditions were performed. In order to do this, we 
first had to write a model that fit the data and described it well.
We first set STATA to handle the data by defining the entity (donor) in the dataset, using 
the command xtset donor. We built the model by using commands that would test for 
interactions between parameters (bleed, group, sex) for all the conditions in the data at 
each time point. The model was written as; xtreg r10 i.bleed##i.group i.bleed##i.sex2
i.sex2##i.group if condition2=2, for condition 2 in this example testing males versus 
females for each bleed group comparison. The model was used for each condition and all 
our analysis was derived from it. We compared cytokine levels of the three vaccine groups 
at 9 months and at 10 months. We also assessed whether being male or female (effect of 
sex) affected cytokine levels in a group. To study sex differences, we directly compared 
males and females within each group at 9 months and at 10 months.
I was not able to do a pre to post comparison for this chapter because it is very difficult and 
cumbersome to interpret a three way comparison, so we did a two way comparison for 
each time point. A pre to post comparison has been done for all the other chapters in the 
thesis. The lincom command (linear combination) was used to calculate linear 
combinations of the parameters of our linear model. This lincom command was used after 
fitting the model to run all our analysis to obtain the P-values, confidence intervals, 
standard errors and coefficient of variation.
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CHAPTER 3
STUDY DESIGN AND COHORT CHARACTERISTICS
3.1 Introduction
3.1.1 The Republic of The Gambia
The Republic of The Gambia is the smallest country in mainland Africa with a population 
of 1,883,051 million ((CIA), 2013) and an annual population growth rate of 2.9% down 
from 4.2% during the 1983 to 1993 inter-census period (Department of Central Statistics, 
2003). The country is narrow and takes its shape from the River Gambia with a total land 
area of 11,295 sq km; 10,000 sq km of which is dry land and 1,295 sq km is covered by 
water. It is less than 48.2 km at its widest end (the mouth of the Atlantic Ocean). The 
Gambia has borders with only one country, Senegal, which surrounds it on three sides 
and has 50 miles of coastline on the Atlantic Ocean on the west ((CIA), 2013).
Figure 3.1 Map o f the Gambia and location o f MRC (UK), Gambia Unit and MRC Sukuta 
field site.
There are 5 major tribes in The Gambia: Mandinka (42%), Fula (18%), W olof (16%), Jola 
(10%), Sarahule (9%), others 4% and non-African 1% (Department of Central Statistics, 
2003). The population comprises approximately 90% Muslims, 9% Christians, with the 
remaining 1% following indigenous beliefs (US. Department of State, 2007).
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3.1.2 Public Health - Infant Immunizations
Life expectancy in The Gambia for males and females is 57 years and 60 years 
respectively. The neonatal mortality rate is 31 per 1,000 live births; <1 year mortality is 57 
per 1,000 live births; and under five mortality is 98 per 1,000 live births ((WHO)-UNICEF, 
2011). Five years after The WHO established The Expanded Programme of Immunization 
(EPI) in 1974, The government of The Gambia implemented the National EPI program in 
1979 which currently offers free vaccination against major diseases such as tuberculosis 
(BCG), diphtheria, tetanus and pertussis (DTwP), measles, polio and yellow fever, 
hepatitis B (HBV), Haemophilus influenza type B (Hib) and Streptococcus pneumonia (13- 
valent conjugated pneumococcal vaccine PCV-13) (see Table 1.1, Chapter 1). At the time 
of doing this study the EPI scheme was slightly different to the current one as shown in 
Table 3.1.
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Table 3.1 The EPI schedule at the time of the study, indicating vaccines 
given and blood samples taken throughout the study period
Vaccine Groups
Age MV Group MV+DTwP Group DTwP Group
Birth O PV /B C G /H B V O P V /B C G /H B V O PV /B C G /H B V
1m O P V O P V O PV
2m DTwP 1 /H  i b/O P V /H  B V DTwP 1 /H  i b/O P V /H  B V DTwP 1 /H  ib/O P V /H  B V
3m D Tw P2/H ib/O PV DTw P2/H ib/O PV D Tw P2/H ib/O PV
4m DTw P3/H ib/O PV/H B V H ib/O PV/HBV H ib/O PV/HBV
6m VitA VitA VitA
9m Blood sample Blood sample Blood sample
9m M V M V/DTwP3 DTwP3
10m Blood sample Blood sample Blood sample
11m Y F /O P V Y F /O P V M V /Y F /O P V
Key
OPV Oral polio vaccine
BCG Bacillus Calmette Guerin
HBV Hepatitis B virus
DTP Diphtheria, tetanus with whole-cell pertussis combined vaccine
Hib Haemophilis influenza B
VitA Vitamin A
MV Measles Vaccine
YF Yellow Fever
The key vaccine differences are in blue text and the age at which the study intervention occurrec 
are shaded in light purple.AII outstanding vaccines were administered at 11 months of age 
(yellow fever andOPV for the MV group and the MV+DTP group, and MV, OPV and YF for the 
DTP group).
It is estimated that 2.5 million child deaths could be prevented each year by vaccination 
with notably higher survival rates in children who received all scheduled vaccines by 9 
months of age. Vaccination therefore is central in the aim to reduce infant mortality and to 
achieve millennium development goal 4 (MDG4) -  the reduction of under-five mortality 
rates by two thirds by 2015 (World Health Organization (WHO), 2005; World Health 
Organization (WHO), 2009). A study in The Gambia to assess vaccine coverage and the 
determinants of immunization in a semi-rural area in The Gambia reported high national 
coverage rates, 73% for measles vaccine, 86% for BCG and 92% for HBV1, but reduced
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coverage in older children (>1 year) (Payne et al., 2013). WHO estimated 95% coverage 
for many immunizations (measles, yellow fever and third dose of DTP, Hib, HBV and 
polio) among 1-year-olds in The Gambia in 2009 ((WHO)-UNICEF, 2011).
3.1.3 MRC Sukuta Field Site
The Sukuta Health Centre is in a peri-urban area in Kombo district, 20 km from the main 
MRC Laboratories in Fajara. It is a Government Health facility and has been collaborating 
with MRC for more than a decade. The MRC clinic was established in January 2001 as a 
field site for clinical trials and provides an excellent setting to examine the development of 
the infant immune system in response to vaccination. Sukuta is a stable community, which 
is very important for follow-up of the children enrolled in studies. The field site consists of 
a team of field workers, qualified nurses and 2 paediatricians. The field workers are 
provided with motorbikes to enable them to visit study participants in their homes during 
follow-up in all seasons. We also have a study database developer and a data entry team 
that double enters and verifies all data collected. All samples collected from the field site 
are transported to MRC Fajara within an hour for processing by the infant immunology 
laboratory team who have extensive experience in handling and processing small volume 
blood samples from infants.
3.2 Study design
3.2.1 Ethical approval and informed consent
The Joint Gambia Government/MRC Ethics Committee, and the London School of 
Hygiene and Tropical Medicine Ethics Committee approved the study protocol. A subject 
information sheet was given to parents/guardians that were considering joining the study. 
For those that could not read, it was read to them in their native language and the field 
worker ensured that the information was well understood. Those who agreed were asked 
to sign or thumbprint the consent form. The subject information sheet and the consent 
form are attached as appendix 1 and 2 respectively at the end of the thesis. The study
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was conducted according to International Conference of Harmonization/ Good Clinical 
Practice (ICH-GCP) guidelines.
3.2.2 Vaccination study groups, follow up and bleeding schedule
The results described in this thesis are part of a larger study (SCC1085) on understanding 
the broad immunological effects of infant measles or DTwP vaccination, or a combination 
of both vaccines. I led the laboratory aspects of the entire study. Infants presenting for 
their first dose of routine DTwP vaccine at 2 months of age at Sukuta Health Centre in 
The Gambia were identified and the parents/guardians approached; the study was 
explained and they were invited to participate in the study. The selection criteria required 
that all vaccines be up-to-date for these infants according to the current EPI schedule 
(Table. 3.1), and that children were healthy and afebrile on the day that they were 
recruited. Sick and underweight infants were therefore excluded. Informed consent was 
obtained from the parent/guardian at this 2 month visit. At 4 months of age the infants 
were randomized into one of three vaccine groups (Table 3.1) by picking an envelope 
containing the vaccine group (envelopes were arranged in sequential order and 
randomization performed in blocks by an independent statistician). Males and females 
were randomised separately to allow stratification by sex.
The randomized infants received different vaccine schedules at 4, 9 and 11 months of age 
according to which study group was randomly selected: Group 1 (MV group) received the 
normal EPI schedule of DTwP3, HBV and OPV at 4 months, whereas Group 2 
(MV+DTwP group) and Group 3 (DTwP group) donors had their DTwP3 dose withheld 
and only had HBV and OPV (Table 3.1) above. At 9 months of age the MV group children 
received a single intramuscular (im) dose of measles vaccine (Edmonston Zagreb, Serum 
Institute of India Ltd, Pune, India) into the right deltoid; the MV+DTP group received MV in 
the left deltoid and an im dose of DTwP (UNICEF) in the thigh; and the DTwP group 
received DTwP alone as for MV+DTwP group. Any child that dropped out of the study was
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given any missed vaccines according to the recommended EPI schedule and a drop out 
form was completed.
3.2.3 Blood handling
4.5 mis of venous blood was collected from the 9-month old study participants prior to 
vaccination into a heparinized tube (7.5 units heparin per ml of blood) and at 4 weeks 
post-vaccination (10 months old); and 0.5 mis of whole blood was also collected into a 
Paxgene tube (Qiagen) for later RNA extraction and whole genome microarray 
transcriptome analysis at both time points. All samples were immediately transported to 
MRC Fajara for processing or storage as appropriate (Figure 3.2).MRC field staff recorded 
the vaccines given and these were then entered into a database and a schedule of follow 
up was set up to maintain the appropriate vaccine schedules for each child.
On arrival at the laboratory, 250pl of blood was used for full blood count (FBC) analysis on 
a CA620-20 Balder parameter system (Boule Medonic, Stockholm, Sweden). 1.2 ml of 
whole blood was used (100pl/well) for setting up the cultures in two separate plates for 
overnight intracellular staining (ICS) and for analysis of cytokines in culture supernatants 
by Bio-plex assay, as indicated in the flowchart (Figure 3.2). The remaining blood was 
spun and plasma collected and stored at -20°C until required for use for the vaccine 
antibody assays, and PBMC separated and stored in liquid nitrogen for future use. 
PAXgene blood samples were stored at -70°C for later RNA extraction in batches.
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Medonic FBC
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Whole Blood
Supernatant
(5 0 p L )
All cells for ICS 
Flow panel
4.5 mLs 
Whole Blood
Medium aCD3/aCD28 Measles ‘H’ Pool TT PPD
ICS overnight culture & culture for 
supernatant cytokines in separate 96 
well plates (600pL = 100pL per 
antigen/plate)
-70°C
PAXgene Blood Sample 
(0.5 mLs)
i
-70°C
1f
Extracted RNA
-70°C
Figure 3.2 Blood handling flowchart. On arrival in the laboratory, the blood samples 
were divided between the assays to be performed as indicated in the flowchart.
3.2.4 Study Documentation
A series of case report forms (CRFs) were prepared for the study. At the first study visit 
information about the child’s contact details and health were collected including a full 
vaccination history. Children were then followed up monthly from 2 months of age to 19 
months, and CRFs completed including health details and vaccines given and recording 
those blood samples taken. If a child failed to attend for a scheduled visit the reasons 
were documented and efforts made to retain the child in the study. If a child dropped out 
of the study, a drop out form was completed and any missing vaccines were given. 
Separate forms documented the location of stored samples and results of the FBC from 
the Medonic analyzer. The data management team created a secure Microsoft Access 
database that held all the subject information.
106
3.3 Study numbers & cohort characteristics
3.3.1 Study numbers
A total of 368 infants were sensitized at 2 months of age in order to ensure adequate 
study numbers, and 302 of them were randomized into the study at 4 months of age. 
Blood samples were received from 273 infants at the 9 month time point and 254 at the 10 
month time point. Thus, 29 infants (9.6%) dropped out of the study between 4 and 9 
months, and a further 19 (6.3%) more infants dropped out by the 10 month bleed (Figure 
3.3). Of these approximately half were males and half females since males and females 
were randomized separately.
Drop out by 10 
month bleed (19)
Sensitized at 2 
months (368)
Drop out by 9 
month bleed (29)
Dropped out before 
joining study (66)
Bled at 9 months 
(273)
Bled at 10 months 
(254)
Randomized at 4 
months (302
Figure 3.3 Hierarchy flow chart: demonstrating the subjects retained and lost from the 
study at each time point
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3.3.2 Study Dropouts
There were a total of 48 study participants that dropped out of the study for various 
reasons by 10 months, accounting for 16% of the 302 recruited into this study, which is 
less than the predicted 20% dropout rate. This rate is similar to previous longitudinal 
studies carried out in Sukuta. Any child that deviated from the study protocol was removed 
from the study and a drop out form completed. Table 3.2 provides details of the reasons 
for participant drop out.
Table 3.2 No of drop outs and reason for dropping out of the study
Reason for Drop out 9 month 10 month
Withdrew consent 13 9
Deviated from Protocol 2 1
Travelled 7 4
Died 1* 0
Relocated 6 5
Total 29 19
* Subject died after recruitment and before receiving any vaccine
The number of participants that dropped out after recruitment and the reasons for doing 
so. Those that travelled dropped out because they missed a bleed and their time of return 
was not known.
3.3.3 Cohort Characteristics
There was no difference in ethnicity between the groups with the majority being Mandinka, 
while Wolof and Fula constituted between 2 - 3% and 2 - 6% in the three vaccine groups 
respectively (Table 3.3). The median weight of the male children was slightly higher at 
baseline compared to females in all 3 groups (Table 3.3). All females and males infants in 
the study were being breastfed at baseline in the three groups. Formula milk feeding was 
not common in the three groups. These variables are therefore unlikely to be confounders 
in this study as the numbers are similar in female and male infants in the three vaccine 
groups.
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Table 3.3 Cohort characteristics for the three vaccine groups
MV group MV+DTwP group DTwP group
Characteristics Female Male Female Male Female Male
No. in Study 48 58 56 sg 37 44
Ethnicity Mother (Father) %
Mandinka 38 (31) 42 (34) 47 (47) 41 (36) 27 (23) 29 (28)
Wolof 1(5) 5 (4 ) 3 (4 ) 3 (4 ) 2 (4 ) 3 (4 )
Fula 3(5 ) 6(10) 3 (3 ) 7(11) 5 (4 ) 5 (5 )
Jola 3 (4 ) 2 (4 ) 0 (0 ) 3 (1 ) 1 (2) 3 (1 )
Other 3(3 ) 3 (6 ) 3 (2 ) 5 (7 ) 2 (4 ) 4 (6 )
Education Mother (years)
<3 yrs 6 12 10 6 4 3
3-10 yrs 30 36 32 36 23 30
>10 yrs g g 21 10 8 8
Unknown 3 1 2 4 2 4
Breasfeeding status
Yes 48 57 56 5g 37 44
No 0 1 0 0 0 0
Formula (milk) feeding 
No 31 36 31 31 23 20
Yes 2 8 7 10 1 1
Unknown 15 14 18 18 13 14
Other fluid
No 13 14 18 18 12 14
Yes 34 43 36 38 25 30
Unknown 1 1 2 3 0 0
Water
No 1 3 1 1 0 0
Yes 34 41 37 40 25 30
Unknown 13 14 18 18 12 14
Weight of child ( Kg)
(Median, IQR) 6.6 (6.1 - 7.2) 7.3 (6 .7 -8 .1 ) 6.5 (5.g - 7.2) 7.1 (6 .6 -7 .8 ) 6.3 (5.g - 6.8) 7.3 (6.6 - 8)
Lived in Sukuta (years)
<2 yrs 1 0 4 3 3 3
2-10 yrs 10 12 16 18 7 13
>10 yrs 12 10 g 14 10 14
always 24 36 27 24 17 15
Unknown 1 0 0 0 0 0
3.3.4 Full blood count results
A full blood count (FBC) was performed on all children at 9 and 10 months of age. No 
significant differences were found between any of the vaccine groups for any of the blood 
indices pre-vaccination when males and females were analyzed together. No sex 
differences were found for any of the parameters tested (Table 3.4).
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Table 3.4 Summary of FBC results in males and females pre-vaccination (9 months)
Pre-vaccination (9M)
MV MV+DTwP DTwP
Median Median Median Median Median Median
(IQ range) (IQ range) (IQ range) (IQ range) (IQ range) (IQ range)
M F M F M F
Haemoglobin (Hb) g/dL 10.2 10.2 9.8 9.9 10 10.1
(9.2-11.1) (9.3 -10.8) (8.9 -10.9) (8.7 - 9.9) (9.4 -10.7) (9.6-10.5
White blood cell (WBC) x 103/gl 7.8 8.4 8.8 8.8 9.2 9.9
(5.3 - 9.8) (7-10.6 ) (6.7-12.1) (7.3-11.4) (6.3-10.2) (7.1-11.1)
Lymphocytes % 61.1 63.4 62.3 64.8 63.4 62.6
(55.8 - 67.8) (52.4 - 74.5) (60.5 - 66.4) (59.6-72.1) (50-69.1) (56.3 - 69)
Red blood cell (RBC) x 106/pl 5.2 4.7 4.7 4.5 4.6 4.5
(4.2 - 5.2) (4.4-4.9) (4.3 - 5.3) (4.2-4.7) (4.3 - 5.0) (4..3-5.1)
Packed cell volume (PCV) % 32.6 33.2 31.9 32.3 31.9 32.4
(29.7 - 34.5) (29.8 - 34.7) (29.2 - 35.7) (29.1 - 33.8) (30.5 - 34.6) (31 -34.5)
Mean cell volume (MCV) fL 68.9 70.8 68 71.9 68 71.9
(62.1 -71.9) (67.5 - 73.4) (65.6 - 72.5) (8.7-76.1) (64.4-73.1) (66 - 76.5)
Mean cell Haemoglobin 31.1 30.9 31.1 31.2 30.9 31.3
concentration (MCHC) g/dL (30.1-31.9) (30-31.4) (29.8 - 32.3) (29.8 - 32.0) (30.3-31.6) (30-31.7)
Platelets (x 109 cells /L) 141 165 183 197 208 178
(103-251) (104-265) (121 -267) (135-272) (122-263) (144 - 265)
Median and Interquartile range (IQR) of blood indices at baseline (9 months) in males and 
females in the three vaccine groups.
3.3.5 Co-infections
We did not assess the HIV status of the infants, but based on the UNICEF 2011 statistics 
for Gambia, seroprevalence among adults was 1.5% and 0.1% among children (0-14 
years of age) (UNICEF, 2005). This implies that very few children were likely to be HIV 
positive considering the sample size of this study. Low levels of helminth infections have 
been reported in other studies conducted near to Sukuta, with levels ranging from 0-3% in 
the adult population (Finney et al., 2009)and there is no schistosomiasis or filariasis in the 
area; it is therefore also unlikely that helminth infection would be a significant confounder 
in this study.
Overall the characteristics of this study cohort were very similar to previous infant studies 
carried out in Sukuta (Miles et al., 2008; Burl et al., 2010; Flanagan et al., 2010), 
indicating that our cohort is a true representation of the Sukuta community.
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CHAPTER 4
VACCINE ANTIBODY TITRES ARE NOT AFFECTED BY COMBINING MV WITH DTWP
OR BY THE SEX OF THE INFANT
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4.1 Introduction
Generally, the mainstay of vaccine research and development has focused on the induction 
of protective antibodies. B cells are produced in the bone marrow and are essential for 
production of antibodies to induce long-lasting protection after vaccination. Apart from 
fighting infections, CD4+ T cells, in particular Th2 cells, are also vital for providing help to B 
cells for antibody production (Reviewed in (Plotkin, 2001). Upon first encounter of infants to 
an antigenic agent, production of immunoglobulin M (IgM) results, but this later undergoes 
class switching to the isotypes IgG and IgA, which are more protective (Reviewed in (Achkar 
and Ziegenbalg, 2012).
IgG generated in utero generally wanes after the first 6 months of life (Achkar and 
Ziegenbalg, 2012), with only 30% of infants still having an appreciable level of circulating 
maternal antibodies. The titre of maternal antibodies (MAb) present at the time of 
immunization is thought to be the main determinant of the MAb-mediated inhibition of 
antibody responses in both mice and humans (Markowitz et al., 1996; Gans et al., 1998; 
Siegrist et al., 1998a; Siegrist et al., 1998b; Gans et al., 1999). In order to overcome this, 
EPI vaccines are either given early in multiples e.g. DTwP vaccine at 8, 12 and 16 weeks of 
age; or the vaccine is given after maternal antibody levels have waned e.g. the first dose of 
measles vaccine is given at 9 months of age in The Gambia.
Measurement of antibodies is crucial in determining the induction of protection against many 
infectious diseases. The terminology “protective antibody titres” usually refers to protection 
under usual conditions of exposure, with an average challenge dose and in the absence of 
inhibiting host factors (Plotkin, 2001). A study in rural Senegal reported a high degree of 
protection against measles infection in immunized and unimmunized children with 
neutralizing measles antibody titres >125 mlU (Samb et al., 1995). Antitoxin antibodies can 
prevent diphtheria and tetanus infections. Partial protection is achieved between 0.01 and
0.1 IU of antibodies with complete protection achieved above this concentration (Reviewed
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in (Plotkin, 2001)). Protective titres for pertussis have not yet been established, but it has 
been shown that pertussis toxoid on its own can confer protection (Trollfors et al., 1995).
Human studies examining sex-based differences in vaccine antibody responses are few 
butantibody responses to viral and bacterial vaccines have consistently revealed higher tires 
in females than males (Cook, 2008; Klein et al., 2010). Geometric mean titres of maternal 
measles antibodies were found to be significantly higher in girls at 9 months of age than 
boys (P=0.007) (Martins et al., 2009). In another study the prevalence of serum IgG 
antibodies against measles, mumps, and rubella was greatly increased in girls than in boys 
who received the MMR vaccine at 12-15 months after birth (Dominguez et al., 2006); and 
others reported significantly higher antibodies to standard titre measles vaccine in young 
female adults than males (Green et al., 1994).Adult females have also been shown to have 
higher antibody titres in response to the combined hepatitis A and B virus vaccine than 
males (Van der Wielen et al., 2006; Hohler et al., 2007); and females aged 1 8 - 4 0  years 
had significantly higher neutralizing antibody titers to smallpox vaccine than males (Kennedy 
et al., 2009). In this chapter we describe the role of sex and vaccine schedule on vaccine- 
induced antibody levels in Gambian infants.
4.2 Aims
1. To determine whether co-administering MV with the third dose of DTwP will alter the 
vaccine-specific EPI antibody levels compared to giving MV or DTwP alone.
2. To determine whether there are any sex differences in EPI antibody levels in the different 
vaccine groups, and whether a particular gender was more susceptible to the effects of 
combining the vaccines.
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4.3 Methods
4.3.1 Donor samples
Plasma was obtained from centrifuged heparinized whole blood samples (9 month baseline 
and 4 weeks after vaccination) for measurement of EPI antibody titres as described in 
Methods (Chapter 2). The total number of samples used for the measurement of EPI 
antibody titres and the number of samples assayed for males and females are indicated in 
Table 4.1 below.
Table 4.1 Number of samples assayed for vaccine antibodies at each time point
MV group MV+DTwP group DTwP group
Total Males Females Males Females Males Females
MV Abs 9 months 260 48 41 53 53 33 32
MV Abs 10 months 254 51 39 49 49 33 33
DTwP Abs 9 months 260 47 40 55 53 33 32
DTwP Abs 10 months 256 50 40 51 49 33 33
Total number of samples analyzed for measles Abs by HAI, and DTwP antibodies by 
multiplex assay by group and sex. MV Abs refers to measles antibodies and DTwP Abs 
refers to Diphtheria, Tetanus and Pertussis antibodies.
4.3.2 Diphtheria, tetanus and pertussis antibodies by multiplex
The diphtheria toxoid (DTx), tetanus toxoid (TTx) and pertussis toxoid (PTx) multiplex 
antibody assays were carried out by our collaborators at The National Institute for Public 
Health and The Environment (RIVM), Bilthoven, The Netherlands as described in Methods 
(Chapter 2). Full protective levels for DTx and TTx were defined as greater than or equal to 
0.1 lU/ml while partial protection is achieved at a titre of 0.01 - 0.09 lU/ml (van Gageldonk et 
al., 2011). A correlate of protection has yet to be established for pertussis, but PTx 
protective titres were defined by the lower limit of detection (LLOD) of each analyte as 
determined by interpolation of the +2 SD in the assay from the relevant reference curve. 
From the LLOD the lower limit of quantitation (LLOQ) was calculated as 3 x LLOD (van 
Gageldonk et al., 2008). An LLOQ of 1 Endotoxin Units (EU)/ml was applied for this study. 
Although there is no established correlate of protection for pertussis, a titre of ;>20 (EU)/m! is
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often used in literature (de Greeff et al., 2010). The protective titre for PTx for this study was 
thus defined as &20 EU/ml.
It is worth remembering that all children had received DTwP at 8 and 12 weeks of age 
according to the EPI schedule, and the MV group also received their 3rd dose at 16 weeks of 
age. The MV+DTwP and DTwP groups had theirthird dose delayed until 9 months of age. 
Thus all children were expected to have detectable DTP antibody levels at the baseline 
bleed at 9 months of age.
4.3.3 Measles (HAI) antibody assay
The measles haemagglutinin inhibition (HAI) antibody assay was carried out at the Medical 
Research Council (MRC) Laboratories in The Gambia by Jainaba Njie-Jobe and Lady Chilel 
Sanyang as described in Methods (Chapter 2). The minimum detection level is 3.12 IU, and 
a protective measles antibody titre by HAI is defined as >12.5 IU antibody or a log2 titre >3, 
as described (Samb et al., 1995). Measles HAI antibody tires have been found to correlate 
with neutralizing antibody titres (Samb et al., 1995), and the assay is therefore considered a 
functional assay.
4.3.4 Statistical analysis
Differences in antibody levels between the 3 vaccine groups pre- and post-vaccination were 
analysed using a Kruskal-Wallis test followed by Dunn’s post test comparision. Mann- 
Whitney U-tests were used to determine differences between pre- and post-vaccination 
antibody levels for each group and between males and females within each group. A p- 
value <0.05 was considered significant and are indicated by: *= p<0.05; ** = p<0.01; *** = 
p<0.001 and **** = p<0.0001. P-values <0.035 were considered significant to account for 
FDR
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4.4 Results
4.4.1 No effect of administering MV and DTwP together on vaccine-specific 
antibody responses compared to giving either vaccine alone
There were no group differences in measles titres pre-vaccination. A handful of subjects had 
low level pre-existing measles antibody titres at 9 months in all three vaccine groups which 
would be of maternal origin since none had received measles vaccine, and there had been 
no circulating measles infections in the area for some years (Figure 4.1 A). Most of the pre­
existing measles Ab levels were below the protective level of 3.0 suggesting that waning 
had occurred by 9 months of age. As expected the MV group and MV+DTwP groups had 
significantly higher antibody titres than the DTwP group post-vaccination since both the 
former received measles vaccine at 9 months whereas the DTwP group did not (Figure
4.1 A). There was no difference in measles Ab titres when DTwP was administered with MV 
(MV+DTwP group) compared to when MV was given alone (MV group) (Figure 4.1 A). 
Therefore giving measles vaccine alone or in combination with DTwP induced similar 
antibody titres in these children (Figure 4.1 A). However, 30% of infants(36/133 male and 
41/121 female) failed to achieve protective levels post vaccination in the MV group and 
MV+DTwP group.Interestingly, the majority of these infants did not have pre-existing 
maternal antibodies at 9 months except for two female infants in the DTwP group 
suggesting maternal antibodies are important for generating protective levels after 
vaccination.
Prior to Measles vaccination DTx antibody titres were significantly higher in the MV group 
than the MV+DTwP group (Figure 4.1 B), which is expected since the former had received 3 
does of DTwP, whereas the MV+DTwP and DTwP groups had only received two doses. 
Post-vaccination, the MV+DTwP and DTwP groups boosted to equivalent levels, which were 
higher than the MV alone group, since they did not receive a DTwP booster. Almost all 
boosted infants achieved protective DTx titres (Figure 4.1 B).
There were no vaccine group differences in TTx antibody titres pre-vaccination, even for the 
MV group who had received one more dose of DTwP than the MV+DTwP and DTwP
116
groups. As expected, the MV+DTwP and DTwP groups significantly boosted their TTx 
antibody levels post-vaccination but not groupl who did not receive a dose of DTwP (Figure
4.1 C). 99% of boosted infants achieved protective TTx Ab levels, and the levels were 
comparable whether DTwP was given with MV or not.
Pertussis antibody titres pre-vaccination were significantly higher in the MV group than the 
DTwP group after correction for multiple testing. As expected, at 10 months, the MV+DTwP 
and DTwP groups had significantly higher PTx antibody levels than the MV group (Figure
4.1 D); the majority of the infants in the MV+DTwP and DTwP group boosted above 
protective levels, although a significant number failed to suggesting that the protective cutoff 
may be an overestimate. Again, no difference in PTx Abs was observed if MV was delivered 
at the same time (MV+DTwP group) compared to alone (DTwP group) (Figure 4.1 D).
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Figure 4.1 EPI antibody titres. MV (Gp1), MV+DTwP (Gp2) and DTwP (Gp3) antibody 
titres to measles (A), diphtheria toxoid (DTx) (B), tetanus toxoid (TTx) (C) and pertussis 
toxoid (PTx) (D) pre-vaccination and post-vaccination in the 3 study groups. Titres pre­
vaccination are indicated by blue dots, and post-vaccination by red dots. The median is 
indicated by the horizontal line. The horizontal line across all groups indicates the protective 
titre for that particular antibody. The Kruskal-Wallis test and Dunn’s post-test comparision 
was used to compare antibody levels between the three vaccine groups. Adjusted P-values 
are shown as stars at the top of the graph, * indicates P< 0.05, *** indicates P<0.001 and 
**** indicates P< 0.0001.
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4.4.2 Antibody responses are comparable in males and females
When analysed by sex, no differences were seen in pre- or post-vaccination measles 
antibody titres within the same vaccine group (Figure 4.2A). After vaccination both males 
and females boosted their measles titres in the MV groups and MV+DTwP group as 
expected (Figure 4.2B).
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Figure 4.2 Measles antibody titres by sex.
Measles-specific antibody titres in the 3 study group male and female vaccinees pre­
vaccination at 9 months (A) and post-vaccination at 10 months (B). Antibody titres in male 
subjects are indicated by blue dots, and females by red dots. The median is indicated by the 
horizontal line. Measles-specific antibody titres are expressed log2 titre. Protective levels are 
considered to be a titre of >3.0. Horizontal line across all groups indicates the protective titre 
of that particular antibody. The Kruskal-Wallis test and Dunn’s post-test comparision was 
used to compare antibody levels between the three vaccine groups. Adjusted P-values are 
shown as stars at the top of the graph. *** indicates P< 0.0001.
Males and females had equivalent Ab titres to DTx and TTx pre- and post-vaccination atin 
each vaccine group (Figure 4.3A and C)and the expected boost occurred in the MV+DTwP 
and DTwP vaccinated groups (Figure 4.3B and D). By contrast, there were sex differences 
in PTx antibody levels both pre- (Figure 4.3E) and post-vaccination (Figure 4.3F). The 
DTwP vaccinated females had higher PTx Abs than males both pre-vaccination (P=0.0053) 
and post-vaccination (P=0.0104). The expected post-boost increase occurred in the 
MV+DTwP and DTwP groups.
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Figure 4.3 DTP antibody titres by sex.
Diphtheria toxoid (DTx), tetanus toxoid (TTx) and pertussis toxoid (PTx) antibody titres in 
MV, MV+DTP and DTP male and female vaccinees pre-vaccination (A, C and E) and post­
vaccination (B, D and F). Antibody titres in male subjects are indicated by blue dots, and 
females by red dots. The median is indicated by the horizontal line. DTx, TTx PTx-specific 
antibody titres are expressed on a logarithmic (log10) scale. Protective levels for DTx and 
TTx are considered to be >0.1, and for PTx >20 Endotoxin Units (EU)/ml. Horizontal line 
across all groups indicates the protective titre of that particular antibody. The Kruskal-Wallis 
test and Dunn’s post-test comparision was used to compare antibody levels between the 
three vaccine groups. Adjusted P-values are shown as stars at the top of the graph, * 
indicates P< 0.05, ** indicates P< 0.001 and *** indicates P< 0.0001, ns indicates P-values 
were not significant after Dunn’s post test comparison.
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4.5 Discussion
Overall, our results suggest that combining MV with DTwP has no effect on vaccine 
antibody titres compared to when either vaccine is given alone. The booster dose of DTwP3 
administered at 9 months to the MV+DTwP group and the DTwP group infants produced a 
significant recall antibody response four weeks after vaccination, with almost all infants 
achieving protective levels. This demonstrates that a booster dose of DTwP at 9 months of 
age does improve antibody levels. Even though no antibody correlate of protection has yet 
been established for pertussis, it is reassuring that pertussis antibody titres were 
comparable in subjects vaccinated with measles plus DTwP and those vaccinated with 
DTwP alone, with both groups boosting their pre-vaccination level. In a study in which 
children were vaccinated at 3, 4, and 5 months of age with DTwP vaccine, the authors 
reported adequate protection against diphtheria, tetanus and pertussis until the age of 
preschool booster (Ramsay et al., 1991).
Thirty percent of measles vaccinated infants failed to achieve protective measles antibody 
titres 4 weeks after vaccination. This was not due to pre-existing maternal antibodies, as 
only two infants with pre-existing maternal antibodies were amongst those that failed to 
achieve protective levels. It may partly be attributed to the fact that these infants were 
measles naive and this was the first dose administered to them.
There were no sex differences in measles, diphtheria toxoid or tetanus toxoid antibody titres 
in the MV, MV+DTwP or DTwP groups after vaccination. There was a significantly lower 
PTx titre in males in the DTwP group at baseline, which is difficult to understand since they 
should have behaved similarly to the MV+DTwP group at baseline since both had received 
2 doses of DTwP. The low baseline titre probably accounted for the same male / female 
difference observed post-vaccination, albeit less pronounced than at baseline. However it 
does fit with the paradigm that females generally have higher vaccine Ab levels than males, 
as described in the introduction. The high number of infants with PTx titres below protective 
levels four weeks after vaccination in the MV+DTwP and the DTwP groups suggests that
120
the protective titre may be set too high given that these infants are thought to be protected 
against pertussis infection. Overall however, our data do not support clear male female 
differences in Ab titres to measles or DTwP vaccines but do show that combining vaccines 
is not detrimental to inducing protective antibody titres to any of the study-specific vaccines 
we used.
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CHAPTER 5
ANALYSIS OF SOLUBLE CYTOKINE PROFILES IN INFANTS IN RESPONSE TO 
VACCINE-SPECIFIC AND NON-SPECIFIC ANTIGENS DEPENDING ON 
THEIR VACCINATION STATUS AND SEX
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5.1 Introduction
In Chapter 4, vaccine group or sex did not affect vaccine antibody titres. We next wanted 
todetermine if there was an influence on innate and adaptive responses byanalysing the 
secreted cytokine pattern after culture with vaccine specific and un-related antigens in the 
three vaccine groups. The primary aim was to determine if there were differences for sex 
and vaccine group as well as non-specific effects of the vaccines administered by using 
non-vaccine related antigens. There are many reports regarding induction of vaccine- 
specific T cell responses and immune polarization (ie towards a pro- or anti-inflammatory 
response) following administration of measles vaccine (MV) or diphtheria, tetanus, whole 
cell pertussis combined vaccine (DTwP) to animals and humans.However little is known 
about their broader, non-specific immunological effects. Live vaccines such as measles 
vaccine (MV) are generally thought to cause a T helper type 1 (Th1) skewed immune 
response to measles antigens, while killed vaccines such as the combined vaccine 
diphtheria, tetanus, whole cell pertussis (DTwP) are thought to skew towards Th2 type 
immune responses to the vaccine components (Ward and Griffin, 1993). However, while 
MV has been shown to induce a strong pro-inflammatory IFN-y response in humans 
(Pauksen et al., 1997), the Th1-polarising cytokine IL-12 had also been shown to be 
down-regulated by MV, leading to the hypothesis that MV ultimately skews T cells towards 
Th2 (anti-inflammatory) immune responses (Karp et al., 1996).
Despite the fact that such immune skewing by vaccines is well described, there is 
insufficient information regarding the consequences in humans in terms of disease 
patterns and outcomes. It is not known whether such immune polarizing effects apply to 
responses to non-vaccine antigens, but if they do one would predict that they would 
influence the outcome of infections. This is of particular relevance in countries, such as 
The Gambia, with a high level of endemic infections.
The cytokine milieu in which dendritic cells process and present antigen to naive T cells is 
very important in determining polarization into different T cell subsets, and can also cause
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certain populations of memory cells to change their phenotype. The outcome of the 
immune response is dependent on the predominant cytokine secretion pattern. The 
Th1/Th2 focus of previous studies does not take into account other key arms of the 
immune system such as innate responses, which inevitably influence adaptive immunity, 
regulatory cytokines, and the Th17 pro-inflammatory pathway.
The non-specific effects (NSE) of vaccines have been found to be particularly prominent 
in females in epidemiological studies (Aaby et al., 1995; Benn and Aaby, 2012). The 
mechanisms accounting for these sex-differences are not known, but it has been 
suggested that X-linked immune response genes, miRNAs and sex hormones might have 
a role (Flanagan et al., 2011). Few immunological or vaccine studies have analyzed males 
and females separately, thus there are limited data on sex differences in vaccine-induced 
immunity in humans. Understanding the cytokine secretion patterns to non-vaccine 
antigens might identify key sex differences that account for the observed sex differences 
in NSE and mortality.
A major aim of this chapter was to investigate whether the different vaccine schedules 
cause a skewing of the immune profile in response to in vitro stimulation with vaccine 
specific and non-vaccine antigens. We hypothesized that differences would also be 
associated with the sex of the infant.
Specific Aims
1. To evaluate the in vitro cytokine profiles to vaccine and non-vaccine antigens of 
infants vaccinated with MV alone, DTwP alone or MV+DTwP administered at the 
same time.
2. To determine whether males and females differ in their cytokine responses 
following the different vaccine regimens.
3. To determine immune profiles that might account for beneficial / deleterious NSE 
of MV and DTwP respectively that can be tested in future prospective studies.
124
5.2 Methods
5.2.1 Antigen stimulation
100|jl of heparinized whole blood from infants was stimulated for 16 hours with vaccine- 
specific and non-vaccine antigens. All available blood samples from 9 month (pre­
vaccination baseline, n = 169) and 10 month (4 weeks post-vaccination, n = 170) old 
infants were analysed. As detailed in Chapter 3, all infants had received their routine EPI 
vaccines up to 12 weeks of age, and all had received at least two doses of DTwP. The 
conditions tested in vitro were:
1. Tetanus toxoid (TT), 10 pg/ml (to determine the DTP-specific response)
2. Measles haemagglutinin 20-mer peptide pool, 1 pg/ml for each peptide (to test for 
MV-specific response)
3. Purified protein derivative (PPD) of Mycobacterium tuberculosis, 10 pg/ml (to test 
for reactivity to an unrelated recall antigen). All infants had received the BCG 
vaccine in the first week of life.
4. Anti-CD3/anti-CD28, each at 5 pg/ml (as a global T cell stimulus (positive control))
5. Unstimulated i.e. 100pl of whole blood without antigen stimulation (negative control 
for spontaneous cytokine production)
5.2.2 Multiplex cytokine assay
Following overnight stimulation, supernatants were collected and assayed using the 
Bioplex assay protocol (Bio-Rad Laboratories, France), as described in section 2.2.2 of 
Methods, for the cytokines detailed in Table 5.1. An initial 27-plex assay was performed 
on selected samples as described in Methods and the 10 most informative cytokines 
which differentiated vaccine groups were selected for analysis of all remaining samples.
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Table 5.1 Cytokines selected for the 10-plex assays
Polarity Analyte
Th1 IFN-y, IL-12(p70), TNF-a
Th2 IL-4, IL-10
Regulatory IL-10
Innate IL-1P, TNF-a, GM-CSF, PDGF-BB, VEGF, Eotaxin
Cytokines selected for the 10-plex assay were interferon gamma (IFN-y), interleukin- 
12(p70), interleukin-4, interleukin-10, interleukin-1 (S, tumour necrosis factor-a (TNF-a), 
granulocyte macrophage-colony stimulating factor (GM-CSF), platelet-derived growth 
factor-BB (PBGF-BB), vascular endothelial growth factor (VEGF) and eotaxin.
Spider plots were generated for easy visualization of cytokine data using Microsoft Excel® 
for Mac 2011, Version 14.2.2. Log-io of each cytokine median value was plotted around a 
vertical axis creating a global view of the changes in cytokine profile in the three vaccine 
groups. All median values less than 1 were first set to 1 to give a log10 value of 0.
5.2.3 Generalized Least-Squares (GLS) Regression Analysis
Background (unstimulated) cytokine production was subtracted prior to analysis of 
antigen-specific cytokine levels. Cytokine production in the unstimulated cultures was also 
analyzed, as this is informative for the underlying cytokine milieu in the different vaccine 
groups. STATA 12.1, Copyright 1985-2011 StataCorp LP, Statacorp USA, was used for all 
analyses (http://www.stata.com). The data were ranked and fitted to a Generalized Least- 
Squares (GLS) regression model to compare differences between groups and between 
males and females within each group at each time point, which seemed the most 
appropriate approach for analysing the non-parametrically distributed cytokine data. The 
GLS approach uses parametric methods of analysis for which a number of non-normal 
distributions can be specified. After writing and fitting the model, data checks were 
performed and normalization done so that the data becomes approximately normal in 
distribution. The model was used for each condition and all our analysis was derived from 
it. We compared cytokine levels of the three vaccine groups at 9 months and at 10
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months. We also assessed whether being male or female (effect of sex) affected cytokine 
levels in a group. To study sex differences, we directly compared males and females 
within each group at 9 months and at 10 months. False Discovery Rate (henceforth 
refered to as FDR) was applied for p-value adjustment (Benjamini and Hochberg, 2005). 
The FDR accounts for multiple adjustments when more than 1 parameter is being 
measured in an assay. It controls the false discovery rate, that is, the expected proportion 
of false positives among the variables for which there is a significant difference. After 
calculation, an unadjusted p-value of <0.035 was taken as significant to account for the 
FDR and are indicated.
5.3 Results
5.3.1 Responses to positive and negative control antigens were unaffected by 
vaccine group when all infants were analysed together
In the unstimulated samples , there were no differences in any cytokines regardless of the 
stimuli, the vaccine group or the time-point. Similarly, when all donors are analysed 
together, stimulation with the aCD3/aCD28 positive control showed no significant 
differences between the three vaccine groups pre-or post-vaccination for any of the 10 
cytokines tested (Tables 5.2, 5.3 and 5.4).
5.3.2 Differences in vaccine-specific responses (MV Pool and TT cultures)
As expected, following measles peptide pool cultures there was significantly higher IFN-y 
production in infants who received MV or MV+DTwP compared to those vaccinated with 
DTwP alone (p=0.014 and 0.007 respectively) (Figures 5.1 and 5.2; Table 5.4). This type 
1 cytokine bias is expected since only these 2 groups received MV 4 weeks earlier, and 
supports induction of an early measles-specific IFN-y response following MV 
administration. There was no induction of IL-4 or IL-10 in MV pool cultures post­
vaccination, and VEGF, PDGFBB, GM-CSF, Eotaxin and IL-12(p70) levels were negligible 
in measles pool cultures (Figures 5.1A-C; Table 5.3). It is apparent from the spider plots
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that IFN-y is the main cytokine induced by measles vaccination, compared to baseline 
responses at 9 months when infants were MV naive (Figure 5.1).
Measles Peptide Pool cultures
A
MV IFN-y
TNF-a JL-12p(70)
PDGFBB IL-10
GM-CSF IL-4
Eotaxin VEGF
IL-1 P
B MV+DTwP IFN-y
TNF-a JL-12p(70)
PDGFBB IL-10
GM-CSF IL-4
Eotaxin VEGF
IL-1 P
DTwP IFN-y
TNF-a JL-12p(70)
PDGFBB IL-10
GM-CSF IL-4
Eotaxin VEGF
IL-1 P
Figure 5.1 Spider plots showing changes in cytokine responses in measles peptide 
pool cultures. Logw of all median values were plotted in the spider plots around a vertical 
axis creating a global view of the changes in cytokine profile in the three vaccine groups. 
Blue line = pre-vaccination responses and purple line = post-vaccination responses. All 
median values <1 were set to 1 to give log10 value of 0.
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Figure 5.2 IFN-y concentrations in supernatants following stimulation with measles 
peptide pool. Median and interquartile range of IFN-y following background subtraction in 
the three vaccine groups (MV, MV+DTwP and DTwP) pre and post-vaccination. P-values 
were derived using GLS regression model and are indicated at the top of the bars. P- 
values <0.035 were considered significant to account for FDR and are indicated.
There was also a boosting of TT reactivity at 10 months in the MV+DTwP and DTwP as 
expected, but not the MV group who were not boosted (Figure 5.3). Stimulation with TT 
revealed significantly higher post-vaccination levels of IL-10, TNF-a, GM-CSF and PDGF­
BB in the MV+DTwP group compared to the MV group who did not receive a booster (P 
values =0.021, 0.031, 0.008, 0.002 respectively) (Figures 5.3 and 5.4; Table 5.4). From 
the global view provided by the spider plots, the DTwP group seems to have boosted to 
similar levels to the MV+DTwP group (Figures 5.3B and C), but this group had higher 
baseline TT responses for IFN-y, PDGF-BB and IL-1 (3.
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TT cultures
A
IFN-yMV
TNF-a, JL-12p(70)
PDGFBB IL-10
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B
IFN-yMV+DTwP
TNF-a, 1L-12p(70)
PDGFBB IL-10
GM-CSF IL-4
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IL-1 P
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Figure 5.3 Spider plots showing changes in cytokine responses in TT cultures.
Log 10 of all median values were plotted in the spider plots around a vertical axis creating a 
global view of the changes in cytokine profile in the three vaccine groups. Blue line = pre­
vaccination responses and purple line = post-vaccination responses. All median values <1 
were set to 1 to give log10 value of 0.
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Figure 5.4 IL-10,TNF-a, GM-CSF and PDGF-BB concentrations supernatants 
following TT stimulation. Median and interquartile range of the cytokines following 
background subtraction in the three vaccine groups (MV, MV+DTwP and DTwP) pre- and 
post-vaccination. P-values were derived using GLS regression model and are indicated at 
the top of the bars. P-values <0.035 were considered significant to account for FDR and 
are indicated.
5.3.3 Responses to the non-vaccine antigen PPD are altered by vaccination group
BCG was routinely given to all children in the first week of life but was not one of the 
vaccines administered at 9 months as part of the study protocol. Thus any differential 
differential modification of PPD reactivity at 10 months of age (4 weeks after MV, DTwP or 
MV+DTwP vaccination) in the different vaccine groups would support an 
immunomodulatory non-specific or heterologous effect of vaccine administration. 
Following PPD stimulation, there were differences between groups both pre- and post­
vaccination. The MV+DTwP group had higher basline TNF-a production to PPD than the 
DTwP or MV groups pre-vaccination (P=0.023 and 0.004 respectively). After vaccination it
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was the MV group that had higher TNF responses than the MV+DTwP group suggesting 
enhanced reactivity to PPD in the MV infants (Figure 5.5A-C). There were also higher pre­
vaccination levels of IL-12p(70) and VEGF in the MV+DTwP group compared to the MV 
group, although the median values were negative and thus the baseline difference was 
not lilely of biological relevance (Figures 5.5A and B; Table 5.4). Production of IL-4 in PPD 
cultures was also significantly higher in the MV group than in the DTwP group post­
vaccination (P=0.020) (Figures 5.5A & C and 5.6B) (Tables 5.2 and 5.3).
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PPD cultures
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TNF-a IL-12p(70)
PDGFBB IL-10
GM-CSF IL-4
Eotaxin VEGF
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Figure 5.5 Spider plots showing changes in cytokine responses in PPD cultures.
Logw of all median values were plotted in the spider plots around a vertical axis creating a 
global view of the changes in cytokine profile in the three vaccine groups. Blue line = pre­
vaccination responses and purple line = post-vaccination responses. All median values <1 
were set to 1 to give log10 value of 0.
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Figure 5.6 TNF-a and IL-4 concentrations in supernatants following PPD 
stimulation. Median and interquartile range of the cytokines following background 
subtraction in the three-vaccine groups (MV, MV+DTwP and DTwP) pre and post­
vaccination. P-values were derived using GLS regression model and are indicated at the 
top of the bars. P-values <0.035 were considered significant to account for FDR and are 
indicated.
134
iterquartile ranges (IQ ranges) for all groups in the different stimulations pre-vaccination (9 months)
MV Pool PPD TT aCD3/CD28
Median 
(IQ range)
Median 
(IQ range)
Median 
(IQ range)
Median 
(IQ range)
Gp3 Gp1 Gp2 Gp3 Gp1 Gp2 Gp3 Gp1 Gp2 Gp3 Gp1 Gp2 Gp3
360 -9 -28 37 1068 1908 1854 200 40 178 1348 1319 2721
(216-526) (-239-119) (-475-33) (-76-2169) (299-2623) (461-14385) (672-9801) (30-1207) (-131-707) (0-1915) (-52-7592) (-70-8150) (73-9907)
48 1 2 15 66 325 236 99 26 22 2313 4862 8198
(7-130) (-21-46) (-23-55) (-2-1819) (3-1920) (20-15613) (0-7349) (3-523) (-24-277) (-1.4-1517) (-2-18266) (2-18596) (25-25138)
6 -1 0 0 1 2 2 2 0 1 6 8 11
(3-12) (-3-2) (-2-1.6) (-2-17) (-0.6-9) (-1.2-11) (0-17) (-0.4-8) (-1-2) (-1-10) (-0.3-20) (-0.5-17) (1.4-25)
97 -19 -14 -9 -2 3 -1 4 -5 0 42 52 68
(45-256) (-62-8) (-41-11) (-44-140) (-58-79) (-20-98) (-31-153) (-38-47) (-31-11) (-39-79) (-46-162) (-33-130) (-2.3-170)
42 0 -2 0 243 217 299 23 9 9 2293 1982 2786
(20-260) (-50-24) (-142-12) (-26-1005) (34-1224) (33-2406) (67-2737) (-5-261) (-33-104) (-16-1345) (14-3985) (72-4825) (422-7046)
23 14 5 17 331 320 444 67 9 29 2840 3279 5413
(6-210) (-5-205) (-27-69) (-25-10277) (37-2341) (11-6661) (32-8360) (5-4108) (-37-166) (-29-6935) (2.7-8870) (39-8708) (1475-14374)
97 -1 0 1 -12 0 -3 -16 -20 -9 -4 -1 19
(65-153) (-22-44) (-30-45) (-24-118) (-57-11) (-29-148) (-36-58) (-59-14) (-20-3.2) (-35-19) (-41-27) (-31-57) (-41-95)
12 0 0 0 2 7 4 2 3 8 10 20 31
(0.3-101) (-18-1.4) (-5-0.9) (-4-81) (0-19) (0-47) (0-47) (0-34) (-0.6-22) (0-40) (0-91) (0-59) (0-107)
5110 -925 -866 -669 52 420 565 498 29 681 2591 1607 3776
2017-9425) (-3277-522) (-2938-676) (-1367-1986) (-1812-2775) (-1051-4849) (-780-6931) (-1121-3647) (-1349-2185) (-963-6453) (-917-6354) (-684-6731) (245-10940)
495 -19 -35 30 -80 -37 -1 -127 -127 -56 -20 66 226
(322-1120) (-175-104) (-224-70) (-172-725) (-296-79) (-140-318) (-230-479) (-369-76) (-392-(-10)) (-221-299) (-229-375) (-94-630) (-236-775)
values and interquartile ranges (IQR) for all cytokines analysed following all culture conditions.
iterquartile ranges (IQ ranges) for all groups in the different stimulations post-vaccination (10 months)
MV Pool PPD TT aCD3/CD28
Median 
(IQ range)
Median 
(IQ range)
Median 
(IQ range)
Median 
(IQ range)
Gp3 Gp1 Gp2 Gp3 Gp1 Gp2 Gp3 Gp1 Gp2 Gp3 Gp1 Gp2 Gp3
263 501 369 23 2664 2932 1240 561 736 575 1701 416 1072
(148-1310) (-42-1516) (-80-3877) (-160-1034) (580-6506) (843-16272) (84-11623) (-281-2309) (70-3261) (17-1805) (-37-5778) (-496-6048) (-75-5980)
20 21 37 26 384 112 108 49 656 497 7937 559 3227
(7-117) (-14-1595) (-8-6978) (-19-7741) (64-13874) (22-7126) (24-6694) (-12-5536) (17-7558) (22-5851) (4-27111) (-18-16432) (-13-14265)
4 1 0 0 6 2 2 2 3 2 9 2 7
(2-9) (-3-11) (-2-10) (-3-9) (0.3-13) (-0.4-11) (-0.1-8) (-0.7-12) (-0.6-12) (0-8) (-0.4-19) (-5-14) (-0.3-13)
103 -15 -15 -7 27 -8 13 9 7 4 57 5 19
(53-216) (-108-148) (-80-99) (-55-129) (-25-151) (-37-109) (-26-93) (-43-118) (-52-82) (-29-123) (-45-156) (-69-104) (-17-97)
49 4 8 3 262 342 236 0 73 17 2063 1249 1982
(22-2513) (-26-676) (-43-1497) (-49-1131) (50-2143) (73-3261) (48-2124) (-57-586) (-8-2332) (-15-1059) (26-5662) (5-6701) (16-5226)
33 38 43 48 441 223 428 71 214 171 2551 2263 3042
(8-302) (-1.33-8367) (-50-3976) (-30-25928) (324-3885) (18-3164) (52-12367) (-4-2712) (0-4707) (129-11694) (2-18453) (19-10433) (0.86-14738)
83 0 4 0 -2 -2 8 -3 0 -22 -1 6 21
(32-127) (-31-38) (-12-35) (-25-72) (-31-12) (-32-28) (-18-35) (-31-11) (-36-16) (-51-26) (-42-23) (-31-50) (-18-76)
0 0 0 0 9 11 8 1 35 39 29 6 14
(0.31-14) (-1.83-46) (-0.3-39) (-2.5-82) (0-53) (0-59) (0-55) (0-67) (0-230) (2-261) (0-158) (0-77) (0-81)
7146 -711 -507 -468 249 851 1198 87 3033 3732 1247 1252 4666
>422-11703) (-2873-1045) (-2870-2223) (-1486-3561) (-2370-3296) (-1532-3370) (-303-5602) (-1472-2924) (-34-8497) (-991-9863) (-1182-5812) (-2612-4682) (-129-10191)
483 0 0 46 10 1 24 -17 0 -47 99 73 211
(207-930) (-127-251) (-259-329) (-140-412) (-274-257) (-188-199) (-115-353) (-223-112) (-274-303) (-305-117) (-213-408) (-180-484) (-101-513)
values and interquartile ranges (IQR) for all cytokines analysed following all culture conditions.
Table 5.4 A summary of the interactions between groups
Stimulation Cytokine P-value Responses
PRE-VACCINATION
IL-12p70 0.005 MV+DTwP > MV
PPD TNF-a 0.004 MV+DTwP > MV
VEGF 0.017 MV+DTwP > MV
TNF-a 0.023 MV+DTwP > DTwP
POST-VACCINATION
Measles IFN-y 0.007 MV+DTwP > DTwP
IFN-y 0.014 MV > DTwP
TNF-a 0.014 MV > MV+DTwP
PPD
IL-4 0.020 MV > DTwP
IL-10 0.021 MV+DTwP > MV
TT TNF-a 0.031 MV+DTwP > MV
GMCSF 0.008 MV+DTwP > MV
PDGFBB 0.002 MV+DTwP > MV
Only significant differences after FDR correction are shown in the table. PPD = purified 
protein derivative; Measles = measles peptide pool and TT = Tetanus toxoid. MV refers to 
the MV group; MV+DTwP refers to MV+DTwP group and DTwP refers to the DTwP group. 
>indicates responses that are higher in one group compared to the other, e.g. MV> DTwP 
= responses are significantly higher in the MV group than the DTwP group. P-values 
<0.035 were considered significant to account for FDR and are indicated.
5.3.4 Distinct cytokine pattern changes when the vaccine groups were analysed by 
sex
In order to get an idea of the overall pattern of cytokine changes by group and sex we 
calculated the fold-change post-vaccination in cytokine production following each stimulus 
for each cytokine compared to pre-vaccination levels. These were then plotted as heat- 
maps providing a global overview of the effect of vaccine group by sex (Figure 5.7). A few 
patterns were apparent using this approach. Firstly, the MV+DTwP females appeared to 
have more up-regulated (red) cytokines than MV females, whereas the MV+DTwP males 
seemed to down-regulate (blue) cytokines compared to the MV group males. The MV 
males had more up-regulated cytokines than MV females, and MV+DTwP females had 
more up-regulated cytokines than males. The MV group males had more up-regulated
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cytokines than either the MV+DTwP or DTwP group, whereas for females it was the 
MV+DTwP group that had the most up-regulated profile after vaccination. Responses to 
the non-specific T cell stimulus aCD3/aCD28 and the unrelated antigen PPD also seem to 
vary according to vaccine group, supporting an influence of vaccination on reactivity to 
these antigens, and thus potential non-specific effects of vaccination on cellular immunity.
MV group MV+DTP group DTP group
aCD3/28 Measles PPD TT aCD3/28 Measles PPD TT aCD3/28 Measles PPD TT
-10 0 +10
Figure 5.7 Heatmaps o f fold-change differences in cytokine concentrations.
Fold change differences in cytokine levels post-vaccination compared to pre-vaccination  
in females and males in the three vaccine groups. The 10 cytokines tested are indicated  
on the x-axis. Whole blood  was stimulated overnight with aCD3/28, measles pool, PPD or 
TT and supernatants analysed for levels o f IL-4, IL1b, IL-10, IL-12(p70), Eotaxin, GMCSF, 
IFN-y, PDGFBB, TNF-a, VEGF. Red =increase, blue = decrease, white = no change post­
vaccination compared to pre-vaccination (baseline).
5.3.5 Cytokine down-regulation to aCD3/aCD28 in females following DTwP 
vaccination
Interestingly, following aCD3/aCD28 stimulation, DTwP vaccinated females showed 
down-regulation of IL-13, IFN-y and TNF-a production to a median value of almost zero 
suggesting a loss of inflammatory T cell function. However, only the reduced IL-1 p was 
significantly lower in females in the DTwP group compared to males after adjusting for 
FDR (P=0.028, Figure 5.9, Table 5.5), while the IFN-y and TNF-a effects were not
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significant. Such a down-regulatory effect was not observed in males (Figures 5.8F, 5.9C 
and D) and the spider plots reveal similar cytokine profiles in males and females pre­
vaccination (Figure 5.8A-C).
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Figure 5.8 Spider plots showing changes in cytokine responses in aCD3/aCD28 
cultures. Log10 of all median values were plotted in the spider plots around a vertical axis 
creating a global view of the changes in cytokine profile in the three vaccine group before 
and after vaccination by sex. Purple line = responses in females and blue line = 
responses in males pre (A-C) and post-vaccination (D-F). All median values <1 were set 
to 1 to give log10 value of 0.
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Figure 5.9 Median cytokine levels in aCD3/aCD28 cultures for IL-1 (3 in the 3 vaccine 
groups before and after vacciantion in males and females. The error bar indicates the 
upper quartile. P-values were dervied form the GLS model analysis and indicate the 
vaccine time point at which there was a significant effect of sex.
5.3.6 Sex differences in vaccine-specific responses following vaccination in the MV 
group
There were significant sex differences post-vaccination following stimulation with the 
vaccine-specific antigens. The MV males had higher IFN-y reactivity to MV Pool than MV 
females (P=0.031; Figures 5.10A, 5.11B; Table 5.5). The MV group also had higher VEGF 
to measles antigen stimulation, than the MV+DTwP group who had almost no VEGF 
response (Figure 5.10A & B).
In the TT cultures, the MV group females had significantly lower TNF-a, GM-CSF, PDGF­
BB and IL-10 production to TT than males post-vaccination (P = 0.030, 0.002, 0.003, 
0.027, respectively), suggesting that MV enhanced reactivity in males (Figure 5.10D, 
Table 5.5). This male / female difference in TT reactivity was not observed when MV was
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given with DTwP (Figure 5.1 OB), however this group had received a DTwP booster and 
therefore cannot be compared to the MV group. The spider plots demonstrate that males 
and females have comparable TT reactivity following a DTwP boost in both the MV+DTwP 
and DTwP groups (Figure 5.10 E and F).
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Figure 5.10 Spider plots showing changes in cytokine responses following 
stimulation with measles peptide pool and with TT. Log10 of all median values were 
plotted in the spider plots around a vertical axis creating a global view of the changes in 
cytokine profile in the three vaccine group before and after vaccination by sex. Purple line 
= responses in females and blue line = responses in males in measles peptide pool 
cultures (A-C) and TT cultures (D-F) post-vaccination. All median values <1 were set to 1 
to give log10 value of 0. A star next to a cytokine name indicates a significant difference 
between males and females.
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Figure 5.11 Median cytokine levels in Measles pool cultures for IFN-y in the 3 vaccine 
groups before and after vacciantion in males and females. The error bar indicates the 
upper quartile. P-values were dervied form the GLS model analysis and indicate the 
vaccine time point at which there was a significant effect of sex.
5.3.7 Differences in PPD responses by sex
Females had lower baseline PPD reactivity than males to a number of cytokines (Table 
5.5). TNF -a levels were lower in females compared to males in the MV and DTwP groups 
(P=0.004; and P=0.008 respectively; Table 5.5), while VEGF levels were lower in females 
compared to males in the MV group (P=0.018; Table 5.5) (Figure 5.12A, Table 5.5); and 
IL-12p70, IFN-y and eotaxin were lower in females compared to males in the DTwP group 
(P=0.006; 0.013; and 0.015 respectively; Figure 5.12C, Table 5.5).
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Figure 5.12 Spider plots showing changes in cytokine responses in PPD cultures.
Log10 of all median values were plotted in the spider plots around a vertical axis creating a 
global view of the changes in cytokine profile in the three vaccine group before and after 
vaccination by sex. Purple line = responses in females and blue line = responses in males 
pre (A-C) and post-vaccination (D-F). All median values <1 were set to 1 to give logw 
value of 0. A star next to a cytokine name indicates a significant difference between males 
and females.
In the DTwP group the males had higher post-vaccination IFN-y production following PPD 
stimulation compared to females (P=0.017; Figures 5.12F and 5.13, Table 5.5). 
Conversely, MV+DTwP group females had higher post-vaccination TNF-a production 
following PPD stimulation than males (P=0.024; Figure 5.12E, Table 5.5).
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Figure 5.13 Median cytokine levels in PPD cultures for IFN-y in the 3 vaccine groups 
before and after vacciantion in males and females. The error bar indicates the upper 
quartile. P-values were dervied form the GLS model analysis and indicate the vaccine 
time point at which there was a significant effect of sex.
5.3.8 Post-vaccination Sex Differences in the Ratio of IFN-y to IL-10
The ratio of the pro- to anti-inflammatory cytokines may be a better predictor of the 
outcome of an immune challenge than simply analysing indivdual cytokine levels. We 
therefore analyzed the ratio of IFN-y to IL-10 using the raw data without background 
subtraction to avoid negative ratios, which are not informative. The data was analyzed 
using GLS regression modelling. The only difference found was that DTwP vaccinated 
females had significantly lower IFN-y to IL-10 ratios post-vaccination following 
aCD3/aCD28 stimulation than DTwP males (P=0.008; Figure 5.14).
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Table 5.5 Summary of sex differences in the different stimulations
Stimulation Group_______ Cytokine P-value_____Responses
Interactions between group and time of vaccination in males and females - Pre-vacc
PPD DTwP Eotaxin 0.015 M>F
Comparison of females versus males within each vaccine group - Pre-vacc
PPD MV IL-12p(70) 0.006 F>M
TNF-a 0.004 M>F
VEGF 0.018 M>F
DTwP IL-12p(70) 0.006 M>F
IFN-y 0.013 M>F
TNF-a 0.013 M>F
Interactions between group and time of vaccination in males and females - Post-vacc
Measles MV IFN-y 0.031 M>F
PPD DTwP IFN-y 0.017 M>F
aCD3/aCD28 DTwP IL-1 p 0.028 M>F
Comparison of females versus males within each vaccine group - Post-vacc
PPD MV+DTwP TNF-a 0.024 F>M
TT MV IL-10 0.027 M>F
GMCSF 0.002 M>F
PDGFBB 0.003 M>F
TNF-a 0.030 M>F
Summary of the interactions between group and time of vaccination by sex, as well as 
direct comparison between males and females within each vaccine group, for the different 
stimulations from the GLS regression modeling results. Stimulations in which we found a 
significant effect of sex in a groups’ response at the pre or post-vaccination time point are 
indicated.P-values <0.035 were considered significant to account for FDR and are 
indicated.
5.4 Discussion
In this chapter, we investigated the effects of giving DTwP with measles vaccine 
(MV+DTwP), MV alone or DTwP alone to 9-month old infants on cytokine production to 
vaccine-specific and non-vaccine antigens 4 weeks later. Overall a number of vaccine 
group and sex differences were observed following administration of the different 
vaccines, but these need to be interpreted with caution given the wide variation in 
responses between individuals, and the existence of group and sex differences prior to 
vaccination too.
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5.4.1 Vaccine-specific effects
MV is thought to induce an early pro-inflammatory IFN-y response in humans (Pauksen et 
al., 1997) followed by a later Th2 profile (Griffin and Ward, 1993). In concordance with 
this, those infants who received MV at 9 months (MV group and MV+DTwP group) had 
significantly increased IFN-y production in measles peptide cultures than the DTwP group 
who did not receive MV; while IL-4 reactivity to measles peptides was negligible, 
suggesting a type 1 bias to the early measles specific response following infant 
vaccination at 9 months.
Infants given DTwP at the same time as MV had increased post-vaccination levels of IL- 
10, TNF -a, GM-CSF and PDGF-BB in response to TT stimulation in vitro compared to the 
MV group, whereas responses were comparable to the DTP alone group. This indicates a 
boosting of TT-specific innate reactivity in the 2 groups that received a DTwP booster 
compared to the group that did not.
The MV males had greater post-vaccination TNF-a, IL-10, GMCSF and PDGF-BB 
production following TT stimulation than females from the same group, supporting an 
enhancement of these responses to an unrelated antigen in MV males but not females 
post vaccination. This would be in keeping with the enhanced pro-inflammatory effects 
following vaccination with another live vaccine, BCG, both in adults (Kleinnijenhuis et al., 
2012) and neonates (Jensen et al., 2014). In the latter study the females were more 
susceptible to the enhancing effects of BCG than males, while we found the opposite for 
MV. In the group given MV with DTP males and females had similar responses, although 
the groups cannot be compared for TT reactivity since this group had a DTwP boost at 9 
months, whereas the MV group did not.
5.4.2 Heterologous effects on aCD3/aCD28 and PPD responses
Responses were examined to stimulation with soluble aCD3/aCD28, which stimulates 
and expands CD4 and CD8 T cells in vitro, allowing them to release cytokines in an
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MHC unrestricted manner. These responses were similar for all vaccine groups when 
males and females were analysed together. However, when separated by sex we 
found that the DTwP vaccinated females had down regulated IL-1 p cytokine production 
and lower IFN-y:IL-10 ratios following aCD3/aCD28 stimulation compared to DTwP 
vaccinated males, suggesting an immunosuppressive effect of DTwP vaccination in 
females. DTwP vaccination has been implicated in many studies as having possible 
deleterious effects in females, with increased susceptibility to non-vaccine related 
infections and increased all-cause mortality (Aaby et al., 2004a; Aaby et al., August 
2006; Benn and Aaby, 2012). A T cell immunosuppressive effect of DTwP could 
potentially enhance disease susceptibility, and this warrants further investigation.
Similar to their vaccine-specific responses, both the MV and the DTwP vaccinated males 
had a more pro-inflammatory profile with greater IL-13 +/- IFN-y following stimulation with 
aCD3/aCD28 compared to females, but this was not the case in the MV+DTwP group. 
This suggests a modification of this effect when the 2 vaccines are administered together, 
which supports the epidemiological data which shows that NSE of the invidivual vaccines 
are lost or modified when vaccines are given together.
The MV+DTwP had a more pro-inflammatory profile (IL-12p70 and TNF-a) to PPD at 
the prevaccination baseline than the MV group. All groups were vaccinated with BCG in 
the first week of life; but the MV group had received 3 doses of DTwP compared to only 
2 in the MV+DTwP group, so this may have played a modulatory role. Alternatively this 
may be due to differences in exposure to environmental mycobacteria and /or 
tuberculosis leading to baseline differences. Following vaccination, the reverse was 
observed in that the MV alone group had higher PPD-stimulated TNF-a reactivity than 
the MV+DTwP group, suggesting a vaccine modifying effect. When males and females 
were analysed separately, PPD stimulated TNF-a responses were higher in females 
than males in the MV+DTwP group, supporting sex-specific modification of 
heterologous responses when MV is given with DTwP.
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At pre-the vaccination baseline, males had more IFN-y, TNF-a, IL-12p(70) and VEGF 
production following PPD stimulation in the MV and DTwP groups, and this baseline 
sex difference was retained post-vaccination in the DTP group with males having 
higher IFN-y to PPD than females.
In females, the effects observed when DTwP was given alone did not occur when 
DTwP was given with MV, supporting our hypothesis that combining MV with DTwP 
alters the immune profile. Males had more pro-inflammatory responses than females to 
non-specific antigens both before vaccination and after MV or DTwP, but not after 
combined MV+DTwP vaccination when females produced more TNF-a to PPD than 
males. TNF-a is a key innate pro-inflammatory cytokine to infectious challenge. It is 
mainly produced by activated macrophages, although CD4+ T cells and NK cells also 
produce it. A previous Gambian study showed a relative risk of death of 5.59 (2.10; 
14.8) for children having a third DTwP (DTP3) together with MV compared with children 
having MV only (Aaby et al., 2006b). A study from Congo showed a mortality rate ratio 
(MRR) of 5.38 (1.37; 21.15) (Aaby et al., 2006a) and from Malawi of 5.27 (1.11; 25.0) 
for children who received DTP together with MV compared with children who received 
only MV (Aaby et al., 2006). Alterations in pro- or anti-inflammatory responses to non­
vaccine antigens could provide a possible explanation as to why vaccines might exert 
altered susceptibility to unrelated infections. Further longitudinal analyses of the pro- 
and anti-inflammatory cytokine profiles / ratios would be needed to fully understand the 
dynamics of the response to vaccination in the different groups and sexes.
5.4.3 Study Limitations
There are a number of limitations in this study. We were only able to assess supernatant 
cytokine levels after overnight culture rather than longer term, and thus most of the 
responses we describe in this chapter are innate or very early T cell responses. Longer 
culture periods would have provided more robust T cell reactivity. Furthermore these are
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whole blood cultures and we don’t know which cells are producing the cytokines putatively 
affected by vaccination. Another limitation is that we did not include more unrelated 
antigens due to the small sample volume available. Furthermore, the relatively small 
sample size, large number of cytokines and culture conditions tested, and huge inter­
donor variability characteristic of human studies of this nature make it difficult to detect 
convincing statistically significant changes between groups. There were a number of 
group and sex differences at baseline sampling, maybe in part due to differences in the 
DTwP dosing schedule at 4 months, but also due to normal human variation due to 
differences in exposure to other environmental antigens by 9 months of age, and due to 
genetic differences.
5.4.4 Overall conclusions
Our data indicate that the different vaccine schedules result in different cytokine profiles 
following stimulation with vaccine-specific and non-specific antigens.
The vaccine-specific responses were as expected; boosted measles-specific IFN-y 
reactivity in those that had MV; and boosted pro-inflammatory cytokine and IL-10 TT 
reactivity in those that had DTwP.
The DTwP females have suppressed pro-inflammatory T cell reactivity, and lower pro- 
inflammatory responses to PPD than males. MV male infants have enhanced reactivity to 
unrelated antigens, but not when MV was given with DTwP, suggesting a dampening 
effect of DTwP on the pro-inflammatory effects of MV. These data are subject to the 
limitations described above, but lend support to sex-differential effects of vaccines on 
immunity to unrelated antigens. They also provide potential explanations for the 
epidemiological observations of deleterious effects of DTwP in females; the beneficial 
effects of MV; and the fact that these effects are modified when both vaccines are 
administered together. The results pave the way for future hypothesis driven analyses of
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the mechanisms of the heterologous effects of these vaccines both in animal models and 
human studies.
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CHAPTER 6
POLYCHROMATIC FLOW CYTOMETRIC EVALUATION OF INNATE AND 
ADAPTIVE IMMUNE RESPONSES TO VACCINE SPECIFIC AND NON-VACCINE 
ANTIGENS IN INFANTS: INFLUENCE OF VACCINE SCHEDULE AND SEX
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6.1 Introduction
The previous chapter describes the cytokine production in whole blood cultures following 
stimulation with vaccine-specific and non-vaccine antigens. Whilst this provides the pattern 
of cytokines released, it provides no information regarding the cellular source of the 
cytokines. The development and refinement of polychromatic flow cytometry and 
intracellular cytokine staining (ICS) technology allows for the phenotyping of cells 
producing one or more cytokines. Since we have hypothesized that the divergent 
heterologous effects of measles vaccine (MV) and the combined diphtheria, tetanus, whole 
cell pertussis vaccine (DTwP) could be related to differential immune skewing, we set out 
to further investigate the cellular source of type 1 (IFN-y, IL-2) and type 2 (IL10, IL-13) 
cytokines. The present chapter focuses on the production of these cytokines by CD4+ and 
CD8+ T cells, and CD56+ innate cells. Since the heterologous effect of MV and DTwP are 
more pronounced in females, we further analysed by sex to assess for differences in cell 
phenotype and function in males and females.
6.2 Methods
6.2.1 Blood Cultures and Cell Staining
Whole blood samples from study children at 9 and 10 months of age were stimulated 
overnight with vaccine specific antigens (measles haemagglutinin antigen (HA) peptide 
pool and tetanus toxoid (TT)); the non-vaccine specific recall antigen purified protein 
derivative (PPD); and the TLR4 agonist lipopolysaccharide (LPS). The measles HA antigen 
petide pool was used to analyse for vaccine-specific reactivity to measles, and TT was 
used to analyse for vaccine-specific responses to the tetanus toxoid component of DTwP 
vaccine. Anti-CD3/CD28 was used as a positive control and medium alone served as the 
negative control for spontaneous cytokine production (background). Intracellular cytokine 
staining (ICS) was performed as described in Chapter 2. Briefly, whole blood in 96-well 
plates was cultured at 37°C, 5% C02 for 16 hours with the addition of Brefeldin A after the 
first 2 hours of culture. Cells were then surface stained with the antibodies anti-CD4 APC- 
Cy7 and anti-CD8 PerCP for detection of CD4+ and CD8+ T cells respectively and anti-
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CD56 PE-Cy7 for detection of innate cells. After fixation and permeabilization, ceils were 
stained intracellularly with antibodies to IFN-y APC, IL-2 PE, 1L-10 PB and IL-13 FITC.
6.2.2 ICS Gating Strategy
Cells were acquired using a CyAn ADP™ 9-colour flow cytometer (Beckman Coulter, USA). 
Lymphocytes were gated according to FSC and SSC and compensation performed. At 
least 100,000 lymphocytes were acquired and analysis was performed using FlowJo 
software version 9.4.7 (Treestar, USA). From the lymphocyte gate (Figure 6.1 A), we gated 
on single cells using forward scatter and pulse width (Figure 6.1 B). From the singlet 
population we then gated on CD4+, CD8+ and CD56+ cells (Figure 6.1C and 6.1 H). From 
each of these cell populations we then gated on the cytokine-positive population using 
Boolean gating. This allowed us to determine combinatorial cytokine production using 
FlowJo. Grouped analysis of Th1 (IL-2 and IFN-y) or Th2 (IL10 and IL13) was performed.
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Figure 6.1Gating strategy for cytokine producing cells. Lymphocytes were gated using 
side and forward scatter (A). Singlets were then gated using forward scatter and pulse 
width (B). CD4+, CD8+ (C) and CD56+ cells (H) were then gated and analysed for the 
proportion of cytokine producing cells within each subset using Boolean gating (D-G, l-J).
After determining the percentages of CD4+, CD8+ and CD56+ cells that expressed 
intracellular IFN-y, IL-2, IL-10, IL-13 or a combination of these cytokines, background 
cytokine responses from medium (negative control) cultures were subtracted from antigen 
stimulated cytokine responses. All net values £0.01% were given a value of zero since this
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was assumed to represent background production, as previously described (Hanekom et 
al., 2004).
6.2.3 Statistical Analysis
Differences between the 3 vaccine groups pre- and post-vaccination were analysed using a 
Kruskal-Wallis test followed by Dunn’s test after which the P-values were corrected for 
multiple test comparison using False Discovery Rates (FDR). Mann-Whitney U-tests were 
used to determine differences between pre- and post-vaccination responses for each group 
and between males and females within each group. P-values <0.035 were considered 
significant to account for FDR.
6.3 Results
6.3.1 Measles-Specific CD4+ and CD8+ T Cell Responses
Following stimulation with measles antigen (measles peptide pool), there were no 
differences in the frequency of CD4+IFN-y+ T cells between the groups pre- or post­
vaccination (Figure 6.2A, Table 6.1). The proportion of CD8+IFN-y+ T cells was 
significantly increased post-vaccination in the MV group compared to pre-vaccination levels 
(P=0.002; Figure 6.2A, Table 6.1); no differences were seen in the other vaccine groups.
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Figure 6.2 T cell frequencies in the MV, MV+DTwP and DTwP groups (patterned bars) 
pre-vaccination and post-vaccination (filled bars) in the measles stimulated cultures. (A) 
Shows the frequency of IFN-y+ CD4+ and CD8+ T cells, (B) shows the frequency of IL-2+ 
CD4+ and CD8+ T cells, (C) shows the frequency of IL-10+ CD4 and CD8+ T cells, (D) 
shows the frequency of IL-13+ CD4 and CD8+ T cells, (E) shows the frequency of IFN- 
Y+IL-2+ CD4+ and CD8+ T cells and (F) shows the frequency of IL-10+IL-13+ CD4+ and 
CD8+ T cells. The error bar indicates the upper quartile. P-values were generated using 
Mann-Whitney U-test for differences between pre- and post-vaccination frequencies within 
the same vaccine group, and ANOVA with Dunn’s test for differences across all groups. P- 
values <0.035 were considered significant to account for FDR.
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There was no difference in the percentage of measles pool stimulated IL-2+, IL-10+ or IL- 
13+ CD4+ or CD8+ cells following vaccination (Figure 6.2B, C and D, Table 6.1). There 
was no significant difference in the proportion of double positive (IFN-Y+IL-2+ or IL-10+IL- 
13+) cells in any of the groups in measles pool cultures after vaccination (Figure 6.2E and 
F).
The proportions of CD4+ T cells producing both IL-10 and IL-13 in measles cultures was 
significantly higher in males (median 0.04, IQR 0-0.06) in the DTwP group compared to 
females (median 0.01, IQR 0-0.04) post-vaccination (P=0.028; Table 6.2). All infants in the 
three vaccine groups were measles naive pre-vaccination and the DTwP group remained 
naive as they only received DTwP.
6.3.2 TT-Specific CD4+ and CD8+ T cell Responses
The only difference in TT responses was a significantly increased proportion of IL- 
13+CD8+ T cells following vaccination in the MV+DTwP group (median 0.05, IQR 0-0.27) 
(P=0.017; Table 6.1). This was not observed in the DTwP alone group.
We further investigated whether sex has an effect on T cell responses to TT stimulation. 
MV+DTwP group females had a significantly higher proportion of CD4+IFN-y+IL-2+ T cells 
compared to MV+DTwP males pre-vaccination (P=0.003; Table 6.2); but no difference 
was seen post-vaccination. Following vaccination, DTwP males had a higher proportion of 
CD4+IL-10+IL-13+ T cells compared to females (P=0.011; Table 6.2).
6.3.3 CD4+ and CD8+ T Cell Responses to the Broad T Cell Stimulant Anti-CD3/anti- 
CD28
Any effects of vaccination on responses to the general T cell stimulant anti-CD3/CD28 
(positive control) would suggest a broad immune modulatory effect. The DTwP vaccinated 
infants had a decreased proportion of CD4+IFN-y+ (P=0.002), CD4+IFN-y+IL-2+ double 
positive (P=0.021) and CD4+IL-10+ (P=0.008) cells post-vaccination compared to pre­
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vaccination levels (Table 6.1). There was also a decrease in the proportion of CD8+IL-2+ 
cells post-vaccination in DTwP vaccinated individuals compared to pre-vaccination levels 
(median 0.42, IQR 0.01-0.95 and median 0.11, IQR 0.0-0.05, respectively, P=0.027). No 
sex differences were observed for anti-CD3/CD28 responses within or between groups 
(Table 6.2).
6.3.4 CD4+ and CD8+ T cell Responses to PPD
BCG was administered to all children in the first week of life as part of the Gambian EPI 
vaccine schedule and thus they might be expected to have in vitro PPD reactivity at 9 
months of age which could also be due to exposure to environmental mycobacteria. We 
found no difference in responses to PPD by ICS for CD4+ or CD8+ T cells for single 
cytokine positive cells (IFN-y, IL-2, IL-10 or IL-13) or IL-10+IL-13+ double cytokine positive 
cells (Figure 6.3 A-D and H) either between vaccine groups or pre to post comparison 
within the same group. As expected, there was higher production of IFN-y from CD4+ T 
cells than from the CD8+ T cells (Figure 6.3A).
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Figure 6.3 T cell frequencies in the MV, MV+DTwP and DTwP group (patterned bars) pre­
vaccination and post-vaccination (filled bars) in the PPD stimulated cultures. (A) The 
frequency of IFN-y+ CD4+ and CD8+ T cells; (B) The frequency of IL-2+ CD4+ and CD8+ T 
cells; (C) The frequency of IL-10+ CD4 and CD8+ T cells; (D) The frequency of IL-13+ CD4 
and CD8+ T cells; (E) The frequency of IFN-y+IL-2+ CD4+ and CD8+ T cells; (F) The 
frequency of IL-10+IL-13+ CD4+ and CD8+ T cells. The error bar indicates the upper 
quartile. P-values were generated using Mann-Whitney U-test for differences between pre- 
and post-vaccination frequencies within the same vaccine group, and ANOVA with Dunn’s 
test for differences across all groups. P-values <0.035 were considered significant to 
account for FDR.
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There were no differences in CD4+ T cell responses between males and females following 
PPD stimulation. However, the proportion of CD8+IL-13+ cells was significantly higher in 
MV males compared to MV females post-vaccination (P=0.008; Table 6.2)
Table 6.1 Summary of the significant differences in T cell frequencies between 
vaccine groups and between pre- and post-vaccination time points for the different 
stimulations
Antigen (Stimulant) Vaccine Group Cytokine+ cells Pre-vacc 
(IQ Range)
Post-vacc 
(IQ Range)
P-value Responses 
t  or i
Pre vs Post-vaccination
CD4
aCD3/aCD28 DTwP IFN-7 + 0.09 (0 -  0.47)
0
(0 - 0 .1 1 ) 0 .0 0 2 Pre > Post
IL-10+ 0 .1 2  
(0  -  0.26)
0.04
(0 -0 .1 4 ) 0.008 Pre > Post
IFN-Y+IL-2+ 0(0 -  0.04)
0
(0 - 0 .0 1 ) 0 .0 2 1 Pre > Post
CD8
Measles MV IFN-Y+ 0(0 -  0.13)
0.08
(0 - 0 .2 2 ) 0 .0 0 2 Post > Pre
TT MV+DTwP IL-13+ 0 .0 1  
(0  -  0.08)
0.05
(0 -0 .2 7
0.017 Post > Pre
aCD3/CD28 DTwP IL-2 + 0.42 (0.01 -  0.95)
0.15
(0 -0 .5 5 ) 0.027 Pre > Post
Antigen (Stimulant) Vaccine Group Cytokine+ cells Post-vacc (IQ Range MV grp)
Post-vacc 
(IQ Range DTwP grp) P-value
Responses 
t or 1
Between Group Differences (Post-vaccination)
CD4
aCD3/aCD28 MV vs DTwP IF fH + 0.09 (0 -  0.39)
0
(0 - 0 .1 1 ) 0 .0 0 2 MV > DTwP
The table shows median values from stimulations in which we found significant differences. 
ANOVA with Dunn’s multiple comparison tests was used for differences across all groups. 
P-values are reported on the table and were generated using Mann-Whitney U-test for 
differences between pre- and post-vaccination frequencies within the same vaccine group. 
P-values <0.035 were considered significant to account for FDR and are indicated.
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Table 6.2 Summary of significant differences in T cell and NK cell frequencies
between males and females pre- and post-vaccination for the different stimulations
Pre-vaccination sex differences
Vaccine group Cytokine+ cells
Pre-vacc 
(IQ range) P-value Sex difference
M F
CD4
TT M V+DTwP IFNjy+IL-2+
0
(0  -  0 .0 0 )
0
(0 -  0.03 0.003 F>M
PPD MV+DTwP IL-2+
0
( 0 -0 .1 4 )
0 .1 1  
(0 -  0.27) 0 .0 2 1 F>M
LPS MV+DTwP IL-2+
0
(0 -  0.09)
0.06
(0 -0 .3 9 ) 0.005 F>M
CD56
TT MV+DTwP IL-2+
0
(0 -  0.33)
0.32
(0 -0 .9 3 ) 0.013 F>M
TT DTwP IL-10+
0.09 
(0 -  0.46)
0
(0 -  0.05) 0.018 M>F
PPD M V+DTwP IL-13+
0
(0 -  0.35)
0.04
(0 -1 .3 2 ) 0.023 F>M
Post-vaccination sex differences
Vaccine group Cytokine+ cells
Post-vacc 
(IQ range) P-value Sex difference
CD4
Measles DTwP IL-10+IL-13+
0.04
(0 -0 .0 6 )
0 .0 1  
(0 -  0.04) 0.028 M>F
TT DTwP IL-10+IL-13+
0 .0 1  
(0 -  0.03)
0
(0 - 0 .0 1 ) 0 .0 1 1 M>F
LPS DTwP IL-10+IL-13+
0 .0 2  
(0 -  0.07)
0
(0 - 0 .0 2 ) 0.009 M>F
CD 8
PPD MV IL-13+
0.06 
(0 -  0.40)
0
( 0 -0 .0 9 ) 0.008 M>F
CD56
aCD3/CD28 DTwP IF N -/+
1.49
(0 -3 .5 1 )
0
(0 - 0 .6 6 ) 0.014 M>F
PPD DTwP IL-10+
0
(0 -  0.35)
0.31
(0 -0 .9 1 ) 0.025 F>M
Significant differences in CD4+ and CD8+ T cell and CD56+ cell frequencies between 
males and females in MV group, MV+DTwP group and DTwP group pre-vaccination and 
post-vaccination. The table shows median values from stimulations in which we found  
significant sex differences. P-values were generated using Mann-Whitney U-test for 
differences between males and females pre-and post-vaccination frequencies within the 
same vaccine group, followed by Dunn’s multiple comparison test for differences across all 
groups. P-values <0.035 were considered significant to account for FDR and are indicated.
6.3.5 T Cell Responses to LPS (TLR4 Agonist) Stimulation
TLR agonists have been shown to increase adaptive immune responses in infants (Wu et 
al., 2004; Wille-Reece et al., 2005) and have the potential to boost vaccine efficacy.
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Therefore we wanted to determine if the different vaccine groups responded differently to 
TLR agonist stimulation. Following LPS (TLR4 agonist) stimulation, there were no 
significant differences between the groups for single-positive for IFN-y, IL-2 and IL-10 or 
dual-positive (IFN-y+IL-2+ or IL-10+IL-13+) CD4+ or CD8+ T cells before or after 
vaccination when all donors were analysed together. Overall there was a greater 
production of IL-13 by CD8+ T cells than the CD4+ population in LPS cultures both pre- 
and post-vaccination (Figure 6.4). The frequency of CD4+IL-13+ cells was significantly 
higher post-vaccination compared to pre-vaccination in the MV+DTwP group (P=0.007; 
Figure 6.4, Table 6.4).
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Figure 6.4 Frequencies of IL-13+ CD4 and CD8+ T cells in the MV, MV+DTwP and DTwP 
group (patterned bars) pre-vaccination and post-vaccination (filled bars) in the LPS 
cultures. P-values were generated using Mann-Whitney U-test for differences between pre- 
and post-vaccination frequencies within the same vaccine group and ANOVA with Dunn’s 
post-test comparison for differences across all groups. The error bar indicates the upper 
quartile. P-values <0.035 were considered significant to account for FDR and are indicated.
In the sex analysis, there was a significantly lower proportion of CD4+IL-2+ T cells in 
MV+DTwP males than females pre-vaccination (P=0.005; Table 6.2), but this was not 
sustained post-vaccination. The post-vaccination frequency of CD8+IFN-y+ T cells 
following LPS stimulation was significantly higher in males in the MV group compared to 
males in both other groups (P=0.003 and P=0.002 respectively, Table 6.3). DTwP males
% IL-13+
MVpre 
EH MV+DTP pre 
DTP pre 
■  MVpost 
n  MV+DTP post 
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had a significantly higher proportion of CD4+IL-10+IL-13+ T cells post-vaccination 
compared to females (P=0.009; Table 6.2), but no sex differences were observed in the 
DTwP vaccinated group CD8+ T cell response (Table 6.2).
Table 6.3 Post-vaccination group differences in T cell frequencies in LPS stimulated 
cultures by sex
Antigen
(Stimulant) Vaccine Group Sex
Post-vacc 
Cytokine+ (IQ Range 1st Group)
Post-vacc 
(IQ Range 2nd Group) P-value
Responses 
t  or 1
Post-vaccination Group differences by sex
CD8
0 .2 0 0
LPS MV vs MV+DTwP Males IFN-7 + (0.01 -  0.40) 
0 .2 0
(0 -  0.14) 
0
0.003 MV > MV+DTwP
LPS MV vs DTwP Males IFN-^+ (0.01 -  0.40) (0 -0 .1 5 ) 0 .0 0 2 MV > DTwP
Significant difference in CD8+ T cell frequencies in LPS cultures between MV group, 
MV+DTwP group and DTwP group post-vaccination when analysed by sex; median values 
are shown. Only comparisons with significant differences are shown for LPS cultures. P- 
values were generated using Mann-Whitney U-test for differences between groups in 
males and females. ANOVA with Dunn’s multiple comparison tests was used for 
differences across all groups. P-values <0.035 were considered significant to account for 
FDR and are indicated.
6.3.6 High levels of cytokine production by NK cells in response to MV peptide 
stimulation
IFN-y production was more than 5-fold higher from CD56+ NK cells compared to CD4+ or 
CD8+T cells (Figure 6.5) following stimulation with measles peptides confirming that the 
bulk of the IFN-y production detected by luminex is innate derived. The percentage of NK 
cells producing IFN-y, IL-2, IL-10 or IL-13 showed no differences between the vaccine 
groups pre-vaccination when all donors were analysed together. No significant differences 
were seen when responses were analysed by sex.
164
CD56
CD56
Figure 6.5 Flow cytometry plot of CD56 gated against CD8 (A) and IFN-y production from 
T cells and CD56+ cells (B-D). CD56+ cells were generally distinct from the CD8+ subset, 
and produced all 4 cytokines (IFN-y, IL-2, IL-10 and IL-13). The CD56+ population includes 
NK cells, NK T cells and yS T cells. The CD56+CD8low tend to be the NKT and/or yd T 
cells. Percentages of IFN-y production to measles antigen stimulation in CD4+ cells (B), 
CD8+ cells (C), and CD56+ cells (D) in one individual in response to measles antigen 
stimulation.
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Table 6.4 Summary of the significant differences in T cell and CD56+ cell frequencies 
betweenvaccine groups and between pre- and post-vaccination time points for the 
different stimulations
A ntigen (Stim ulant) V accine G roup C ytokine+ cells Pre-vacc  
(IQ  Range)
Post-vacc  
(IQ  Range)
P-value R esponses  
t  o r 1
Pre vs Post-vaccination
CD56
0.25
(0 - 1 .0 0 )
TT DTwP IL-13+ 0
(0 -  0.33)
0.006 Pre > Post
M V IL-10+IL13+ 0(0 -  0.00)
0
(0 -  0.27)
0.019 P ost > Pre
PPD MV+DTwP IL-2+
0.34
(0 - 1 .0 2 )
0
(0 -  0.56) 0.019 Pre > Post
DTwP IL-13+ 0.39( 0 - 1 .2 3 )
0
(0 -  0.53) 0.026 Pre > Post
M V+DTw P IFN j y+IL-2+
0
(0 -  0.27)
0
(0 -  0.00) 0.001 Pre > Post
LPS M V+DTw P IL-2+
0.44
( 0 - 1 .2 1 )
0
( 0 - 0 .6 1 ) 0.006 Pre > Post
: CD4
0.08  
(0 -  0.26)
—.... . ...... •—............ ■......
LPS M V+DTw P IL-13+ 0
( 0 - 0 .1 3 )
0.007 Post > Pre
Significant differences in CD4+ T cell and CD56+ cell frequencies in the MV group, 
MV+DTwP group and DTwP group pre-vaccination compared to post-vaccination. Results 
from stimulations with significant differences are shown. P-values were generated using 
Mann-Whitney U-test for differences between pre- and post-vaccination frequencies within 
the same vaccine group.P-values <0.035 were considered significant to account for FDR 
and are indicated.
6.3.7 NK cell responses to TT Stimulation
TT reactivity in CD56+ cells was very low, with many median values being zero both before 
and after vaccination. There were no differences between the groups pre- or post­
vaccination but the % of CD56+IL-13+ cells was significantly lower following vaccination in 
the DTwP group compared to pre-vaccination levels (P=0.006; Table 6.4).
In the sex analysis females had a higher percentage of CD56+IL-2+ (P=0.013) and lower 
CD56+IL-10+ cells (P=0.0181) than males at pre-vaccination baseline in the MV+DTwP 
group and the DTwP groups respectively (Table 6.2). These differences were lost post­
vaccination.
6.3.8 NK cell responses to aCD3/aCD28 stimulation
IFN-y production by CD56+ cells in aCD3/28 cultures was higher than in the measles, PPD 
and TT stimulated cultures (Figure 6.6). There were no differences in cytokine production
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between the 3 groups, and no changes following vaccination in any of the groups in 
aCD3/aCD28 cultures. When analysed by sex, the percentage of CD56+IFN-y+ cells was 
significantly higher in DTwP vaccinated males (median 1.49, IQR 0.0-3.51) compared to 
females (median 0.0, IQR 0.0-0.66) post-vaccination (P=0.014; Table 6.2).
6.3.9 NK cell responses to PPD
Following PPD stimulation, the proportion of CD56+IFN-y+ cells was similar between the 
vaccine groups. However, the proportion of CD56+ cells producing IL-2 alone or in 
combination with IFN-y was reduced following vaccination in the MV+DTwP group 
(P=0.019 and P=0.001 respectively; Table 6.4). A decreased percentage of CD56+IL-13+ 
cells was also found post-vaccination in the DTwP group (median 0.0, IQR 0-0.53) 
compared to pre-vaccination (median 0.39, IQR 0.0-1.23; P=0.026; Table 6.13).
The MV+DTwP females had a higher pre-vaccination proportion of CD56+IL-13+ cell 
frequencies in PPD cultures (median 0.04, IQR 0.0-1.32) compared to males (median 0.0, 
IQR 0.0-0.35) (P=0.023; Table 6.2). In addition, the percentage of CD56+IL-10+ cells was 
significantly higher in DTwP vaccinated females post-vaccination (median 0.31, IQR 0.0- 
0.91) compared to males (median 0.0, IQR 0.0-0.35) (P=0.025; Table 6.2).
6.3.10 NK cell responses to LPS (TLR4 agonist)stimulation
IFN-y production by CD56+ cells was higher in LPS cultures compared to PPD, TT, 
measles pool and aCD3/aCD28 cultures (Figure 6.6). There was no difference in CD56+ 
cell cytokine production between groups either before or after vaccination following LPS 
stimulation. However, within the MV+DTwP group, proportions of CD56+IL-2+ cells 
following LPS stimulation decreased significantly post-vaccination (median 0.0, IQR 0.0- 
0.61) compared to pre-vaccination levels (median 0.44, IQR 0.0-1.21) (P=0.006; Table 
6.4). There were no sex differences in CD56+ cell frequencies in LPS cultures.
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Figure 6.6 Proportions of IFN-y produced by CD56+ cells. Comparison of IFN-y 
production by CD56+ cells in the different antigen cultures (A-E) in the three vaccine 
groups. The error bar indicates the upper quartile.
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6.4 Discussion
The aim of this chapter was to determine whether giving DTwP with MV, MV alone or 
DTwP alone altered cytokine responses following vaccine-specific, recall or TLR agonist 
stimulation by NK cells and T cells at the single-cell level. Production of IFN-y, IL-2, IL-10 
and IL-13 was assessed using intracellular cytokine staining to determine the cellular 
source of cytokines observed in chapter 5.
6.4.1 Antigen Specific T Cell Effects
In measles antigen cultures, the expected enhanced Tc1 IFN-y CD8 T cell response was 
observed in the MV group 4 weeks after vaccination, but not in the DTwP vaccine 
recipients. This suggests that MV alone results in a predominant Tc1 CD8+ response. This 
was not apparent in the MV+DTwP group suggesting interference with stimulating a 
memory response to MV when DTwP is given simultaneously. The stronger Th2 responses 
(CD4+ IL-10+IL13+) in measles pool cultures in males compared to females in the DTwP 
group probably represents an innate response to intrinsic innate agonists in this live 
vaccine since this group was measles naive.
In vitro TT responses were of low level, perhaps due to the relatively short culture period of 
16 hours which may have been insufficient for the adequate detection of this recall antigen 
response. As a result there did not appear to be any boosted TT reactivity 4 weeks after 
vaccination in the DTwP vaccine recipients. This is in concordance with our soluble 
cytokine results where TT responses were low level, and the DTwP vaccinated group failed 
to significantly increase responses to TT compared to the MV group, although there was an 
enhancement for most cytokines tested in the MV+DTwP group.
6.4.2 Non-Specific T Cell Responses
Reactivity to the general T cell stimulus aCD3/aCD28 was interesting in that the DTwP 
group had suppressed CD4 (Th1 and Th2) T cell reactivity 4 weeks after vaccination. By 
contrast, the aCD3/aCD28 response was not affected after MV or MV+DTwP vaccination.
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This was not observed in the soluble cytokine results for which there were no differences 
between the vaccine groups in response to the positive control stimulation when all donors 
were analysed together. However, in the previous chapter DTwP vaccination had a 
suppressive effect on supernatant IL-1 (3 responses to aCD3/aCD28 stimulation in females, 
so overall the data support immunosuppressive effects of DTwP vaccination, particularly in 
females.
There was no effect of DTwP vaccination on PPD-specific ICS T cell responses 4 weeks 
later, but the MV+DTwP group had a decreased Th1 response to PPD, suggesting a 
decrease in a potentially protective Th1 response to tuberculosis (TB). MV males had 
enhanced Tc2 reactivity to PPD compared to females, which could reduce their protection 
against TB since type 1 cytokine (IFN-y) responses are thought to be protective, although 
the precise correlates of TB protection are still not known. Alteration in anti-tuberculous 
immunity following administration of an unrelated vaccine suggests that responses to 
heterologous antigens might be altered by vaccination.The only other significant difference 
following PPD stimulation was a lower frequency of CD4+IL-2+ T cells in MV+DTwP males 
compared to females pre-vaccination (Table 6.2), but not post-vaccination. We observed 
similar findings in the previous chapter in which the luminex profiles also showed more 
differences in PPD reactivity pre-vaccination. Pre-vaccination sex differences in PPD 
reactivity in 1 group only could be due to baseline group differences in TB / mycobacterial 
exposure, group differences in BCG reactivity, but could also be due to chance and may 
not be a truly significant finding.
6.4.3 Effects on Innate Immune Responses to Vaccine Antigens
Innate immunity was assessed by gating on all CD56+ cells and looking at their 
intracellular cytokine profile; and by stimulating with the TLR4 agonist LPS and analyzing 
ICS cytokine percentages in CD56+ cells and also T cells. The marker CD56 was used to 
detect NK cells, although strictly speaking these should be further subdivided into CD56bnght 
and CD56dim, and the markers CD16 and CD8 may be further used to differentiate between
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various NK cell populations (Reviewed in (Poli et al., 2009)). Due to limits on the number of 
fluorochromes that could be tested, the marker CD3 was not available in the panel to 
confirm that the cells were truly CD3 negative and therefore NK cells. Thus by simply 
gating on all CD56+ cells there was likely a mix of NK and NK T cells represented in the 
subset analysed in this study. CD3bnghtCD56+ cells are typical of y8T cells, which are likely 
to be more abundant in infants than adults and thus these would also be represented in our 
gating strategy. Thus by gating on CD56+ cells we are potentially describing cytokine 
production from NK cells, NK T cells, and y8 T cells combined, all of which are innate 
immune cells.
The recently discovered innate lymphoid cells (ILCs) have been shown to have a role in the 
control of diseases. These cells produce many of the Th cell type cytokines but lack cell 
surface markers found on other immune cells, hence named lineage marker-negative 
(ILN), and they do not express a T cell receptor. The ILCs have been divided into three 
groups. The group which relates to this chapter are the ILC group 1. This encompass the 
ILN-ILC1 and NK cells. The ILN-ILC1s express the surface marker CD56 and secrete IFN- 
y as it’s signature cytokine (Reviewed in (Walker et al., 2013)). Thus these cells could be a 
key source of the IFN-y measured in CD56+ cells in this study. It will be interesting to apply 
additional makers in future studies to gate on the ILN-ILC1 subset for more indepth 
analysis.
Overnight stimulation with the vaccine antigens led to low-level cytokine production in 
CD56+ cells. In the DTwP group there was a decrease in CD56+IL-13+ cells in TT cultures 
post-vaccination which suggests a possible suppression of type 2 innate immunity. This 
effect was not apparent when MV and DTwP were administered at the same time, in 
support of altered responses when the live MV is given at the same time.
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6.4.4 Effects on Innate Responses to LPS, PPD and aCD3/aCD28
Due to its broad specificity, reactivity to aCD3/aCD28 was generally about double that 
observed to the measles pool, TT or PPD. The only differential effect to aCD3/aCD28 
stimulation was observed in the DTwP group, whereby males had significantly higher levels 
of CD56+IFN-y+ cells compared to females post-vaccination; while females produced more 
of the regulatory cytokine IL-10 in CD56+ cells from PPD cultures, suggesting a pro- 
inflammatory innate effect in males and an immunosuppressive innate effect in females. It 
is possible that the aCD3/aCD28 effect is from NK T cells and y5 T cells within the CD56+ 
population since these would be stimulated by aCD3/aCD28, although this requires 
confirmation in future studies.
The LPS reactivity was higher than that observed to aCD3/aCD28, in particular IFN-y+ 
CD56+ cells, which might be expected when conducting overnight cultures using whole 
blood in which the innate response is likely to be a major contributor. That NK cells 
respond to LPS (TLR4 agonist) is a fairly new discovery and Duriez et al has reported high 
IFN-y production by decidual NK cells (Duriez et al., 2014). The surface expression 
(O'Connor et al., 2006) as well as the functional activity of TLR4 (Mian et al., 2010) has 
been detected in human NK cells. A study by Kanevskiy and colleagues using LPS 
stimulation of purified TLR4CD56+ NK cells followed by intracellular cytokine staining has 
shown a high production of IFN-y form these cells but not from other cell types, suggesting 
an alternative method of LPS signalling distinct from the known surface TLR4 mediated 
signalling (Kanevskiy et al., 2013). NK cells and DCs also express CD8 receptor and it is 
possible that LPS uses this receptor for signalling in these cells.
The increased Th2 (CD4+IL-13+) and decreased type 1 innate cell (CD56+IL-2+) 
responses in LPS cultures in the MV+DTP vaccinated group suggests a type 2 innate 
skewing following vaccination with MV and DTP simultaneously. By contrast, MV 
vaccinated males had greater Tc1 (CD8+IFN-y+) reactivity to LPS after vaccination
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compared to the other male groups, supporting an innate bias towards type 1 immunity 
following MV in males but not females. The DTwP group males had more Th2 (CD4+IL- 
10+IL-13+) reactivity to LPS than females following vaccination. Thus innate type 1 
skewing by MV may be lost when DTP is given with MV.
6.4.5 Limitations
There are a number of limitations that should be borne in mind when interpreting the 
results of this chapter. The percentages of the cells expressing the various cytokines were 
very low, although this is well recognised for this methodology and our data are 
comparable to most other studies using ICS methodology to detect cytokine producing 
cells (Suni et al., 1998; Godoy-Ramirez et al., 2004; Pahar et al., 2005; Van Hemelen et 
al., 2011; Yamashita et al., 2013). All cell subsets were detectable by flow cytometry, and 
were very low in the negative control samples, while our positive controls generated higher 
proportions of cytokine-producing cells. There were multiple cell subets analysed for 
different culture conditions, with different vaccine groups compared both before and after 
vaccination and by sex, and thus the issue of multiple testing and false positive significant 
results increases. For this reason we have only reported significant results after correcting 
for FDR. Thus we are confident that those differences detected, whilst small, are likely to 
be meaningful.
We observed a number of pre-vaccination differences, making post-vaccination differences 
more difficult to interpret. Since the infants were 9 months old at baseline, their immune 
responses would be influenced by prior exposure to environmental stimuli, previous 
infections and vaccinations, maternal factors such as maternal antibodies and breast 
feeding, and genetics. Furthermore, the MV group had received 3 doses of DTwP while the 
other 2 groups had only received two, which could account for baseline differences 
between the MV group and the other 2 vaccine groups although some baseline differences 
were also observed exclusively in one of the other groups, likely to be due to a combination 
of the factors above.
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6.4.6 Overall conclusions
Despite the limitations above, vaccine group and sex differences were observed post­
vaccination. Furthermore, the data suggest that co-adminstration of MV with DTP interferes 
with the priming of the measles specific response; and also leads to a different immune 
profile compared to when the vaccines are given alone, generally with decreased type 1 
and enhanced type 2 responses. The putative immunosuppressive effects of DTwP 
suggested in the previous chapter are further supported by decreased CD4 reactivity in 
aCD3/aCD28 cultures after DTwP vaccination observed in this chapter.
Where male / female differences were observed, the males generally had stronger 
responses than females following MV or DTwP vaccination, while no sex differences were 
observed in the MV+DTwP group. This is consistent with the cytokine data from the 
previous chapter.
Therefore this chapter further characterizes vaccine group and sex differences that might 
account for the differential heterologous effects of the different vaccine schedules. The 
data are subject to many limitations and would require confirmation in further studies.
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CHAPTER 7
WHOLE HUMAN GENOME TRANSCRIPTOME PROFILING REVEALS SEX- 
DIFFERENTIAL EFFECTS FOLLOWING VACCINATION WITH DTwP AND MEASLES
VACCINES
175
7.1 Introduction
Conventional methods employed in immunological profiling of vaccine responses such as 
the enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunosorbent spot 
(ELISpot) assay, intracellular staining (ICS) by flow cytometry and cytokine analysis by 
multiplex technology, can only test a limited number of parameters, which is a particular 
problem in infants where small volumes of blood are available. The advent of systems 
biology technology, including transcriptome microarray, allows the rapid and simultaneous 
analysis of thousands of genes, and is beginning to provide new insights into the complex 
nature of the immune response to vaccines (Flanagan et al., 2013a).
As discussed throughout this thesis, there is increasing evidence for sex differences in 
immunity to vaccines, and our luminex and ICS data support this (Chapters 5 and 6 
respsectively). In a re-analysis of the data in the Querec paper (Querec et al., 2009), Klein 
and colleagues found that females differentially expressed many more innate immune 
response genes than males following yellow fever vaccination, with limited overlap in the 
genes differentially expressed in males and females (Klein et al., 2010). Data from 
Flanagan and colleagues replicates these findings in measles vaccinated infants (Flanagan 
et al, in preparation). Analysing males and females together may therefore lead to a loss of 
information since changes in gene expression may only become apparent when males and 
females are analysed separately.
Transcriptional profiling technology has not been used to study the heterologous or non­
specific effects of vaccines to date. In this chapter, we therefore undertook whole human 
genome transcriptome profiling before and after vaccination in order to analyse for 
differential gene expression after vaccination in the three vaccine groups. In our previous 
chapters we have found sex differences for some of the parameters tested, and we 
therefore sought to analyse for sex differences in the transcription profile. In particular, we 
hoped to gain further insights into the nature of the immunosuppressive effects of DTwP in 
females, and the reversal in the MV+DTwP group of the normal pattern in which males
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have stronger inflammatory responses than females. Overall, we hoped to use this 
technology to identify biomarkers / gene signatures that might be responsible for the 
beneficial and deleterious effects of vaccines, which might then be tested prospectively in 
future studies.
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7.2 Methods
RNA was extracted at the MRC Unit, The Gambia from whole blood in PAXgene tubes 
from all available 9 and 10 month old study infant samples as detailed in Methods (chapter 
2). RNA samples were sent to the Division of Pathway Medicine (DPM), University of 
Edinburgh for transcriptional profile analysis. Dr. Paul Dickinson at DPM, in partnership 
with Gen-Probe, Inc., performed the transcriptome analysis assays for this chapter. Dr. 
Paul Dickinson and Thorsten Forster at DPM, in partnership with Dr. Al Ivens, Fios 
Genomics Ltd., performed the statistical analysis for the transcriptome data. Please note 
that while I had the opportunity to visit Edinburgh and learn the technology, I did not carry 
out the assays or perform the analysis.
The samples available consisted of 202 donors with pre- and post-vaccination RNA 
samples available. Quality control using the Agilent Bioanalyser 2100 and Nanodrop 
ND1000 was used to determine those RNA samples of sufficient quality and quantity and 
360 samples were selected for subsequent microarray analysis, of which 348 samples 
contributed data to the final dataset (192 female samples and 196 male samples) (Table
7.1). The lllumina HT12v4 Array containing 47,293 array probes was used for the analysis 
as detailed in Methods (chapter 2). Linear modelling was used to explore the data after 
which empirical Bayesian analysis was applied (including vertical (within a given 
comparison) p value adjustment for multiple testing, which controls for false discovery 
rate). The Bioconductor package limma was used (Smyth et al., 2005)). Multiple samples 
from the same individual were taken into account when modelling the data.
Table 7.1 Number of donors analyzed by group and sex
Males Males Females Females
Unpaired Paired Unpaired Paired
Pre Post Pre Post Pre Post Pre Post
MV 32 31 31 31 26 27 24 24
MV+DTwP 30 31 29 29 35 35 32 32
DTwP 26 26 26 26 25 24 23 23
Total 88 88 86 86 86 86 79 79
The number of donors analyzed for each vaccine group for each sex in the paired and 
unpaired analysis.
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100ng total RNA was converted to double-stranded cDNA, followed by an amplification 
step (in vitro transcription) to generate labelled cRNA, using the Ambion lllumina 
TotalPrep-96 RNA Amplification Kit. This produced an amplified pool of biotin-labelled 
cRNA corresponding to the polyadenylated (mRNA) fraction. The cRNA was quantified 
using the Nanodrop ND1000, cRNA quantity was normalised and then hybridised onto the 
lllumina HT12 arrays for 14-20 hours at 58°C. The unhybridized and non-specifically 
hybridized cRNA was washed away and arrays stained with Cy3-Streptavidin to bind to the 
analytical probes hybridized to the array and allow differential detection of signals when the 
arrays were scanned.
Arrays were scanned with an lllumina IScan two-color laser scanner (532 nm/658 nm) with 
a 0.53 pm spatial resolution capable of exciting the fluorophores generated during the 
staining step of the protocol. Light emissions from these fluors were then recorded in high- 
resolution images of the arrays. Intensities of the images were extracted using 
GenomeStudio (2010.3) Gene Expresssion Module (1.8.0) software. Normalization of data 
and statistical tests are detailed in Methods (chapter 2).
To identify differentially expressed genes post-vaccination relative to pre-vaccination in the 
three vaccine groups stratified according to sex, statistical analysis using linear model 
fitting and an empirical Bayes approach was used as detailed in Methods (chapter 2). 
Multipe testing correction was applied to the statistical testing using Benjamini-Hochberg p 
value adjustment for multiple testing implemented in the limma software package for R, 
which controls for false discovery rate. Expression networks were constructed employing 
the Ingenuity Pathway Analysis (IPA) software (Ingenuity® Systems, www.ingenuity.com). 
lllumina Probe IDs were imported into the Ingenuity software and mapped to the Gene 
Symbol from the Ingenuity database as detailed in Methods (chapter 2).
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7.3 Results
7.3.1 Divergent gene expression profiles is revealed in females and males 
depending on vaccination group
A total of 5,915 non-redundant array features were significant at raw p<0.01 (unadjusted) 
in one or more of the comparisons as detailed in Methods (chapter 2). Figure 7.1 shows 
the non-redundant set of 5,915 significant genes (X-axis) broken down by comparisons (Y- 
axis), with the number of significant genes for each comparison shown in parentheses after 
the comparison description. Upregulated genes are shown in red, down-regulated genes in 
blue; while loci that were not significant in a given comparison are shown in grey. 
Comparisons with no significant genes were removed. The comparisons are ordered in the 
plot such that the one with the highest number of significant changes is shown at the 
bottom. The significance landscape view of the data provides a direct visual representation 
of which array features were significant in which comparison, thus enabling "condition" 
specific and/or enriched loci to be rapidly identified.
Statistical profiles for each of the comparisons were obtained. For each comparison, the 
number of array features significant at various statistical thresholds were tallied but for 
statistical robustness, only those with an adjusted p value <0.05 were considered (Table
7.2).
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Figure 7.1 Significance landscape of differentially expressed probes. The non- 
redundant set of 5,915 significant genes (X-axis), by comparisons (Y-axis; the number of 
significant genes in each comparison are shown in parentheses after the comparison 
description); comparisons with the highest number of significant changes are shown at the 
bottom. Red = upregulated, blue = down-regulated, grey = nonsignificant in a given 
comparison.
Table 7.2 Array features significant at various statistical thresholds
Index Contrast__________________ rawP<0.05 rawP<0.01 rawP<0.001 rawP<0.0001 adjP<0.05 adjP<0.01 adjP<0.001 adjP<0.0001 B>=0
17 M V post_pre 2294 486 42 3 0 0 0 0 7
18 DTP post_pre 3409 748 89 12 0 0 0 0 29
19 M V +D TP  post_pre 2233 448 44 5 0 0 0 0 111 M V  F post_pre 2627 619 80 17 1 0 0 0 192 M V  M  post_pre 2544 485 53 8 0 0 0 0 6
3 DTP F post_pre 2856 642 86 10 0 0 0 0 14
4 D TP M post_pre 5998 1889 250 22 0 0 0 0 86
5 M V+D TP F post_pre 1910 385 35 3 0 0 0 0 36 M V+D TP M post_pre 2390 457 52 5 0 0 0 0 321 M V  post_pre_paired 2182 425 31 3 0 0 0 0 522 DTP post_pre_paired 2967 642 82 10 0 0 0 0 21
23 M V +D TP post_pre_paired 2168 440 51 7 0 0 0 0 11
9 M V  F post_pre_paired 2424 548 59 18 1 1 0 0 1510 M V  M post_pre_paired 2796 501 51 7 0 0 0 0 411 DTP F post_pre_paired 3157 773 89 9 0 0 0 0 2512 DTP M post_pre_paired 5994 1895 244 19 0 0 0 0 85
13 M VDTP F post_pre_paired 1944 404 51 2 0 0 0 0 2
14 M VDTP M post_pre_paired 2410 458 56 7 0 0 0 0 4
- Non-redundant markerset (nr set) 19512 5915 779 99 1 1 0 0 201
The number of array features significant at various statistical thresholds for each 
comparison post- relative to pre-vaccination for paired and unpaired data. Probesets with B 
>0 are more likely to be differentially expressed than not. F = Females, M = males where 
the data is analyzed by sex. DTwP is shortened to DTP for lack of space.
After multiple test adjustment (corrected using Benjamini & Hochberg method for multiple
testing implemented in the limma software package for R) only 2 comparisons showed any
statistically significant genes (MV females paired and unpaired -  1 probe only). In light of
this and in order to attempt to understand the nature of any transcriptional changes
between vaccine treatments it was felt that for this dataset a less stringent approach was
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required. It was therefore decided to examine differential fold-change instead. Genes were 
filtered by fold-change in expression to produce a subset of genes that show differential 
expression of at least 1.5 fold in one or more groups. To gain a global perspective of the 
responses in the three vaccine groups, heat maps of the differentially expressed probes 
were generated (Figure 7.2). The caveat to this approach is that this can only be 
suggestive of possible changes between conditions and that any changes observed would 
need further follow up to confirm their validity.
70 probes were differentially expressed that exhibited a 1.5 fold difference in expression. 
Clear sex and vaccine group differences were apparent from the global view provided by 
the heat map; clustered by genes and conditions using Pearson dissimilarity (Figure 7.2). 
DTwP females had mostly down-regulated genes (indicated in blue) in contrast to their 
male counterparts who had a predominantly up-regulated profile (indicated in red). The 
profile for MV+DTwP females and males were also quite distinct. However, the 
transcriptional profile for MV males and females did not appear to be very different.
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DTP F
DTP P
MV+DTP
MV+DTP
MV+DTP
MV+DTP
MV M P
MV M
MV P
DTP M
DTP M P
MV F P
MV F
MV+DTP
MV+DTP
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Figure 7.2 Hierarchical clustering o f 70 differentially expressed probes
Gene probes (named along the x-axis) exhibiting a 1.5 fold difference in expression in the 
different group and sex comparisons (on the left hand y-axis). Genes are clustered by 
Pearson dissimilarity, white indicates combined (females plus males), pink indicates 
female, and pale blue indicates male (left hand y-axis). Array features are shown on the X- 
axis. The comparisons (ie. vaccine groups) are shown on the Y-axis with F= females, M= 
males and P indicating that the analysis was paired. Where P is not indicated, it means that 
the analysis was unpaired. Where the sex is not indicated, it means that it was a combined 
analysis (females plus males). Red indicates up regulation, and blue down regulation with 
values displayed as log2 fold change.
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7.3.2 Distinct group and sex differences in differentially expressed genes
There was little differential gene expression greater than 1.5 fold unless the vaccine groups 
were separated by sex. The majority of non-redundant differentially expressed probes 
occurred in MV+DTwP males and DTwP males and females post-vaccination compared to 
pre-vaccination. A list of differentially expressed genes was derived from the above 
analyses (Table 7.3) and uploaded into the Ingenuity Pathway Analysis software to 
examine network and functional relationships between genes differentially expressed 
following vaccination with the 3 different schedules. However, the numbers of differentially 
expressed genes in MV vaccinated females and males, and MV+DTwP vaccinated females 
were too small for effective pathway analysis, thus networks were only generated for 
MV+DTwP males and DTwP vaccinated males and females.
Although the number of genes in MV and MV+DTwP females was too small for pathway 
analysis, several probes were differentially expressed in both groups including interferon 
inducible gene 27 (IFI27) which was upregulated in both groups (Table 7.3). TXNDC5 
differentially expressed in MV+DTwP females was upregulated and has a role in protecting 
hypoxic cells from apoptosis. Only one gene (DEFA3) was differentially expressed in MV 
males. This upregulated gene codes for a defensin, which has microbicidal and cytotoxic 
functions, which would aid in defense against invading pathogens. When examining the 
numbers of individuals showing a greater than 1.5 fold differential response for all of the 
differentially expressed probes (Table 7.3) it is clear that there is heterogeneity in the 
response, whereby some probes are highly differential in some individuals while not so in 
others. However, most of the changes are based upon a response in a number of 
individuals often amounting to half of the study group and not just due to a large response 
in one or two individuals.
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Table 7.3 Genes present in non-redundant probe list in the three vaccine groups by
sex
Vaccine 
Group / Sex
Non-redundant probes (paired and unpaired)
MV F IFI27 (10/24), PROK2 (10/24), RPL7 (14/24)
MV M DEFA3 (12/31)
MV+DTwPF IFI27 (19/32), IGJ (18/32), OTOF (14/32), TXNDC5 (17/32)
MV+DTwPM ADRA2C (13/39), ARTN (13/39), C1orf150 (3/29), CSDAP1 (14/29), 
DPYSL5 (13/29), GATSL3 (13/29), LOC100131391 (4/29), 
LOC100131726 (13/29), LOC440313 (13/29), LOC642469 (14/29), 
MUC6 (13/29), IGFBP1 (15/29), RNF213 (13/29), SERPINA13 (13/29), 
SMOX* (15/29), SMOX* (15/30), SPRYD3 (13/29), TPRA1 (13/29)
DTwP F EPSTI1 (10/22), FCGR3B (11/22), GBP1 (10/22), GBP1 (10/22), 
HERC5 (11/22), IFI44 (10/22), IFI44L (10/22), IFI6 (8/22), IFIH1 (8/22), 
I FIT 1 (10/22), IFIT2 (14/22), IFIT3* (10/22), IFIT3* (10/22), IFIT3* 
(10/22), IFITM3 (11/22), IL1RN (9/22), ISG15 (10/22), LAP3 (10/22), 
MX1 (10/22), MARCKS (10/22), OAS1* (10/22), OAS1* (10/22), OAS3 
(10/22), OASL (10/22), RSAD2 (10/22), SERPING1 (10/22), SPATS2L 
(10/22), STX11 (10/22), TRIM22 (8/22)
DTwP M ABHD3 (14/26), ADD3 (11/26), BNIP3L (12/26), CLK1 (11/26), DR1 
(16/26), Hs.657419 (12/26), JMJD1C (13/26), MBNL1 (10/26), MST4 
(9/26), OSBPL8 (2/26), PCMTD1 (12/26), PRNP (11/26), RASGRP1 
(11/26), SENP7 (9/26), TMED5 (11/26), ZFAND5 (11/26)
Genes > 1 . 5  fold expression present in non-redundant probe lists following unpaired and 
paired analyses. * Indicates multiple probes for the same gene represented. Red text = 
upregulated genes and blue text = down-regulated genes. Numbers in parentheses 
represent the number o f individuals that changes o f at least 1.5 fold were found in divided 
by the number o f individuals in the study group.
7.3.3 DTwP vaccinated females have down-regulated innate and antiviral gene 
pathways
DTwP vaccinated females showed down-regulation of genes encoding inflammatory and 
antiviral factors after vaccination, with 29 probes showing greater than 1.5 fold differential 
expression (Table 7.3). When these 29 probes were uploaded to Ingenuity Pathway 
Analysis (IPA) software, 25 genes were analysis ready due to the presence of duplicate 
probes. Allowing networks of up to 70 components created by direct interaction, one major 
network was produced (Network score 67) containing all 25 focus molecules. Top
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canonical pathway associated functions as revealed by network analysis include interferon
signaling and dendritic cell (DC) maturation (Table 7.4; Figure 7.3).
Many of the down-regulated genes are well-known type 1 interferon stimulated genes 
(ISGs), including IRF7, IFIT1, IFIT2, IFIT3, IFITM3, IL1RN, ISG15, MX1, OAS1, OAS3, 
OASL, RSAD2. Most of them are commonly induced by viral infection and play essential 
roles in type 1 IFN signaling, antigen presentation, and cellular and humoral immune 
responses (Table 7.4). For example, the down-regulated radical S-adenosyl methionine 
domain containing 2 (RSAD2) gene plays a key role in anti-viral immunity by promoting 
TLR7 and TLR9 dependent production of IFN-y by pDCs, and also plays a role in CD4+ T 
cell activation and differentiation, in particular optimal Th2 cytokine production. The 
ubiquitin-like modifier (ISG15) gene is involved in the viral sensing RIG-l-like receptor 
signaling pathway as well as interferon signaling and anti-viral immunity. ISG15 also 
activates neutrophils to produce eosinophil chemotactic factors. HECT and RLD domain 
containing E3 ubiquitin protein ligase 5 (HERC5), which has a positive regulatory role in the 
innate antiviral response in cells induced by interferon, was also down-regulated after 
DTwP vaccination of females (Table 7.4). Another interesting down-regulated gene was 
interleukin 1 receptor antagonist (IL1RN), which plays a role in acute phase signaling and 
cell mediated immunity by inhibiting the inflammatory action of 1L-1 a and IL-ip.
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Table 7.4 Pathway description and function of differentially expressed genes in
DTwP vaccinated females
Symbol Pathway Description Gene Name Function Fold
change
IFIT2 Interferon signaling Interferon-induced protein 
with tetratricopeptide 
repeats 2
Cell-mediated 
immune response, 
Antiviral activity
-2.297
RSAD2 Role of Pattern Recognition 
Receptors in Recognition 
of Bacteria and Viruses
Radical S-adenosyl 
methionine domain 
containing 2
Cell-mediated 
immune response, 
Response to virus
-2.144
IFIT1 Interferon Signaling Interferon-induced protein 
with tetratricopeptide 
repeats 1
Molecular Transport, 
Antiviral defense, 
Innate immunity
-2.000
IFIT3 Interferon signaling Interferon-induced protein 
with tetratricopeptide 
repeats 3
Antiviral defense, 
Innate immunity
-1.986
HERC5 Protein modification; 
protein ubiquitination
HECT and RLD domain 
containing E3 ubiquitin 
protein ligase 5
Post-Translational
Modification
-1.945
IFI44 Activation of IRF by 
Cytosolic Pattern 
Recognition Receptors
Interferon-induced protein 
44
Response to virus -1.905
ISG15 RIG-l-like receptor 
signaling pathway; 
Interferon signaling
ISG15 ubiquitin-like 
modifier
Antiviral response -1.840
OAS3 Interferon signaling 2'-5'-oligoadenylate 
synthetase 3
Antiviral response -1.828
IFITM3 Interferon signaling Interferon induced 
transmembrane protein 3
Response to virus -1.828
IFI44L Interferon signaling Interferon-induced protein 
44-like
Immune response; 
defense response to 
virus
-1.828
IL1RN Acute Phase Response 
Signaling
Interleukin 1 receptor 
antagonist
Lipid Metabolism; 
Cell-mediated 
Immune Response
-1.516
Description and functions assigned to the networks of genes that were differentially 
expressed using Ingenuity Pathway Analysis (IPA) software in DTwP vaccinated female 
infants. The top 10 differentially expressed genes were select.
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Figure 7.3 Network for DTwP vaccinated female infants. Differentially expressed genes 
and their associated pathways following DTwP vaccination of infant females. Networks 
were generated using Ingenuity Pathway Analysis software. Green nodes indicate genes 
that are down-regulated.
7.3.4 Upregulated apoptosis and hematological system genes in DTwP vaccinated 
males
In contrast to the down-regulated gene profile in DTwP vaccinated females, males had only 
upregulated genes. In DTwP vaccinated males, 16 probes showed greater than 1.5 fold 
upregulated expression post-vaccination compared to pre-vaccination (Table 7.3). These 
probes were uploaded for analysis using Ingenuity Pathway Analysis (IPA) software, of 
which 1 probe was unmapped and 15 were analysis ready. One major network was 
produced (Network score 38) containing all 15 focus molecules. Major functions associated 
with this network included developmental pathways, RNA transcription complex and post-
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transcriptional modification pathways (Table 7.5, Figure 7.4). The top canonical pathway 
associated functions were assembly of RNA polymerase II complex, T-cell receptor 
signaling and protein kinase A signaling. The major network associated functions mainly 
revealed an up-regulation of genes that are involved in developmental and repair functions.
Two apoptosis pathway genes were upregulated, namely BCL2/adenovirus E1B 19kDa 
interacting protein 3-like (BNIP3L) and serine/threonine protein kinase (MST4); while the 
upregulated prion protein (PRNP) gene plays a role in cell death and survival. The zinc 
finger, AN1-type domain 5 (ZFAND5) gene which is involved in both the TNF-alpha / NF-kB 
signaling pathways and Forkhead box O (FoxO) family signaling was upregulated following 
vaccination. The FoxO family genes regulate genes of cell growth, differentiation and 
proliferation. The adducin 3 gene (ADD3), jumonji domain containing 1C (JMJD1C) and 
RAS guanyl-releasing protein 1 (RASGRP1) genes are all involved in hematological 
system development. Only one upregulated gene - down-regulator of transcription 1 (DR1), 
is involved in transcription processes.
188
Table 7.5 Pathway description and function of differentially expressed genes in
DTwP vaccinated males
Symbol Pathway Description Gene Name Function Fold
change
ADD3 Activation of cAMP- 
Dependent PKA
Adducin 3 (gamma) Hematological System 
Development and 
Function; Tissue 
Morphology
1.625
JMJD1C Leukocyte
Extravasation
Signaling
Jumonji domain containing 
1C
Hematopoiesis 1.580
MST4 Apoptotic pathway Serine/threonine protein 
kinase MST4
Cellular Growth and 
Proliferation
1.580
ANKRD10 N/A ankyrin repeat domain 10 N/A 1.558
ZFAND5 TNF-alpha/NF-kB  
Signaling Pathway; 
FoxO family signaling
Zinc finger, AN 1-type 
domain 5
N/A 1.558
DR1 Chromatin Regulation 
/  Acetylation
Down-regulator of 
transcription 1, TBP- 
binding (negative cofactor 
2)
Assembly of RNA 
Polymerase II Complex
1.548
OSBPL8 N/A Oxysterol binding protein­
like 8
N/A 1.548
RASGRP1 Gas Signaling, T  cell 
receptor signaling 
pathway
RAS guanyl releasing 
protein 1 (calcium and 
DAG-regulated)
Hematological System 
Development and 
Function; Cellular 
Development
1.548
PRNP Prion diseases Prion protein Cellular Development; 
Cell Death and Survival
1.537
BNIP3L Apoptosis BCL2/adenovirus E1B 
19kDa interacting protein 
3-like
Cancer; Induces 
apoptosis
1.526
Description and functions assigned to the networks of genes that were differentially 
expressed using Ingenuity Pathway Analysis (IPA) software in DTwP vaccinated male 
infants. The top 10 differentially expressed genes were select.
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Figure 7.4 Network for DTwP vaccinated males. Differentially expressed genes and their 
associated pathways following DTwP vaccination of infant males. Networks were 
generated using Ingenuity Pathway Analysis software. Red nodes indicate genes that are 
upregulated.
7.3.5 Males vaccinated with MV+DTwP have down-regulated gene pathways
While DTwP vaccinated males had only upregulated genes post-vaccination, males 
vaccinated with MV at the same time as DTwP had only down-regulated genes with 18 
probes showing greater than 1.5 fold downregulation (Table 7.3). All 18 probes were 
uploaded into IPA and one major network was produced (Network score 26) containing 10 
focus genes (Figure 7.5). All of the associated network functions in MV+DTwP vaccinated 
males are involved in developmental pathways (Table 7.6). The top canonical pathway 
associated functions were for down-regulated amino acid metabolism and signaling 
processes.
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Table 7.6 Pathway description and function of differentially expressed genes in
MV+DTwP vaccinated males
S ym bol P athw ay Descrip tion G ene Nam e Function Fold
change
S M O X Amine and polyamine 
degradation; spermine 
degradation
Sperm ine oxidase Regulation of 
polyamine intracellular 
concentration
-1.647
DPYSL5 Axon guidance Dihydropyrimidinase-like
5
Neural development -1 .636
DVL1 W nt signaling pathway, 
Notch signaling 
pathway, Pathways in 
cancer
Dishevelled, dsh homolog 
1 (Drosophila)
Regulation of cell 
proliferation, Cancer, 
Dermatological 
Conditions
-1.613
RN F213 Protein modification; 
protein ubiquitination.
Ring finger protein 213 Ubiquitin-protein ligase 
activity
-1 .580
SP R Y D 3 N/A S P R Y  domain containing 
3
N/A -1.548
TPRA1 G-protein coupled 
receptor signaling 
pathway
Transm embrane protein, 
adipocyte asscociated 1
Small Molecule 
Biochemistry
-1 .537
M UC6 N/A Mucin 6, oligomeric 
mucus/gel-forming
Tissue Development -1.526
A RTN N/A Artemin Cellular growth and 
proliferation
-1.516
A D R A 2C Neuroactive ligand- 
receptor interaction
Adrenergic, alpha-2C, 
receptor
Nervous system  
development and 
function
-1.516
IGFBP1 Insulin receptor 
signaling pathway
Insulin-like growth factor 
binding protein 1
Cellular growth and 
proliferation
-1.505
Description and functions assigned to the networks of genes that were differentially 
expressed using Ingenuity Pathway Analysis (IPA) software in MV+DTwP vaccinated male 
infants. The top 10 differentially expressed genes were select.
Genes involved in protein and amino acid metabolism include spermine oxidase (SMOX) 
and ring finger protein 213 (RNF213) (Table 7.6). Artemin (ARTN) and insulin-like growth 
factor binding protein 1 (IGFBP1) were down-regulated, both of which promote cellular 
growth and proliferation; as was the disheveled segment polarity protein 1 (DVL1) gene 
which is a regulator of cell proliferation. Two of the genes, dihydropyrimidinase-like 5 
(DPYSL5) and adrenergic, alpha-2C, receptor (ADRA2C), are important in nervous system 
development and function. The spry domain containing 3 (SRPYD3) gene is associated 
with agammaglobulinaemia suggesting a role in IgG production; and the mucin 6 (MUC6)
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gene plays an important role in the cytoprotection of epithelial surfaces, including the 
gastro-intestinal tract. The down-regulated transmembrane protein, adipocyte associated 1 
(TPRA1) is a G-protein signaling molecule of uncertain significance.
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Figure 7.5 Network for MV+DTP vaccinated males. Differentially expressed genes and 
their associated pathways following MV+DTwP vaccination of infant males. Networks were 
generated using Ingenuity Pathway Analysis software. Green nodes indicate genes that 
are down-regulated.
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7.4 Discussion
We aimed to use transcriptome analysis to help identify signatures that might account for 
beneficial or deleterious effects of vaccines, and further analyse for key sex differences. It 
is apparent using this approach that females and males in the different vaccine groups 
have distinct transcriptional profiles 4 weeks after vaccination. It should be borne in mind 
that the 4 week time point is not an ideal time point at which to analyze for transcriptional 
changes post-vaccination with very few statistically significant differences observed 
between any of the pre- and post-vaccination groups following false discovery correction. 
Differential gene expression was weak and we had to use less stringent analysis criteria to 
tease out group and sex differences than we had intended. Data published after the study 
was designed show that early signatures from 1-7 days post-vaccination predict vaccine 
responses, and might thus have been more informative. Indeed, in a time course 
transcriptome profiling study carried out in the same study site in The Gambia, responses 
to measles vaccination of 9 month old infants peaked at 1 week and had declined by 4 
weeks (Flanagan et al, in preparation). However, it was not possible to collect an extra 
early blood sample for logistic reasons, and furthermore we were more interested in non­
specific effects of vaccination, which are thought to last for months after the vaccine is 
given.
7.4.1 Down-regulated type 1 IFN pathways and DC function could explain 
deleterious effects of DTwP vaccination among female infants
One major finding in this study was the marked down-regulation of interferon response 
pathways in females 4 weeks after vaccination with DTwP. Type 1 interferons are very 
important in the control of viral infections in particular, but also certain intracellular bacteria 
such as Mycobacterium tuberculosis. Typel IFNs and typel interferon stimulated genes 
(ISGs) play a significant role in the innate immune response, but can also modulate the 
type and magnitude of the subsequent adaptive immune response via dendritic cells (Stark 
et al., 1998; Santini et al., 2002; Tough, 2004; Kawada et al., 2006; Steinman and Hemmi, 
2006; Katze et al., 2008; Proud et al., 2008; Yao et al., 2009). A sustained or delayed
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down-regulation of type 1 IFN response pathway in DTwP vaccinated females following 
vaccination could be a possible explanation for the non-specific effects of DTwP 
vaccination of females (Aaby et al., 2003c; Aaby et al., 2007; Benn et al., 2009a; Benn et 
al., 2010; Roth et al., 2010). Again, this is speculative and would need to be validated in 
future experiments. Such a down-regulation would be hypothesised to lead to an increased 
susceptibility to viral infections.
These data fit with the protein data in which we saw immunosuppression for multiple 
parameters in DTwP vaccinated females. DTwP vaccinated females had suppressed 
response to PPD stimulation with suppressed CD8 (Tc1) T cell reactivity by ICS. They also 
had broadly suppressed reactivity to aCD3/aCD28 stimulation with suppressed IFN-y/IL-10 
ratio in culture supernatants. The DTwP vaccinated group in general had suppressed CD4 
(IFN-y) and CD8 (IFN-y) T cell reactivity to aCD3/aCD28 and LPS stimulations respectively 
by ICS. These would need to be validated in future studies.
Children vaccinated with live attenuated influenza vaccine (LAIV) had higher differential 
expression of type 1 IFN and ISGs, but this was not the case in the study group vaccinated 
with trivalent inactivated influenza vaccine (TIV) (Zhu et al., 2010b). This would suggest 
that live vaccines are more likely to stimulate type 1 IFN genes than inactivated vaccines. 
However, the authors do not describe a down-regulation of type 1 IFN genes following TIV 
vaccination. Since we only have the 4 week post-vaccination time point we do not know if 
these genes are up-regulated at any point following DTwP vaccination in females, and this 
will remain the work of future studies.
7.4.2 Upregulated genes involved in cell development and repair in DTwP 
vaccinated males
In contrast to the generalized down-regulation of genes in DTwP vaccinated females, the 
DTwP vaccinated males had upregulated genes only. Furthermore, the upregulated genes
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were completely different to those down-regulated in the females, with the major pathways 
upregulated being those involved in development and repair.
There was upregulation of several genes involved in apoptosis and cell survival in DTwP 
vaccinated males. The BNIP-3L gene protects cells from viral-induced cell death, while 
MST4 is thought to play a role in the apoptotic pathway. The upregulation of the ZFAND5 
gene, involved in the regulation of TNF-a / NF-kB signaling pathways, may also play a role 
in apoptosis. It would therefore be of interest to study the effect of DTwP vaccination on 
immune cell apoptosis and cell death in males and females.
The down-regulator of transcription 1 (DR1) gene was upregulated after vaccination. This 
gene encodes a protein that represses and controls the rate of RNA polymerase II 
transcription. A recent study showed that OSBPL8 is important in the interferon antiviral 
response. The mechanism of this antiviral response involves the recruitment of STAT1 to 
the promoter region of the ch25h gene resulting in the transcription and translation of a 
single oxysterol (25HC) by macrophages (Blanc et al., 2013). Other studies report the role 
of OSBPL8, as a negative regulator of cholesterol efflux from macrophages (Yan et al., 
2008). This would therefore suggest that DTwP vaccination may affect macrophage 
function in males.
There were several upregulated genes that are involved in haematological functions in 
DTwP vaccinated males. The ADD3 gene plays an important role in hematological system 
development and function, and the JMJD1C gene is involved in hematopoiesis. The 
upregulated RASGRP1 gene activates the Erk/MAP kinase cascade and regulates T and B 
cell development, homeostasis and differentiation. An upregulation of such functions would 
be hypothesised to be beneficial to the host.
Thus DTwP vaccinated males would be hypothesised to have better cellular repair 
processes, less apoptosis and improved cell survival following vaccination than DTwP
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vaccinated females. They may also have improved anti-viral IFN responses via enhanced 
macrophage function. This would be in keeping with the enhanced pro-inflammatory innate 
and T cell functions in males compared to females in the cytokine and ICS studies. These 
putative effects would need to be verified in more detailed functional studies, but would 
presumably be beneficial to the infant.
It is interesting that the genes that were differentially expressed in DTwP vaccinated 
females were all downregulated and are quite different to the upregulated genes in DTwP 
vaccinated males. This would be hypothesised to be due to sex differences. It is important 
to note that the microarray analysis is only indicative of changes that may occur upon 
vaccination and can be used to direct further work to validate these potential alterations. 
We would like to stress that these results are preliminary and would need to be followed up 
with validation experiments.
7.4.3 Negative transcription effects in MV+DTwP vaccinated males
In contrast to the DTwP vaccinated males, co-administration of MV with DTwP resulted in 
down-regulated developmental pathways in males, particularly of genes involved in amino 
acid metabolism and signaling processes. Several of the down-regulated genes promote 
cell growth and proliferation, and thus one would predict negative effects of this gene 
down-regulation. The down-regulated MUC6 gene might lead to less protected epithelial 
barriers against pathogen challenge.
This suggests that combining the MV and DTwP vaccines may cause a switch from 
generalized gene upregulation in DTwP vaccinated males, to down-regulation when both 
vaccines were administered together. Overall we would hypothesise that this would have 
negative effects in these males.
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7.4.4. Limitations
This study had several limitations that should be noted. Samples were collected at a single 
time point 4 weeks after vaccination and the dynamics of the immune response in males 
and females may be different. We had to use less stringent analyses to enable us to 
identify differential expression and these data are also preliminary and require validation, 
therfore the transcriptome data should be interpreted with caution.
7.4.5 Overall Conclusions
There are quite diverse genes and pathways involved in mediating immunologic memory 
and these can change quickly. Measuring multiple genes and pathways over time using 
microarray analysis is therefore helpful in understanding the immune response to 
vaccination. It provides a broad overview of the multitude of immune pathways affected by 
vaccination, and when used in conjunction with other assays that measure antibody and 
cellular responses, it provides an in-depth knowledge of innate and adaptive responses to 
vaccines. This may in turn allow identification of predictors of vaccine efficacy, vaccine 
reactogenicity and non-targeted effects of vaccines on the immune system.
Our data contribute to our understanding of the immunological effects of measles and 
DTwP vaccination of infants, and the effect of administering the two vaccines at the same 
time. In keeping with the protein data in the previous 2 chapters, there were distinct 
differences both between vaccine groups and sexes. Furthermore, the RNA data gave 
further indications as to the nature of some of the observed protein effects. The down- 
regulated innate / type 1 IFN pathways in DTwP vaccinated females is in concordance with 
the immunosuppressive effects post-vaccination in vitro. By contrast, the upregulated 
genes in DTwP males corresponds with the more pro-inflammatory profiles in this group in 
vitro. When MV was given with DTwP the males switched to a down-regulation of genes, 
which fits with the protein data which shows that males become less inflammatory when 
both vaccines are given together. These results will however need validation since these 
results are priliminary.
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The down-regulation of the type 1 IFN-stimulated genes might serve as a potential 
biomarker for the deleterious effects of DTwP in females if validated. We were unable to 
investigate the dynamics of this RNA response or whether innate genes are up-regulated 
at any point following vaccination in this study. However, the fact that they are down- 
regulated 4 weeks after vaccination could mean that the innate response would be weaker 
in these females thus increasing their susceptibility to infectious challenge. This is of 
particular importance in early life when the child is more reliant on the innate immune 
system for protection against invading organisms. This poorer innate immune response 
would be hypothesised to affect the development of the subsequent adaptive response, 
since they are intrinsically linked.
These data can now be used to select candidate genes or pathways that might account for 
some of the sex differences and non-specific effects of vaccines. These candidate genes 
can be selected alongside the protein data in order to determine biomarkers or signatures 
that might predict the beneficial or non-specific effects of vaccines. This is the subject of 
ongoing studies.
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CHAPTER 8 
CONCLUDING REMARKS
8.1 Final conclusions
The expanded programme of immunization (EPI) was introduced in The Gambia over 30 
years ago, using empirically developed vaccines with limited understanding of exactly how 
they work. Observational studies showing vaccines may have heterologous beneficial or 
deleterious effects on disease susceptibility, dependent on sex, have been controversial, 
with no immunological data to support these epidemiological findings (Aaby et al., 1995; 
Aaby et al., 2003c; Aaby et al., 2004b; Aaby et al., 2009; Agergaard et al., 2011; Aaby and 
Benn, 2011; Benn and Aaby, 2012).
In 2012 the Strategic Advisory Group of Experts on immunization (SAGE) at WHO 
commissioned a review of the evidence for the non-specific effects of vaccines. Two 
independent systematic reviews were conducted of the epidemiological and the 
immunological evidence respectively, focusing on BCG, DTP and measles vaccines in 
under 5 year olds. While recognising the plausibility of heterologous immunological effects 
of vaccines, they concluded that the existing data neither excluded nor confirmed a 
deleterious heterologous effect of DTwP on all-cause mortality; but acknowledged a 
possible beneficial heterologous effect of MV on all-cause mortality ((WHO), 2014). The 
expert group emphasised the need for further randomized trials with sufficient power to 
explore sex differences, and the need to explore and understand the immunological 
mechanisms.
This study is the first longitudinal randomized trial investigating the immunological 
consequences of vaccination with a live (Measles vaccine (MV)) or killed (Diptheria, 
Tetanus, whole-cell Pertussis (DTwP)) vaccine or a combination of the two, with the aim of 
determining whether these vaccines have heterologous or non-specific effects which differ 
in males and females. Few studies have assessed antigen specific cytokine responses to 
vaccines in humans, but changes in the type-1 and type-2 immune profile would be 
expected to affect downstream immune responses. Therefore, a major aim of this thesis 
was to assess the effect of vaccination of cytokine profiles.
2 0 0
This study provides evidence for different immunological responses depending on the 
vaccine schedule and sex of the infant. We show evidence for sex-differential effects on 
immune responses to non-vaccine recall and innate antigens, which could potentially 
account for some of the previous epidemiological observations. These will need further 
analyses in carefully designed prospective studies.
8.1.1 Vaccine-specific effects
IgG antibody levels to all vaccines were comparable in males and females and importantly, 
were not affected when MV and DTwP were administered at the same time indicating that 
different schedules still resulted in protection to the different vaccines, at least in terms of 
antibody levels.
Cytokine profiles following culture with measles peptides showed a type 1 cytokine bias in 
measles vaccinated infants, and ICS results suggested a CD8 T cell source of the IFN-y. 
There were certain differences in measles pool cytokine reactivity dependent on the sex of 
the infant both before and after vaccination. After vaccination, males had higher IFN-y 
responses to measles peptides than females in the MV group.
Although protective antibody levels were induced to DTwP vaccination, cellular responses 
to TT antigen were very low in the DTwP vaccinated groups. However, TT responses were 
boosted in the MV+DTwP and DTwP groups, although more so in the MV+DTwP group. 
This suggests that MV has an adjuvant effect on DTwP responses with enhanced TT- 
specific immunity. The adjuvant effect by MV would be in keeping with the adjuvant effect 
provided by another live vaccine, BCG (Ota et al., 2002; Ritz et al., 2013). One could 
hypothesise that these enhanced immune responses would be beneficial in terms of 
pathogen clearance, but alternatively might lead to excessive inflammation and poorer 
outcomes, but again, this is speculative and will need to be investigated in future trials.
2 0 1
These effects on vaccine specific responses add novel data to our current understanding of
the immunological effects of MV and DTwP vaccination.
8.1.2 Non-specific effects on responses to aCD3/aCD28 and PPD stimulation
Responses following PPD and aCD3/aCD28 stimulation allowed us to determine whether 
different vaccine schedules impacted on cellular responses to non-vaccine related stimuli. 
One common feature was an immunosuppressive effect of DTwP, particularly in females. 
The combined vaccine group generally behaved differently to the single vaccine groups in 
terms of male/female differences with males in both the MV and DTwP groups having 
greater pro-inflammatory responses to PPD and aCD3/aCD28 than females; while in the 
MV+DTwP group males and females generally had comparable responses or females has 
higher reactivity.
8.1.3 Effects on RNA transcription
Differential gene expression following vaccination was extremely low level and the 
stringency of the analysis had to be decreased in order to identify sex and group 
differences. Since the samples were taken 4 weeks after vaccination and analysed for 
differential gene expression from whole unstimulated blood then this is not unexpected, 
and perhaps it is more surprising that any differences emerged at all. No group differences 
were observed unless the data were analyzed separately by sex. There was evidence of a 
down-regulation of interferon response pathways in females four weeks after vaccination 
with DTwP, further supporting an immunosuppressive effect of DTwP vaccination in 
females. The down-regulated genes were mainly type 1 interferon induced genes which 
are crucial to the innate control of many infections.
In contrast all the genes differentially expressed 4-week after DTwP vaccination in males 
were up-regulated, particularly genes involved in developmental pathways. Interestingly, 
four weeks after MV+DTwP, males had a quite different profile with all differentially 
expressed genes being down regulated. These data are consistent with the protein data in
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which we observed a more pro-inflammatory profile in DTwP males compared to females,
but a reversal or loss of this difference in the MV+DTwP group.
8.2 A putative model to account for the beneficial effects of MV and deleterious 
effects of DTwP vaccine
Bearing in mind the exploratory nature of the results in this thesis and the need for further 
validation, we propose a model of heterologous effects of MV and DTwP whereby:
(1) A less robust innate and T cell immunity in measles vaccinated females is beneficial to 
them.
(2) DTwP causes a downregulation of innate gene transcription and suppression of innate 
and T cell immunity in females which increases their susceptibility to infections.
(3) Co-administration of DTwP with MV causes females to become more pro-inflammatory, 
reducing the MV benefits to females; while dampening the immunosuppressive effects 
of DTwP in females.
The above are hypotheses and are speculative and require validation, preferably in 
prospective studies. However they do provide plausible immunological explanations for the 
observed beneficial and non-specific effects of MV and DTwP vaccines. It is important to 
note that whatever differences were observed at both the genetic and protein levels did not 
interfere with the infants’ ability to generate protective antibodies to the vaccines 
administered.
8.3 Limitations of the study
8.3.1 Multiplex vaccine antibody assays
Although not a limitation, we have to point out that at the time of this study, the DTx, TTx 
and PTx antibody measurement by multiplex assay was not available in The Gambia and 
was therefore carried out by a collaborating laboratory at RIVM, Holland. However this
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collaboration has subsequently led to the successful transfer of this technology to The 
MRC Gambia unit where this assay is now available.
A correlate of protection for pertussis toxoid antibody levels is yet to be established, and 
we therefore set an arbitrary cut-off value, which resulted in many of the children not 
achieving protective titres after vaccination. The significance of this finding is therefore not 
known but would suggest that the chosen cut off was too high since DTx and TTx titres 
were not similarly affected.
We were unable to characterize the antibody effects further due to the limited amount of 
plasma available. We therefore were unable to analyze for effects of sex or vaccine group 
on different IgG isotypes, or look at more functional aspects of the antibodies such as 
avidity.
8.3.2 Transcriptional analysis and bioinformatics
The technology for the transcriptional profile analysis was not available in The Gambia and 
therefore a collaboration was established with the Division of Pathway Medicine at the 
University of Edinburgh. The RNA was extracted in The Gambia and then sent to 
Edinburgh where the assays and bioinformatics analysis were carried out. I had the 
opportunity to travel to Edinburgh to learn how the assays were done, but it was well 
outside the scope of this thesis for me to carry out all the assays and analyze the data. It is 
now evident that the early innate transcriptional signatures occur within a week of 
vaccination, and thus our 4 week post-vaccination signatures were weak and differential 
gene expression pathways could not be generated for all groups.
8.3.3 Innate cell phenotyping
Due to the limitation in the number of markers we could use for the ICS panel, we could not 
include CD3 or other NK cell markers. The CD56 marker was thus used to define several
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innate cell populations (NK cells, ILN-ILC1, NK T cells and y5T cells) and ideally we would 
have liked to further delineate the innate cell source of the cytokines.
8.3.4 Single post-vaccination time point
The 4 week time point was chosen for the post-vaccination bleed due to the sheer logistics 
of having 300 children being followed up with pre- and post-vaccination bleeds. This design 
provides no information on the dynamics of the post-vaccination immune profile over time, 
nor how these dynamics might vary by vaccine group. More focused smaller time course 
dynamic studies would be required to test this further.
8.3.5 In vitro  culture time profiles
All cells were cultured in overnight assays for logistic reasons, in addition to the fact that 
we showed in preliminary assays that we got a signal for the antigens and cytokines being 
tested. However, the memory / recall responses were generally low level and culture for 
longer time periods would have detected more robust T cell responses, particularly to the 
vaccine antigens.
8.3.6 Sample size
The sample size of our study was not large enough to have disease incidence or death as 
endpoints. With multiple assays, antigens and cytokines being tested the issue of deriving 
significant values that are not actually significant increases, and yet correcting for multiple 
testing may casue us to remove results that are significant.
8.4 Future directions
To our knowledge, this is the first randomized study that has provided plausible 
immunological explanations for the non-specific and sex differential effects of measles and 
DTwP vaccination. The results have provided us with new hypotheses that can be tested 
and validated in prospective studies to see if they predict beneficial or deleterious 
outcomes in children. Samples have been collected from thousands of children in
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prospective randomized trials in Guinea-Bissau, and we propose to use these samples to 
validate whether particular biomarker patterns predict disease incidence, hospitalization 
and death. Correlation of expression networks with soluble cytokine data in future studies 
will possibly enchance the chances of identifying these biomarker patterns.
Ideally we would like to be able to define an immune risk phenotype shortly after 
vaccination, which might then be used in vaccine studies. Furthermore, we would hope to 
define what constitutes a beneficial non-specific vaccine response with the aim of 
mimicking it in the future using vaccines and adjuvants.
It would be interesting to collect RNA at earlier time points (i.e. 24 hours and up to a week) 
from vaccinated children in order to see whether any key RNA signatures emerge in the 
different vaccine groups and sexes. This would provide further insights into the 
mechanisms of these non-specific effects, and possibly early gene signatures could be 
used as a screening tool for heterologous effects in vaccine trials.
In its recent systematic review, SAGE concluded that the published evidence for a 
deleterious effect of DTwP are still not convincing ((WHO), 2014). The immunosuppressive 
effects of the DTwP vaccine suggested by our data, particularly in females, therefore 
warrants further investigation in order to confirm it and assess whether it might be 
responsible for the epidemiological findings.
It might also be important to study other commonly administered vaccines for non-specific 
effects, and for vaccine interactions for combinations that are frequently given at the same 
time. This will also be apply to novel vaccines, and these effects should be considered 
when introducing new vaccines into existing vaccine schedules. It would also be interesting 
to re-visit existing immunological data sets from vaccine trials and analyze them for sex 
differences.
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APPENDIX I: MV/DTP STUDY (SCC1085) 
SUBJECT INFORMATION SHEET
We would like to thank you for taking the time to consider being in this study. This form 
will explain the study to you.
Vaccines in The Gambia
Vaccines given in the first year of life protect your child from diseases that they might 
otherwise become seriously ill with, or even die from. Vaccines work by teaching your 
immune system to recognise and fight an infection the next time you come into contact 
with it. All children in The Gambia are recommended to receive routine vaccinations in the 
form of the Expanded Programme on Immunization (EPI). This vaccination programme is 
very important for the health of your child and has saved millions of lives worldwide since 
it was introduced.
The Gambian EPI includes having doses of the diphtheria, tetanus, pertussis combined 
vaccine (DTP) at 2, 3 and 4 months of age, and measles vaccine at 9 months of age. 
Sometimes it is not possible to have vaccines on time for reasons such as your child is 
unwell, or you are unable to make it to clinic. If this happens the missed vaccines may be 
given when you next attend. For this reason vaccines are sometimes given together or in 
the wrong order. For example the 3rd dose of DTP is often given with measles vaccine 
when the child present at 9 months of age.
What is the aim of the study?
There is now evidence that measles vaccine and DTP interact with one another if given 
together. This is being investigated in big studies in Guinea Bissau that we are involved in. 
If it is true that they interact then it may not be a good idea to give them together. We want 
to study in detail how they interact and how this effects the immune response of your child 
to infections.
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What happens if you agree to participate?
We will select an envelope to decide whether to give the 3rd dose of DTP at 4 months as 
normal or whether to give it at 9 months. The group that get DTP3 at 9 months will either 
have measles vaccine at 9 months with DTP3 or at 11 months of age. At 11 months all 
children will be given yellow fever and polio vaccines and those that have not had 
measles vaccine will be given it. Thus by 11 months of age your child will have received 
all those vaccines recommended for the 1st year of life. Your child’s immunity to 
diphtheria, tetanus and pertussis should not be compromised by delaying the 3rd dose 
since 2 doses are adequate to provide protection. The delay of yellow fever and measles 
vaccines to 11 months is unlikely to cause an infection since the chance of your child 
encountering one of these diseases in the intervening two months is very low. Your child 
will have received polio vaccine at birth, 1, 2 and 3 months as usual, which is sufficient to 
provide protection, thus giving a 5th dose at 11 months is not likely to cause any problems.
We will need to take a 5 mL blood sample (1 teaspoon of blood) on 4 occasions over the 
study period in order to see what is happening to your child’s immune system. Blood will 
be taken at 9 months of age, 9 1/4 or 10 months (to be confirmed), 16 months and 181A or 
19 months (to be confirmed). We will look at how your child’s blood responds to infections 
and vaccines including measles, tetanus and tuberculosis. This should help us understand 
if the vaccines interact and effect the immune response to other infections. We will extract 
nuclear material (RNA and DNA) from the blood cells and store it in order to look at the 
inherited genetic response to infection. We will also store serum (part of the blood that 
does not contain red cells) for later analysis for factors that might explain these effects. 
We will take a urine sample each time your child has blood taken to test for infection with 
a virus called cytomegalovirus (CMV).
If your child is unwell when they present for vaccination or blood sampling then the 
vaccine / blood sample will not be taken. You may be given an appointment for a later 
date. There are no risks involved with taking a teaspoon of blood from your child.
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Your rights
Your child will receive all their EPI vaccines at Sukuta Health Centre if they agree to 
participate in this study. They will also receive free health care available at Sukuta Health 
Centre for the duration of the study. We will compensate your travel costs to the clinic 
during this study. Should your child require health care outside of the Sukuta Health 
Centre for any reason the MRC will not be responsible.
The blood will not be used for any other study without your consent. All information that 
you give us will be treated as confidential. You are free to leave the study at any time you 
wish without giving a reason for doing so. This will not affect your access to normal 
medical care.
MRC Contacts
Dr Katie Flanagan MRC, Fajara Office 4495442/3 ext 5003
Dr Jane Adetifa Sukuta Health Centre
If you are willing to help us with this study then please sign or fingerprint the consent form. 
THANK YOU.
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APPENDIX II: MV/DTP STUDY (SCC1085)
CONSENT FORM
The information sheet has been read to me and I understand it / I have read and 
understood the information sheet.I understand what participation in the study means for 
me and my child.I understand that the information regarding my child that is collected in 
the course of this study will remain confidential.! understand that laboratory tests will be 
done on the blood / urine samples that my child provides, and that part of the blood will be 
stored for possible future tests, including genetic tests related to immunity to vaccines.
I understand that if my child gets sick during the study period, he/she can go to Sukuta 
clinic, and be examined and treated for free.I understand that I am free to take part in the 
study or refuse, and that I can withdraw my child from the study at any time, and without 
giving any reason. Deciding not to take part or to withdraw from the study will not affect 
the care that my child is normally entitled to.I have had a chance to ask questions and 
have them answered.
Signature or thumb print of mother / father:
Name of child___________________________  Study No MV_DTP |__|__|__|
B I I I I I I I B I I B I I I I I I B a i l l l l l l l B I I I I I I I I I I I I I B I I I I I I I I B I I I B I I l l l l l l l l l l l l l l I I I I I I I I I R I I I B I I
This form has been read by / 1 have read the above to
  (write name of parent)
in a language that he/she understands. I believe that he/she has understood what I 
explained and that he/she has freely agreed for their child to take part in the study.
Signature of field worker:
Name of field worker:
Date: I I 111 I 111 I I I I
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